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PREFACE
When I started my post as Lecturer in the Department of Medicine 
in 1978 the porphyrias were merely an esoteric group of 
small-print conditions that had little relevance to me. I soon 
learnt the frustrating limitations of our knowledge in dealing 
with the suffering of those few unfortunate individuals afflicted 
by these rare disorders. Thanks to the guidance and encouragement 
of Professor Sir Abraham Goldberg I came to realise the unique 
opportunities that a study of such inborn errors of metabolism 
could offer in furthering our understanding of basic physiological 
principles. I am also indebted to Sir Abraham for inculcating in 
me the constant need to think of the patient's interests first and 
foremost before satisfying one's often compelling scientific 
curiosity.
After having spent seven years of clinical involvement with 
patients suffering from acute intermittent porphyria referred to 
our Unit, the experience that I have accumulated is embodied in 
this thesis. Of course, this would not have been possible without 
the enormous help and stimulating discussions I have had with so 
many of my colleagues and referring physicians, too numerous to 
mention individually. Some of the work presented in this thesis 
has already been published, and the rest will soon follow.
Except where acknowledged the work presented has been carried out 
personally by myself.
The writing of this thesis is entirely my own work.
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SUMMARY
This thesis consists of three sections. The first section is a 
general description of porphyrins and biochemical control of haem 
biosynthesis followed by an up-to-date review of the acute hepatic 
porphyrias and their clinical management, with particular emphasis 
on acute intermittent porphyria (AIP).
The second section addresses itself to the pathogenesis of the 
neuropathy of AIP. Following a critical review of the 
histopathological and biochemical work on the subject the results 
of a study on the cardiovascular autonomic function in AIP are 
discussed. Objective evidence for parasympathetic and sympathetic 
dysfunction during an acute attack is provided. Moreover, there 
is suggestion of parasympathetic involvement both in patients who 
have fully recovered from the acute episodes and asymptomatic 
latent cases. These findings support the electrophysiological 
results of Mustajoki and Seppalainen (1975).
Using two different histochemical techniques, cytochrome oxidase 
activity was found to be markedly depressed in muscle biopsies 
taken from AIP patients during an acute attack. Since cytochrome 
oxidase plays a vital role in the terminal oxidative 
phosphorylation pathway, the possibility of a myopathic component 
in the muscle weakness, hitherto attributed to the neuropathy, is 
considered. But more significantly, depression of cytochrome 
oxidase activity in muscle tissue suggests that this might be the 
case in nerve cells. Further support for this concept comes from
(xiv)
other workers who have shown that the activity of the 
cytochrome-P450-dependent mixed-function oxidase system is also 
depressed in porphyric patients.
The cytochrome oxidase study is followed by a clinico-pathological 
discussion on the autopsy findings of a 31-year old AIP patient 
who died of the disease. Detailed documentation of the patient's 
clinical course and the purposeful neuropathological autopsy 
carried out provided us with a rare opportunity to investigate 
further the relative roles of demyelination and axonal 
degeneration in the pathogenesis of the disease. It was indeed 
surprising when independent review of the autopsy material by two 
experienced neuropathologists failed to reveal any of the 
characteristic morphological changes previously described.
The newly discovered association between early-onset chronic renal 
disease and AIP is discussed along three main possibilities: 
analgesic-induced nephropathy, hypertension-related renal disease 
and cytotoxic effects of porphyrin precursors on the kidneys. 
Analgesic-induced nephropathy could be satisfactorily excluded.
On balance evidence is in favour of hypertension-related renal 
disease although a local toxic effect by porphyrin precursors 
cannot be entirely excluded. A strong case can be made for 
the porphyria-associated hypertension to the neurogenic in 
type.
Many AIP patients with severe abdominal pain fail to respond to 
large dosages of opiate analgesics. A study was performed to 
determine whether the porphyric pain was truly resistant to 
opiates. It was found that if the patient failed to respond to
(xv)
the usual therapeutic dosage of one of three opiates: pethidine, 
morphine and buprenorphine, increasing the amount of drug 
administered did not improve the response rate.
In 1981 I observed that the pupils of a porphyric patient in a 
severe attack failed to undergo miosis after parenteral 
administration of large doses of morphine; yet they retained a 
normal response to accommodation and light stimulation. The 
significance of this finding, only recently appreciated, indicate 
the possibility of either dysfunction or depletion of the 
mu-opioid receptors in the optic nervous system.
Attempt to improve the symptoms of an AIP patient by sequential 
haemodialysis and haemoperfusion was unsuccessful despite a 
demonstrable fall in the excretion of plasma and urinary porphyrin 
precursors.
On the basis of these studies I propose a new hypothesis to 
explain the pathophysiology of acute porphyria:
During an acute attack, as a result of a specific block in the 
haem biosynthetic pathway, there ensues a deficiency of cytochrome 
oxidase in the nerve cells. Because neuronal cells have the 
highest metabolic requirements for oxygen in the body the nervous 
system becomes particularly susceptible to the effects of 
cytochrome oxidase deficiency - thus accounting for acute 
porphyria to become manifest as a neuro-psychiatric syndrome. As 
the lack of cytochrome oxidase constitutes a "functional" 
intracellular block it explains why several neuropathological 
studies have failed to reveal any morphological changes in some 
porphyric patients dying from the disease. It is only with a more
(xvi)
severe or prolonged attack that degenerative changes develop in 
the nerve cells. These changes will occur particularly in the 
metabolically more active anterior horn cells of the spinal cord, 
neurones with the longest axons and those with larger motor unit 
innervation.
In the light of recent experimental studies on opioid receptors it 
is suggested that porphyric neuropathy can lead to a depletion or 
dysfunction of opioid receptors in the brain stem as well as other 
parts of the nervous system such as the optic nerves and gut 
innervation. Lack of functional opioid receptors in the brain 
stem region would explain the basis of the neurogenic hypertension 
and tachycardia, inappropriate ADH secretion, and failure of 
analgesic response to different opioid agonists during the severe 
attacks. The gut is richly supplied with endogenous opioids and 
opioid receptors. Depletion of gut opioid receptors could 
conceivably cause an impairment in the modulating inhibitory 
effects of endogenous opioids which act as a neurotransmitter.
This could provide an explanation for the pain of acute porphyria 
to localise primarily to the abdomen.
This hypothesis does not explain the nature of the initial 
peripheral nociceptor stimulus causing the pain. Whether this is 
due to the porphyric neuropathy, as in diabetes, or to a 
circulating metabolite is a matter for further speculation.
In the third section of my thesis two new experimental approaches 
for studying disturbances of the haem pathway in man are 
explored. The first method follows the discovery of a 
non-hereditary case of acute porphyria believed to have been
(xvii)
induced by the anticonvulsant carbamazepine. Subsequent patient 
and volunteer studies confirmed that this drug can produce a 
pattern of porphyrin excretion similar to that seen in AIP, 
Carbamazepine has also been shown to exert a significant 
inhibitory effect on human lymphocyte ALA-dehydratase activity.
The second method follows the successful culture of human 
peripheral blood monocytes in vitro. Monocytes in culture for a 
period of 10 days were found to produce a mean value of 10.37 pmol 
protoporphyrin IX/ug DNA/h. This technique would be particularly 
useful for assessing the potential porphyrinogenicity of drugs and 
chemicals. Culture of a highly purified population of cells of 
bone marrow origin could also provide an excellent tool for 
investigating the molecular basis of the control mechanism for 
haem biosynthesis. Both in vitro methods described hold much 
promise in their future development.
(xviii)
ABBREVIATIONS
Abbreviations used in certain parts of the text 
ALA Delta-aminolaevulinic acid
AIA 2-allyl-2-iso-propylacetamide
AIP Acute intermittent porphyria
DDC 3,5-Diethoxycarbonyl 1-1, 4-dihydrocollidine
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mRNA Messenger RNA
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Haem enzymes
ALA.D
Synonyms [
Erythrocyte Delta-aminolaevulinic Acid 
Dehydrase o^ Dehydratase
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SECTION I
CHAPTER 1
HAEM METABOLISM
1. HAEM METABOLISM
1.1 INTRODUCTION
During the past 30 years much has been learnt about (1) the 
biochemistry of the porphyrins; (2) the properties of the enzymes 
involved in the haem biosynthetic pathway; (3) the molecular 
mechanisms by which these enzymes function and are regulated; and 
(4) the biological significance of certain disturbances of haem 
metabolism either inherited, as in the human porphyrias, or 
induced by drugs and chemicals. The discovery that the 
haem-containing mixed-function oxidase cytochromes P450 play a 
major role in the oxidation and detoxification of a large variety 
of endogenous and exogenous compounds has widened the scope of 
research in the field of porphyrin and haem metabolism. 
Consequently the study of the human porphyrias has aroused great 
interest not only among clinicians but also among biochemists, 
pharmacologists and other basic scientists: those whose research 
is concerned with the biotransformation of chemicals in the body 
and problems of interactions between the gene and the 
environment. The human porphyrias are particularly relevant for 
such studies since the clinical expression of these disorders in 
the genetically susceptible individuals is greatly influenced by 
distinct hormonal and environmental factors.
To study the porphyrias a basic understanding of porphyrin 
chemistry and haem biosynthesis is necessary.
1.2 NOMENCLATURE AND STRUCTURE OF PORPHYRIAS
Porphyrins are cyclic tetrapyrroles. The porphyrin nomenclature 
hitherto in use was developed by Hans Fi^er and his School in 
Munich (Fisher & Orth, 1937). According to this system the basic 
structure of porphyrins is represented by the compound which 
Fisher called "Porphin" - shown in Figure la. It consists of four 
cyclic rings, derived from monopyrroles, designated as A, B, C and 
D which are joined together by four met hen e bridgeso(,p and^.  ^
This macrocycle is a tetrapyrrole. Substitution of the hydrogen 
ions by alkyl groups at the p positions in the macrocycle (ie 
positions 2, 4, 6 and 8) permits the formation of a large 
diversity of porphyrins. Two groups of reference compounds have 
set the basis for isomeric classification of porphyrins - the 
aetio- and meso-porphyrins. When each of the four pyrrole rings 
has one methyl and one ethyl side-chain substitutions the 
resulting porphyrin is known as an aetioporphyrin. There are four 
isomeric forms for the aetioporphyrins depending on the specific
sequence of methyl and ethyl groups in the eight substituted
positions on the ring. Most naturally occurring porphyrins are
aetioporphyrins of the I and III isomers (Fisher & Orth, 1937),
but only the III isomers have significant functional activity. 
Mesoporphyrins have a methyl and ethyl substituent on each of two 
of the adjacent pyrrole rings, and a methyl and propionyl 
side-chain on the remaining two rings of the macrocycle. Fifteen 
isomeric forms can exist for the mesoporphyrins.
Recently a revised system of nomenclature for tetrapyrroles has 
been proposed by the International Union of Pure and Applied
NH
HN
Porphin (Fischer Numeration)
Porphyrin (lUPAC Numeration)
Figure 1: Structure and nomenclature of the porphyrin macrocycle,
Porphyrin (Fisher nomenclature) or porphyrin (lUPAC 
nomenclature) is the basic structure of biologically 
occurring ring tetrapyrroles.
Chemistry and endorsed by the International Union of Biochemistry 
(lUPAC-IUB, 1980), Two important features of this nomenclature 
are that the basic macrocycle is called "a porphyrin" instead of 
"a porphin" (Fig lb), and all carbon and nitrogen atoms are 
numbered from 1 to 24 instead of only numbering the outer carbon 
atoms of the pyrrole rings. Eleven of the well established 
trivial names from the Fisher's system are still retained, and 
these comprise all the terms in use at present for the common 
porphyrins. This new nomenclature is in effect more systematic 
and allows for more accurate designation of unusual porphyrin 
compounds,
1,3 PROPERTIES OF PORPHYRINS
The tetrapyrrole nucleus is essentially planar and hydrophobic.
It has a high degree of chemical stability because of the 
phenomenon of resonance resulting from the conjugated double bond 
system (Smith, 1975), The water solubility of porphyrins 
increases with the number of carboxylic side-chains they possess. 
Thus uroporphyrin (8-carboxylated porphyrin) has a higher 
water-solubility than 4-carboxylated coproporphyrin which in turn 
is more water-soluble than 2-carboxylated protoporphyrin. 
Protoporphyrin is so hydrophobic that it is exclusively excreted 
in bile whereas uro- and copro-porphyrins can be excreted in the 
urine (Sano & Rimington, 1963),
Another common property of porphyrins is their distinctive 
absorption spectrum in the near-ultraviolet and visible regions; 
this permits their ready identification by spectrophotometry and
spectrofluorimetry. The absorption spectrum of porphyrins 
consists of a major absorption band around 400 nm known as the 
Soret band, and four smaller absorption bands between 500 nm and 
630 nm. Metal-free porphyrins emit an intense red fluorescence 
when excited by long wavelength ultraviolet light ( 400 nm).
Porphyrins chelated with diamagnetic metals (eg Mg, Zn, Sn) also 
fluoresce whereas those chelated with paramagnetic metals (eg Fe, 
Co, Or, Ma) do not (Smith, 1975),
Porphyrinogens are the biological precursors of porphyrins. All 
methine bridges in these compounds are reduced; thus they are 
colourless and do not fluoresce,
1,4 HAEM STRUCTURE AND FUNCTION
Porphyrins function in living cells only as metal chelates eg the 
iron porphyrins (haem) and the magnesium porphyrins 
(Chlorophyll), These compounds provide the prosthetic groups 
necessary for the catalysis of the basic energy reactions upon 
which life depends. The evolutional development of haemoproteins 
has allowed economical utilization of metallic iron for a number 
of vital biochemical functions. These can be grouped as follows:
(1) transport of molecular oxygen (haemoglobin and myoglobin);
(2) electron transport for energy transfer (mitochondrial 
cytochromes); (3) activation of oxygen (cytochrome oxidase, 
tryptophan pyrrolase and mixed function oxidases including 
cytochrome P450); (4) activation of hydrogen peroxide 
(peroxidases); and (5) decomposition of hydrogen peroxide 
(catalases) (Granick & Gilder, 1947), These specific functions are
determined by the state of oxidation of the chelated iron, the 
nature of the side—chains on the porphyrin ring and the structure 
of the protein to which haem is bound. The haem of haemoglobin is 
the ferrous chelate of protoporphyrin IX (Fig 2),
1.5 HAEM BIOSYNTHETIC PATHWAY
The biosynthesis of 1 haem molecule requires 8 molecules each of 
glycine and succinyl CoA as starting material. Eight enzymes are 
involved in the haem biosynthetic pathway, four being localised 
within the mitochondrion and four within the cytoplasm (Fig 3),
The first part of the pathway consists of a series of condensation 
reactions initiated by the enzyme delta-aminolaevuiinic acid 
synthase to lead towards the formation of an unstable linear 
tetrapyrrole, hydroxymethylbilane. The first stable intermediate 
in the pathway is delta-aminolaevulinic acid (ALA), a 5-carbon 
aminoketone formed by the condensation of 1 molecule of glycine, 
and 1 molecule of succinyl CoA, Pyridoxal phosphate is an 
essential co-factor for that reaction, ALA then diffuses out of 
the mitochondrion into the cytoplasm where 2 ALA molecules are 
combined under the catalytic action of ALA dehydratase (synonym: 
porphobilinogen synthase) to form the monopyrrole, porphobilinogen 
(PEG),
The next step requires the concerted action of two enzymes, PEG 
deaminase (synonym: uroporphyrinogen-l-synthase) and 
uroporphyinogen III co-synthetase; this is to convert 4 molecules 
of PEG into 1 molecule of the tetrapyrrole, uroporphobilinogen 
III, through the intermediary of hydroxymethylbilane (HMB), HME
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readily undergoes chemical cyclization so that PEG deaminase 
acting alone will only produce the symmetrical uroporphyrinogen I 
isomer. Eut under the catalytic action of uroporphyrinogen III 
co-synthetase a tetrapyrrole ring is formed with reversal of ring 
D to form the asymmetrical isomer, uroporphobilinogen III.
Next in the pathway is the sequential decarboxylation of the 
8-carboxylate, uroporphyrinogen, to the 4-carboxylate 
coproporphyrinogen, under the catalytic activity of 
uroporphyrinogen decarboxylase. Uroporphyrinogen decarboxylase 
can convert both uroporphyrinogen- I and -III to their 
corresponding coproporphyrinogen isomers. Eut only 
coproporphyrinogen III can enter the mitochondrion where 
coproporphyrinogen oxidase catalyzes the combined decarboxylation 
and dehydrogenation of two propionyl residues on rings A and E of 
the porphyrin nucleus to form protoporphyrinogen IX. As 
coproporphyrinogen I isomer cannot proceed any further in the 
pathway it is excreted. Within the mitochondrion 
protoporphyrinogen is oxidised to protoporphyrin by 
protoporphyrinogen oxidase. Under the catalytic action of 
ferrochelatase a ferrous ion is finally inserted into each 
protoporphyrin molecule to form the haem.
The activities of the haem enzymes from human liver are shown in 
Table 1 and three important points emerge. First the substrate 
concentrations measured are much lower than the Michaelis 
constants (km) of the corresponding enzymes. Therefore the rate 
of reaction of these enzymes can be increased several-fold by 
increasing the substrate concentrations until the maximum
Enzyme Activity*
Substrate 
concentration 
nmol/gm wet wt
Apparent 
Km (uM)
ALA synthase 0.26 - -
ALA dehydratase 12.9 (0.04)*** 270
PEG deaminase 0.14 (0.018)** 1.0 6
Uroporphyrinogen III 
decarboxylase 11.0 0.03 1.5+
Coproporphyrinogen
oxidase 13.0 0.07 0.9
Pro toporphyr inogen 
oxidase - - -
Ferrochelatase 16.6 0.38 1.8
17++
* Activities are expressed as nmol ALA or ALA equivalents produced 
or utilized/hr/mg protein
** nmol uroporphyrinogen/hr/mg protein
*** rat liver
+ pentacarboxylate porphyrinogen
++ Fe++
Table 1: Haem biosynthetic enzymes in human liver tissue:
Activities, Substrate concentrations and 
Michaelis constants
velocity, determined by the enzyme concentration, is reached. 
Second, ALA synthase, the main rate-limiting enzyme of the pathway 
and PEG deaminase have the lowest enzyme activities. Third, the 
activities of enzymes converting uroporphyrinogen III to haem are 
relatively high so that any uroporphyrinogen formed is likely to 
be rapidly converted to haem. Thus the unstable porphyrinogen 
intermediates acquire a short half-life which prevents their loss 
from the pathway by oxidation to porphyrins. The reactions 
involved in the conversion of ALA to haem therefore form an 
unbranched irreversible pathway (Elder, 1982): the loss of any 
intermediates primarily arise from transport or leakage out of the 
cells and intracellular oxidation of porphyrinogen to porphyrins. 
Normally the pathway operates very efficiently with little loss of 
intermediates. And as has been shown in the liver the synthesis 
and degradation of haem and the protein moieties of haemoproteins 
are so well co-ordinated that no free haem can be measured (Elder, 
1980).
1.6 HAEM EIOSYNTHESIS IN THE LIVER
Liver cells normally produce about 15 per cent of the total haem 
synthesized in the body, the remainder being made mainly by the 
bone marrow for haemoglobin production (Granick & Sassa, 1971). 
About 65 per cent of hepatic haem is utilized for haemoproteins of 
the cytochrome P450 series; (Tschudy & Lamon, 1980) these 
constitute a major component of the microsomal mixed—function 
oxidase system which play an important part in the metabolism and 
detoxification of drugs, chemicals and other compounds (Meyer & 
Schmid, 1978; Maines, 1984).
Haem production in the liver is largely controlled by the activity 
of mitochondrial ALA synthase. The activity of this enzyme is 
under negative feedback control by the intracellular concentration 
of haem. The rate-limiting nature of ALA synthase is now well 
established (Granick & Urata, 1963; Nakao et al, 1966; Marver et 
al, 1966a; Kappas et al, 1984). Mitochondrial ALA synthase 
appears to have a rapid turnover rate. Its half-life is about 70 
minutes in adult rat liver (Marver et al, 1966b; Hayashi et al, 
1969; Tschudy et al, 1965a) and 3 hr in mouse liver (Gayathri et 
al, 1973) and in cultured chick embryo liver cells (Sassa & 
Granick, 1970). By comparison the average half-life of 
mitochondrial proteins in general is about five days. The short 
half-life and relatively low activity (Table 1) of ALA synthase 
provide an effective mechanism for its regulation by way of 
end-product inhibition. It is interesting to note that ALA 
synthase also has an unusually low affinity for its substrate 
glycine (km 5-19 mM) and the intracellular concentration of 
glycine is only about one-fifth to one-twentieth of the km for ALA 
synthase (Sinclair & Granick, 1977). This suggests that the 
metabolic control of intracellular glycine concentration may have 
a significant regulatory role on the activity of ALA synthase.
1.7 CONTROL MECHANISM BY HAEM
After ALA synthase formation in the liver was shown to be 
controlled by haemin administration (Sass & Granick, 1970) it 
became clear that depletion of haem could lead to derepression of 
ALA synthase followed by compensatory increase in its substrate
concentration in order to maintain haem synthesis, Haem-mediated 
control of ALA synthase seems to occur primarily at the level of
enzyme synthesis rather than by direct enzyme inhibition.
Experiments using cultured avian embryonic liver cells have shown 
that haemin could possibly interfere with ALA synthase synthesis 
at the translational level, shorten the half-life of its mRNA 
(Sassa & Granick, 1970), or repress the synthesis of mRNA for ALA 
synthesis at the transcriptional level (Whiting, 1976). It is 
probable that haem acts by a similar mechanism in human liver but 
this has not yet been directly demonstrated.
Certain drugs and chemical compounds appear to induce ALA synthase 
by several different mechanisms in all of which the depletion of a
regulatory haem pool appears to be the common final event. There
are four main types of situations in which intracellular haem 
balance can be affected. First, compounds that contain terminal 
olefinic or acetylinic bonds such as 2-allyl-2-isopropylacetamide 
(AIA) (De Matteis, 1978) and fluorinated anaesthetics (Ziman et 
al, 1980) can promote autocatalytic destruction of the haem 
prosthetic group of cytochrome P450 which then has to be replaced 
from the regulatory pool. Second, compounds like griseofulvin and 
the dihydrocollidines can convert haem to n-acetyl porphyrin 
derivatives which probably act by specific inhibition of 
ferrochelatase, thus leading to decrease in haem formation (De 
Matteis et al, 1981a). Third, drugs such as phenobarbitone 
promote the utilisation of haem for the synthesis of cytochrome 
P450 dependent mono-oxygenases required for their metabolism.
This in turn stimulates the synthesis of apocytochrome P450 which
10
combine with haem and depletes the regulatory pool (De Matteis,
1978). Fourth, the possibility exists that certain chemicals may 
decrease the affinity and/or the number of haem binding sites.
For a better understanding of the regulatory role of haem in 
relation to its own biosynthesis and catabolism the existence of 
intracellular "free" haem pools has been postulated (De Matteis, 
1978; Ortiz de Montelano & Mico, 1981); this is outlined 
schematically in Figure 4. "Free" haem is considered to be newly 
synthesized haem that is not yet bound to the prosthetic group of 
any specific haemoproteins, and possibly haem that has just been 
released from haemoproteins. "Free" haem probably has a high 
turnover rate and exists in small quantities in the mitochondria, 
cytosol and endoplasmic reticulum among which compartments it 
rapidly reaches equilibrium. To date the existence of "free" haem 
pools remains speculative because of the unavailability of 
reliable methods to measure free haem concentrations in 
subcellular compartments. Nevertheless much indirect evidence is 
already available in support of this hypothesis. (Kappas et al, 
1983; Maines 1984).
As shown in Figure 4 the "free" haem pools could affect haem 
biosynthesis and catabolism in several ways:
(1) "free" mitochondrial haem could regulate the synthesis of the 
mitochondrial cytochrome oxidases;
(2) cytosolic "free" haem could repress the synthesis of ALA 
synthase, and in addition control the activity of haem oxygenase 
which degrades haem into bile pigments;
(3) haem oxygenase activity could also be positively controlled by 
microsomal "free" haem.
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Compounds that inhibit haem formation or destroy haem are known to 
be strong inducers of ALA synthase (De Matteis, 1978; Smith & De 
Matteis, 1980), Although it is attractive to speculate that 
induction of ALA synthase is due to derepression of enzyme 
synthesis following depletion of the "free" haem pool, under 
certain circumstances induction of ALA synthase seems to occur 
independently of changes in haem concentration (Kappas et al, 
1983).
1.8 HAEM SYNTHESIS IN ERYTHROID CELLS
The mechanism by which haem biosynthesis is regulated in 
non-hepatic tissues remains unclear and controversial. In analogy 
to control in the liver it is often assumed that regulation of the 
haem biosynthetic pathway in non-hepatic tissues also operate by 
negative feedback of haem on ALA synthase. This view has recently 
been challenged primarily on the basis of experiments performed in 
tissue cultures, mainly derived from malignant cell lines or cells 
transformed by oncogenic viruses. For instance, Sassa and his 
colleagues performed their studies on cell-culture models using 
mouse Friend-virus transformed erythro-leukemia cells and human 
erythroleukemia cell-1ines, stimulated with dimethylsulfoxide and 
a variety of other chemicals. In addition to an increase in ALA 
synthase, the activities of the other haem enzymes were induced in 
a sequential fashion (Rutherford et al, 1979). Addition of ALA 
to the transformed cells in which ALA synthase, ALA dehydratase, 
and PEG deaminase had already been stimulated by 
dimethylsulphoxide did not accelerate the rate of haem
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biosynthesis (Sassa, 1976), Moreover in the same models treatment 
with haemin induced ALA synthase activity instead of suppressing 
it as in hepatic cells (Granick & Sassa, 1978; Hoffman et al, 
1980). These workers therefore suggested that ALA synthase might 
not be the rate-limiting enzyme for haem biosynthesis in erythroid 
cells; and that ferrochelatase, the final enzyme of the pathway, 
might instead be more important in controlling the rate of haem 
formation in erythroid cells (Kappas et al, 1983). Such proposals 
must obviously be viewed with great caution not only because of 
the contrived nature of the experimental models and the 
considerable inter-species differences, but also because of the 
existence of multiple iso-enzymes with different activities that 
can occur during foetal and adult life.
1.9 HAEM SYNTHESIS IN OTHER ORGANS
In contrast to the well-characterised pathway of haem metabolism 
in the liver little is known about haem biosynthesis and 
degradation in other organs. From what little information there 
is, the regulatory mechanisms controlling the activity of ALA 
synthase would appear to differ from that in the liver. For 
instance, the amount of cytochrome P450-dependent mixed-function 
oxidase in the kidney of certain strains of rats was found to be 
only one-tenth of that in the liver, yet the rate of renal and 
hepatic synthesis and turnover of haem remained comparable 
(Benedetto et al, 1976). And the renal concentration of 
porphyrins was found to be several—fold higher than that in the 
liver (Maines et al, 1978). Renal ALA synthase activity was also
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reported to be refractory to the effect of potent inducers of 
hepatic ALA synthase such as 3, 5, dicarbethoxy—1,
4—dihydrocollidine (DDC), The suggestion that ALA synthase 
activity in the kidney might not be regulated by haem was 
supported by the finding that an increase in ALA synthase activity 
was not necessarily accompanied by a decrease in haem 
concentration (Maines, 1984).
In steroidogenic organs such as adrenals, testes and ovaries the 
main function of cytochrome P450 is to catalyse the synthesis of 
steroids rather than to oxidise and detoxify chemicals. In these 
organs too, control of ALA synthase activity appears to be 
governed by factors different from those operating in the liver. 
For example, following treatment with phénobarbital, AIA or DDC, 
Condie and his associates (1976a and b) failed to induce ALA 
synthase activity or decrease cytochrome P450 levels in the 
adrenals. Furthermore, starvation of the experimental animals 
caused a four-fold increase in adrenal enzyme activity, but not in 
the liver (Condie et al, 1976a).
The complexity of ALA synthase regulation in these organs is also 
reflected in the incomplete refractoriness of ALA synthase 
induction to metallic ions. Certain metals like copper, cadmium 
and mercury can increase ALA synthase activity to very high levels 
(Maines, 1984). These ions do not seem to exert a direct 
regulatory effect on the enzyme. Instead, the induction could be 
due to alterations in the hormonal milieu or to other as yet 
undefined cellular events triggerred only by specific metals 
(Maines, 1984)#
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The inability of hepatic ALA synthase inducers to alter ALA 
synthase activity and cytochrome P450 levels in these organs might 
be regarded as a biological safeguard against the potentially 
adverse consequences of unstable swings in steroid metabolism that 
could be caused by such exogenous agents.
Control of haem biosynthesis in the nervous tissue is discussed 
later (Chapter 4).
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SECTION I
CHAPTER 2
THE PORPHYRIAS
2. THE PORPHYRIAS
2.1 DEFINITION
The porphyrias are inherited and acquired disorders of porphyrin
or porphyrin precursor metabolism characterised by specific 
enzymatic defects in the haem biosynthetic pathway. Consequently, 
each of the porphyrias has a particular pattern of overproduction, 
accumulation and excretion of intermediate compounds of haem 
biosynthesis (Kappas et al, 1983).
2.2 HISTORICAL BACKGROUND
The word "porphyrin" is derived from the Greek "porphoros" meaning 
purple. The term "haematoporphyrin" was first used by 
Hoppe-Seyler (1871) to describe the main constituent of the 
purple-red iron-free haematin. But it was Hans Gunther (1922) who 
first proposed a classification for the diseases of porphyrin 
metabolism. Later in 1937, Waldenstrom introduced the generic 
term "porphyria" rather than "haematoporphyria" to describe these 
diseases. Stokvis (1889) described the first recorded case of 
acute intermittent porphyria in a woman who excreted dark red 
urine after ingestion of sulphonmethane (Sulfonal^) and died of 
the disease, but the first observation that it occurred in members 
of the same family was made by Barker & E^tlTe^s in 1912. A familial 
tendency was similarly noted by Gunther (1922) but it was 
Waldenstrom (1937) who established its hereditary nature.
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2.3 CLASSIFICATION OF THE PORPHYRIAS
The major porphyrias were initially classified as being hepatic or 
erythropoietic according to the major site of haem synthesis where 
the metabolic disorder is expressed. In these disorders, with few 
exceptions such as acquired porphyria cutanea tarda, the enzymatic 
defect occurs in all the cells of the body. Yet the metabolic 
consequences of the haem pathway disturbance give rise to diverse 
clinical syndromes.
Porphyrias that become manifest by acute attacks of neurological 
symptoms are referred to as the acute porphyrias whereas those 
characterised by photosensitive skin eruptions, the cutaneous 
porphyrias. The term "latent porphyria" refers to individuals 
with a specific enzyme defect who have never had any symptoms of 
the disease. This term "latent" is somewhat misleading in that 
the porphyria may still be expressed biochemically causing 
excessive ALA, PEG and porphyrin production despite a complete 
lack of symptoms.
2.3.1 Clinical features of inherited porphyrias 
The acute porphyrias are acute intermittent porphyria (AIP), 
hereditary coproporphyria (HC), variegate porphyria (VP) and the 
recently described homozygous ALA dehydratase deficiency. They 
are all hepatic in type. The non-acute porphyrias include 
congenital porphyria, porphyria cutanea tarda and erythropoietic 
protoporphyria (Table 2). A common feature of the acute hepatic 
porphyrias is the excessive production and excretion of ALA and 
typically suffer from abdominal pain often accompanied by various 
PEG. During an attack patients with the acute hepatic porphyrias
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typically suffer from abdominal pain often accompanied by various 
features of a neuro-psychiatric syndrome. In addition, patients 
with HC and VP can develop cutaneous lesions due to the deposition 
of porphyrins in the skin. On the other hand patients with the 
non-acute porphyrias only display cutaneous manifestations; and 
they do not excrete increased amounts of ALA and PEG in the urine.
2.3.2 Specific enzyme defects in the porphyrias 
Since each type of porphyria is due to a specific haem enzyme 
defect (Fig 5) they all have a characteristic pattern of 
porphyrins and porphyrin precursors in blood and excreta, 
determined by the site of block (Elder, 1982; Kappas et al, 1983; 
Rimington, 1985).
The enzyme deficiency in AIP is PEG deaminase (PEG.D) (also known 
as uroporphyrinogen-I-synthase (URO.S)), in HC coproporphyrinogen 
oxidase, and in VP protoporphyrinogen oxidase. AIP, HC and VP are 
expressed in the heterozygous state as autosomal dominant 
conditions. Eut recently acute poprhyria has been reported in the 
homozygous state for ALA-dehydratase (Doss et al, 1982c), 
coproporphyrinogen oxidase (Grandchamp et al, 1977) and 
protoporphyrinogen oxidase (Korda et al, 1984). In congenital 
porphyria (CP) the defect is uroporphyrinogen-III cosynthetase, in 
porphyria cutanea tarda (PCT) uroporphyrinogen decarboxylase and 
in erythropoietic porphyria (EPP) ferrochelatase. For PCT two 
types are now recognised: an acquired form and a less common
familial form (Kushner et al, 1976; Elder et al, 1978).
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ENZYME DEFECTS OF THE HEREDITARY PORPHYRIAS
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The horizontal dashed line indicates the site affected by the corresponding 
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* Abbreviations are explained in the text; those underlined are the acute porphyrias. 
** New type recently described - not yet named.
Figure 3
2.4 ACUTE INTERMITTENT PORPHYRIA
2.4.1 Introduction
AIP is the commonest type of acute hepatic porphyria in most 
countries in the world. Its prevalence has been estimated at 1.9 
per 100,000 population in Britain (Beattie, 1973b), 3 per 100,000 
(including known latent cases) in Western Australia (Saint & 
Curnow, 1962) and 7.7 per 100,000 in Sweden (Wetterberg, 1967).
The highest known prevalence is in Lapland (100 per 100,000) where 
all AIP subjects seem to belong to a single kindred (Romeo, 1980).
2.4.2 Establishment of the enzyme defect
In 1963 Granick and Urata demonstrated that synthesis of hepatic 
ALA-synthase (ALA.S) could be induced in experimental animals by 
administration of certain chemicals. The first clue to the 
underlying defect in AIP was provided when Granick (1966) showed 
that the induction of hepatic ALA.S by allyl-isopropylacetamide 
(AIA) and dicarbethoxydihydrocollidine (DDC) produced a 
biochemical abnormality that resembled human hepatic porphyria. 
Following these observations a similar but genetically-mediated 
induction of ALA.S was found in AIP patients (Tschudy et al,
1965b) that could explain the excessive production of ALA and PEG 
(Strand et al, 1970; Granick & Sassa, 1971). Subsequent studies 
showed that ALA.S activity was increased not only in AIP but also 
in other types of acute porphyria (Meyer & Schmid, 1973). It thus 
became apparent that the increase in ALA.S was unlikely to be the 
primary inherited defect. The primary cause for each type of 
porphyria could then be explained by a partial block along the 
haem biosynthetic pathway, which by impairing haem formation
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would lead to secondary induction of ALA.S (Meyer, 1973). The 
resulting overproduction of porphyrin precursors would tend to 
restore haem synthesis by increasing the intracellular 
concentration of substrate proximal to the block.
Reduced PBG.D activity in liver cells was the first primary enzyme 
defect of this type to be demonstrated in patients with AIP 
(strand et al, 1970; Miyagi et al, 1971). Subsequently this 
enzyme defect was shown to occur in all cell types studied; 
namely, erythrocytes (Meyer et al, 1972; Strand et al, 1972; Sassa 
et al, 1973), cultured skin fibroblasts (Sassa et al, 1975), 
transformed lymphocytes (Sassa et al, 1978) and cultured amniotic 
cells (Sassa et al, 1975). Expression of the mutant gene appears 
to be relatively constant in so far as the measurable enzymatic 
activity is about 50 per cent in both latent cases and in patients 
suffering from the disease (Meyer, 1973; Meyer & Schmid, 1973), 
Clinical expression of AIP however is highly variable since the 
great majority of heterozygotes remain clinically latent (McColl 
et al, 1982a). It is also established that decreased enzyme 
activity does not alter with disease activity. (Meyer 1973; Sassa 
et al, 1974).
2.4.3 Molecular basis for the enzyme defect 
As a result of studies on the inheritance of rare structural 
variants and experiments with mouse-human somatic cell hybrids 
(Wang et al, 1981) it has been possible to localise the structural 
gene for PBG.D at a single locus on human chromosome llq 23 - 
llq TER. But studies in AIP families have so far failed to link 
the PBG.D defect with known gene markers on chromosome 1, 2, 6 and 
9 (Tongio et al, 1979).
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Using anti—human PBG.D antibody recent immunological 
investigations have shown that AIP can be caused by several types 
of structural gene mutations. Anderson et al (1981) initially 
identified an immunoreactive but functionally inactive form of 
PBG.D in the red cells of 1 of 22 AIP families. This 
dysfunctional protein was detected in all five gene carriers in 
that family, and was thought to be the product of a mutant 
structural gene with different catalytic and substrate-binding 
properties. The genetic heterogeneity of AIP has been further 
characterised in Finnish patients in whom 80% of the mutations 
were of the type without cross-reacting immunological material.
The remaining patients had cross-reacting immunological PBG.D 
material of two types (Mustajoki & Desnick, 1985). One such 
non-catalytic variant was a protein that was bound to substrate 
but the resulting complex was more resistant to intra-erythrocytic 
proteolysis than the normal enzyme (Desnick et al, 1985). Such 
molecular genetic heterogeneity could well explain in part the 
variable phenotypic expression of the disease (Goldberg, 1985).
The type of mutation(s) that commonly occur in AIP patients of 
other countries remains conjectural. Other possible gene defects 
that could arise include defects in structural gene expression, 
unstable gene products, gene deletions and regulatory gene defects 
(Stanbury et al, 1983). Further intriguing evidence for genetic 
heterogeneity in AIP was provided by the recent report of normal 
erythrocyte PBG.D activity in a large family with affected members 
having all the other features of the disease (Mustajoki, 1981).
The possibility of an enzyme variant with an unusually high Km
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value was excluded. The results of PBG.D activity in other tissues 
pertaining to members of this family is awaited with great 
interest since failure to express PBG.D deficiency solely in 
erythrocytes may point to the existence of a gene that controls 
tissue expression of a particular structural gene.
2.4.4 Clinical features
The clinical manifestations of the acute attack in AIP are very 
similar to those of other types of acute hepatic porphyrias, with 
the exception that in hereditary coproporphyria and variegate 
porphyria photosensitive skin eruptions can also occur. Acute 
attacks are rare before puberty (Barclay, 1974). The disease 
tends to become clinically manifest between puberty and 30 years 
of age, attacks being most frequent in the third decade of life. 
There is a preponderance of female sufferers (Goldberg &
Rimington, 1962; Wetterberg, 1967). Males suffering from the 
disease tend to do so later than females (on average 10 years) 
(Stein & Tschudy, 1970). But serious attacks can occur in either 
sex for the first time at any age. In a third of reported cases 
no family history can be obtained, the disease presumably having 
remained latent in the preceding generation or arising from a new 
mutation (Wetterberg, 1967).
Abdominal pain is the most frequent presenting complaint being the 
initial symptom in more than 90% of the acute attacks 
(Waldenstrom, 1957; Goldberg, 1959; Stein & Tschudy, 1970). 
Location of pain over the abdomen can vary from patient to patient 
and from attack to attack in the same patient. It frequently fails 
to conform to any particular neuroanatomical distribution. The
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pain is often diffuse but it can be quite localised, especially to 
the lower part of the abdomen. The intensity of pain can be very 
severe and commanding. Patients often describe the pain as 
"nagging" and "unremitting"; it can also acquire a colicky 
character. Back pain in the lumbar region is a common feature, 
but there is no renal tenderness. Constipation frequently 
accompanies, or may even precede, the abdominal pain but in 10% of 
cases diarrhoea may occur (Goldberg & Rimington, 1962). Nausea 
and vomiting, at times severe and protracted can cause a problem 
with oral fluid intake.
Palpation of the abdomen characteristically reveals a mild degree 
of generalised tenderness which is much less than would be 
expected from the severity of the pain. Some abdominal distention 
with reduced bowel sounds may be present. Ileus can be 
precipitated by administration of narcotic analgesics or drugs 
with anticholinergic action. Muscle guarding is seldom 
encountered. The presence of rebound tenderness should alert the 
clinician to the possibility of peritonitis from other cause. The 
episodes of abdominal pain usually settle spontaneously after a 
few days unless there is persistence of some precipitating 
factor. For a few unfortunate patients, however, the pain can 
linger on for weeks or months despite treatment.
Mo_^ox weakness is the other major feature of the acute attack in 
some 60% of cases (Goldberg, 1959). The peripheral extensor 
muscles are often the first to be affected resulting in wrist or 
foot—drop (Fig 6). At times weakness can initially affect the 
proximal limb muscles, being more prominent in the arms than in
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Figure 6 : This 27-year-old woman suffering from AIP
developed severe quadriparesis within a 
week of the onset of abdominal pain
the legs (Ridley, 1969). Its progression is usually gradual but 
occasionally flaccid paralysis of all extremities can rapidly 
occur within a matter of days (Brezis et al, 1979; Menewat et al,
1979). During the early stages tendon reflexes can be little 
affected but when the neuropathy is advanced reflexes are 
decreased or absent. Unexplained paradoxical preservation of the 
ankle reflexes has been noted in the presence of quadriparesis 
(Ridley, 1969). In addition the patient often complains of limb 
pain accompanied by muscle tenderness. Fasciculation does not 
occur. Severe wasting can progress rapidly. The serum muscle 
enzymes however remain normal (Stein & Tschudy, 1970). Abdominal 
pain and sinus tachycardia nearly always precede the paralytic 
manifestations, sometimes by several weeks (Ridley et al, 1968). 
Conversely slowing of the tachycardia signals subsidence of the 
acute attack. The onset of motor weakness indicates that an 
attack is likely to be more prolonged and debilitating. Isolated 
ptosis and lower motor neurone involvement of the cranial nerves, 
especially of the seventh and tenth, can rarely occur.
Progression of muscle weakness can lead to bulbar palsy and 
eventually respiratory paralysis. These dreaded complications 
have been responsible for most deaths (Goldberg & Rimington,
1962). Case-reports of blindness due to optic nerve (De Francisco 
et al, 1979) or occipital lobe involvement (Lai et al, 1977) have 
been reported in the acute attack. In some cases complete 
recovery from the muscle weakness can take place within days but 
in others it may take several months or years (Sorensen & With, 
1971). The more severely affected patients often have persistent
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wasting of their hand muscles, and eventually develop claw-like 
contraction deformities of their fingers. (Fig 7)
^ensorx .symp_tom2 including paraesthesiae and numbness are less 
common than motor involvement. Although the symptoms may be 
suggestive of a stocking and glove type of neuropathy, objective 
signs of sensory deficit are usually sparse and patchy in 
distribution. Sensory involvement may also have a proximal 
distribution with a bizarre pattern of sensory loss over the 
"bathing trunk" or "long johns" area. Alternatively it may be 
confined to a wide band around the upper arms and thighs when the 
sensory loss may extend from the hips to the knees "as if a pair 
of bathing trunks had slipped" (Ridley, 1984). Loss of touch and 
pain sensation are the most commonly affected modalities. 
Impairment of vibration sense is less frequent, and joint position 
sense is mostly preserved.
Cerebral disturbance can trigger tonic-clonic seizures in the 
absence of other metabolic or structural abnormalities (Ridley,
1969). ^Rarely abnormal movement disorders have been attributed to 
basal ganglia involvement but in such cases drug-induced 
dyskinesia, especially caused by the phenothiazines, must be 
excluded. No abnormalities have been found in the cerebro-spinal 
fluid except for an occasional mild increase in its protein 
content (Stein & Tschudy, 1970).
Features of ^ujtonomic. dy^func.ti.on are frequent during the acute 
attack (Goldberg, 1959). Sinus tachycardia rising to 160 
beats/minute may occur. Hypertension usually accompanies the 
tachycardia and is characteristically labile. Rarely it can reach
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Figure 7: Long-term sequelae of acute porphyria:
wasting of the hand muscles especially 
affecting the extensors leading to 
claw-like deformity of the fingers.
In this photograph patient was attempting 
to straighten the fingers and wrist.
levels at which retinal exudates appear (Fig 8), The patient may 
become unduly restless, sweat profusely and display fine tremor of 
the extremities. Interestingly these sympathomimetic features are 
often accompanied by increased urinary catecholamine excretion 
(Schley et al, 1970; Beattie et al, 1973a;Beal et al, 1977). A 
low-grade fever is not uncommon during the severe attacks. But 
its presence necessitates the exclusion of any underlying 
infection, such as a urinary tract infection, which could have 
precipitated the acute episode in the first instance. A white 
cell count may be useful since leucocytosis is generally absent in 
acute porphyria.
M^d^ex can cause urinary retention, or conversely,
frequency and urgency of micturition. The urinary output is 
invariably low unless vigorous measures are taken to ensure 
adequate fluid replacement.
A wide spectrum of 2.s%c_ho_lo_g^ ic_aJL Ais.tiir^ ance.s and p^ c.h_ia_trj,c 
manifestations ha^ been reported in patients suffering from an 
acute attack (Wetterberg, 1967). Depression is particularly 
frequent. An organic brain syndrome can cause excessive 
irritability, confusion, disorientation, delusions and 
hallucinations. But when some of these mental manifestations such 
as chronic anxiety, depression or emotional lability persist after 
the attack has otherwise settled both biochemically and clinically 
their relationship to porphyria becomes difficult to evaluate. In 
such instances other causes like drug dependence have to be 
considered. Despite previous claims a controlled study could not 
confirm that psychogenic factors constitute a significant
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Figure 8: Hypertensive retinal exudates developing
during an acute attack in a 31-year-old 
woman with AIP. Note accompanying 
retinal artery spasm.
precipitating factor in acute porphyria (Ackner et al, 1962).
Among the other me_tabo_lic_ and e_n_doc^ rin_e disturbances, 
hyponatraemia is the best-known complication. Although 
hyponatraemia can be caused by inappropriate ADH secretion 
(Heilman et al, 1962) it is more commonly the result of protracted 
vomiting and inadequate or inappropriate fluid and electrolyte 
balance (Bales et al, 1971). Patients with hyponatraemia should 
receive intravenous saline if associated with reduced blood volume 
and not treated with fluid restriction, as is the case for severe 
hyponatraemia due to inappropriate ADH secretion. Marked 
hyponatraemia (Na < 125 mM/L) and water intoxication per se can 
cause seizures and mental disturbances (Andreoli, 1985). Less 
well defined electrolyte disturbances have been reported; they 
include hypomagnesaemia (Heilman et al, 1962; Nielsen & Thorn, 
1965), and hypercalcaemia following prolonged immobilisation 
(Barois et al, 1977) and primary hyperaldosteronism (Basiliere & 
Newcomer, 1971). Mild glucose intolerance seems common but frank 
diabetes is rare (Waxman et al, 1967). Inappropriate release of 
growth hormone after a glucose load was initially reported 
(Perlroth et al, 1967), but this was not confirmed in a later 
study (Bonkowsky et al, 1976).
During an acute attack total serum thyroxine and tri-iodothyronine 
are sometimes increased with a concomitant rise in 
thyroxine—binding globulin (Hollander et al, 1967).
Hyperthyroidism has occasionally been reported in AIP patients 
(Mann & De Nardo, 1965) with the suggestion that it could have 
been mediated by a "neurogenic" mechanism (Brodie et al, 1978).
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AIP has also been reported in association with a variety of 
uncommon diseases mostly in the form of case—reports many of which 
were unfortunately poorly documented. These include isolated 
deficiency of ACTH secretion (Waxman et al, 1969), systemic lupus 
erythematosus (Harris et al, 1966), relapsing pancreatitis (Kobza 
et al, 1976), hypermacro-amylasaemia (Hedger & Hardison, 1971) and 
Gilbert's syndrome (Kobza et al, 1976). It has not yet been 
possible to establish whether these associations are merely 
chance-related or whether any pathogenetic links exist between 
these conditions and AIP. With regard to the endocrine 
complications of AIP, it is now known that endogenous opioids play 
a modulatory role in the synthesis and/or release of a number of 
brain hormones (Snyder, 1977; Copolov & Helme, 1983). Opioid 
agonists such as morphine facilitates the release of FSH and 
ACTH. They can also cause an elevation in serum prolactin and 
growth hormone. But since patients in whom the putative endocrine 
complications were reported received opiates and other drugs such 
as chlorpromazine, which can also disturb the endocrine system, 
many of these associations are now suspect.
Hypercholesterolaemia with an increase in low density 
B-lipoproteins has been reported in some 40 per cent of AIP 
patients whereas serum triglycerides were normal (Taddeini et al, 
1964). But neither a specific metabolic nor a genetic 
relationship could be established between hyperlipidaemia and AIP 
because the possible effect of a high calorie intake on lipid 
metabolism was not taken into account. It is interesting however 
that hyperlipidaemia could be induced in animals treated with
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chemically-induced porphyria (Taddeini et al, 1964) and in human 
subjects accidentally exposed to the porphyrinogenic 
dioxin-related chemical TCDD (Pazderova-Vejlupkova et al 1981).
hex System Involvement 
The liver has previously been reported to be histologically normal 
in AIP (Stein & Tschudy, 1970), but Ostrovski et al (1983) have 
recently described the presence of diffuse, moderately severe 
albeit non-specific ultrastructural changes in a high proportion 
of patients with the acute hepatic porphyrias. These abnormalities 
were associated with impaired aminopyrine and bile acid 
clearances. Apart from impaired bromsulphalein (Stein & Tschudy,
1970), antipyrine and bile salt clearances (Anderson et al, 1976; 
Ostrowski et al, 1983) other measurements of liver function remain 
unimpaired during the acute attack (Stein & Tschudy, 1976). These 
biochemical indicators of hepatic involvement do not appear to 
have any clinical significance.
Anaemia is not a feature of the acute hepatic porphyrias. In one 
small study, total blood volumes were found to be slightly reduced 
and red cell survival mildly shortened, but haemoglobin synthesis 
appeared normal (Bloomer et al, 1971). Patients with AIP also 
have normal rates of bilirubin production, mostly of erythroid 
origin (Jones et al, 1971).
2.4.5 Precipitating Factors
In all the acute hepatic porphyrias, the majority of affected 
individuals remain asymptomatic throughout their entire lifetime 
since partial deficiency of the haem enzymes does not necessarily 
cause impairment of haem biosynthesis. Indeed most of the latent
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cases have normal urinary excretion of ALA, PBG and porphyrins, 
indicating that little or no induction of hepatic ALA.S normally 
takes place (McColl et al, 1982a). Moreover cytochrome 
P450—mediated drug metabolism is normal in the majority of latent 
cases (Anderson et al, 1976; Ostrowski et al, 1983). It is now 
well established that certain precipitating factors can alter a 
state of latency into one which becomes clinically manifest.
Drugs and hormonal influence are the most important precipitating 
factors although in some patients alcohol, fasting and infection 
may be contributory to their attack (Goldberg & Rimington, 1962; 
Bales & Disler, 1962; Kappas et al, 1983; Moore & Disler, 1983). 
Many of these factors are known to induce ALA.S activity and 
cytochrome P450 formation in the liver (De Matteis & Gibbs,
1972). The concurrent biochemical changes which result in an 
accumulation of porphyrin intermediates indicate that acute 
attacks may develop whenever a demand for additional haem 
synthesis, such as that imposed by stimulation of cytochrome P450 
synthesis, cannot be met. This is because the rate of synthesis 
that is required exceeds the maximum activity of PBG.D. 
Consequently this leads to derepression of ALA.S, the 
rate-limiting enzyme of the pathway, causing a further increase in 
ALA and PBG formation (Meyer, 1973). As ALA and PBG accumulate 
behind the enzymatic block, loss of ALA and PBG from the 
intracellular pool also increases. In turn urinary excretion 
of these porphyrin precursors becomes correspondingly 
greater.
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Administration of certain drugs can not only precipitate the 
disease in latent cases but also exacerbate the acute attacks, 
often with the development of life—threatening neuropathy 
(Goldberg, 1959; Ridley, 1969). Some patients often appear very 
sensitive to the porphyrinogenicity of these drugs in that a 
single dose may be sufficient to induce an attack (Bales & Linder, 
1962, Bales, 1971). Paradoxically, even the worst offending 
drugs, namely the barbiturates, do not consistently lead to an 
acute attack in some porphyries (Bales, 1979).
A large number of drugs having very diverse chemical structures 
has been implicated. The only physical property they appear to 
share is their high degree of lipid solubility (De Matteis,
1978). Surprisingly perhaps, when these drugs are given to normal 
individuals or experimental animals even in therapeutically toxic 
dosage, they fail to induce a porphyric state (Smith & De Matteis,
1980) except in very rare circumstances (Chapter 11). But they 
can produce measurable changes in the haem biosynthetic pathway in 
experimental animals and cell cultures (Granick, 1966; Anderson, 
1978; De Matteis, 1978, De Verneuil et al, 1983).
Barbiturates have been the most notorious porphyrinogenic drugs 
(Goldberg, 1959). Since their use has been curtailed acute 
attacks appear to have become less frequent among populations 
where porphyria is relatively common (Kramer, 1980). Apart from 
barbiturates, anticonvulsants and alcohol (Disler & Moore, 1983) 
are among the drugs which have definitely been shown to induce 
ALA.S in human liver. Some porphyrinogenic drugs like the 
sulphonamides seem to have an additional direct inhibitory effect
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on hepatic PBG.D which can increase the enzymatic block in AIP 
(Peters et al, 1980). In some patients, the effect of drugs alone 
does not appear to be sufficient to precipitate an attack unless 
other compounding factors such as a change in hormonal milieu 
favour the induction of ALA.S. This could explain why some 
porphyric individuals remained asymptomatic despite having taken 
potentially harmful drugs in the past (Bales, 1979).
The porphyrogenicity of drugs is based on their ability to induce 
ALA.S. For this purpose either whole animals eg. rats or tissue 
cultures are used to screen drugs and chemicals that may 
constitute a risk to porphyric patients (De Matteis, 1978; 
Anderson, 1978). Chick embryo liver in ovo or in culture have 
been found to provide a particularly sensitive model for studying 
human hepatic biosynthetic control (Granick, 1966; Kappas & 
Granick, 1968; De Verneuil et al, 1983). For instance, danazol, a 
harmful steroidal drug in porphyria was shown to induce ALA.S in 
chick embryo liver but not in adult rat liver (Lamon et al,
1979). The avian-embryo hepatic-cell culture is also very 
sensitive to the permissive effects of hormones like insulin, 
tri-iodothyronine and corticosteroids (Granick & Kappas, 1967).
The sensitivity of the culture system to the ALA.S-inducing effect 
of drugs can be enhanced by primary cells initially with a small 
dose of haem pathway inhibitors. For example, DDC accentuates 
porphyrin accumulation in the liver by inhibiting ferrochelatase 
(Anderson, 1978); and AIA converts liver haem into abnormal 
products, thereby acting as a potent ALA.S inducer (Smith & De 
Matteis, 1980). In some instances, the chick embryo model seems
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to be so highly sensitive as to be irrelevant to the human 
situation (Moore & Disler, 1983). Despite the well recognised 
dangers of extrapolating the results of such experimental models 
to man, they still provide the best means of determining the 
potential porphyrinogenicity of drugs. The most valid method, of 
course, is to demonstrate that the drug in question has caused an 
acute attack in porphyric patients. For some drugs like 
barbiturates and sulphonamides the clinical evidence that has 
accumulated as to their porphyrinogenicity is beyond doubt. But 
in many instances the case-reports linking the acute attacks to 
specific drugs are too often anecdotal and lacking in relevant 
details. In others, the presence of other concomitant diseases 
and their treatments obfuscate the possibility of a causal 
relationship.
Several workers have attempted to produce lists of safe and unsafe 
drugs for use in the acute porphyrias (Rifkind, 1976; Moore & 
Disler, 1983; Kappas et al, 1983; Moore, 1985). These drugs are 
often been graded according to their estimated potential 
porphyrinogenic risks depending on the reliability and 
completeness of any available clinical details (Moore & Disler, 
1983). Unfortunately information available for certain drugs is 
conflicting and opinions of different authors vary: a good example 
is in the use of sodium valproate as an anticonvulsant (Doss et 
al, 1981; Brodie & Goldberg, 1980). These lists of drugs still 
represent a formidable collection of chemically and often 
pharmacologically unrelated agents, most of which are of doubtful 
porphyrinogenicity. But until a better screening method becomes
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available, whenever possible, any drug shown to induce ALA.S in 
the experimental models discussed should be avoided. Used in this 
way these lists of safe and unsafe drugs offer a useful guide in 
the management of patients with the acute hepatic porphyrias.
2.4.6 Hormonal influence
Undoubtedly the phenotypic expression of the genetic defects in 
the acute porphyrias is influenced by hormonal factors. This 
would explain the following observations:
1. The rarity of acute attacks before puberty (Barclay, 1974),
2. The predominance of female patients suffering from acute 
porphyria (Waldenstrom, 1957; Goldberg, 1959).
3. The phasic occurrence of symptoms in the menstrual cycle of 
a small proportion of women with the disease (perhaps 
10-20%). Actually serial measurement of leucocyte ALA.S 
activity throughout the menstrual cycle in normal women 
shows a peak prior to menstruation (McColl et al, 1982b).
4. The induction of clinical remission with agents, such as the 
luteinising-hormone-releasing-factor anologues, which 
suppress ovulation (Anderson et al, 1984).
5. The paradoxical but well-documented reports that the oral 
contraceptive hormones can affect porphyrin metabolism and 
exacerbate the disease in some women (Zimmerman et al, 1966) 
while suppressing disease activity in others (Perlroth et 
al, 1965).
6 . Reports of activation of the disease during pregnancy 
(Brodie et al, 1977c).
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7. Alterations in steroid hormone metabolism in symptomatic
patients with AIP which favour the excessive production of 
steroid hormone metabolites shown experimentally to be 
potent hepatic ALA.S inducers (Granick & Kappas, 1967).
When tested experimentally, steroidal hormones with the 5)B-H 
configuration structurally have been found to be potent inducers 
of ALA.S whereas those with the 5c<-H configuration have tended to 
be inactive in that respect (Bradlow et al, 1973). Steroids with 
a double-bond in the 4-5 position can be reduced in the liver 
either to the 5jB-H or 5c<-H derivatives by two different enzymes: a 
soluble 5p reductase and an endoplasmic reticulum 53-reductase.
The majority of symptomatic AIP patients, and not the latent 
cases, have been shown to have about a 50% reduction in the 
activity of hepatic 5d.-reductase (Anderson et al, 1979). This 
second enzyme defect cannot be explained on the basis of the haem 
pathway abnormality per se since it is absent in the other 
porphyrias (Kappas et al, 1972). Family studies have further 
confirmed that it is an acquired abnormality, but how this comes 
about remains enigmatic (Kappas et al, 1983). This decreased 
5*-reductase activity seems confined to the liver which 
biotransforms the bulk of steroidal hormones, and not to other 
organs like the skin. Impairment of 5&—reductase favours the 
compensatory formation of the more porphyrinogenic 5-)B steroidal 
metabolites. Best known among these are aetiocholanolone and 
androstenedione (Paxton et al, 1974). Thus it is now clear that 
both exogenous or endogenous steroid hormones may be 
porphyrinogenic.
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The situation in pregnancy is complex because maternal, placental 
and foetal tissues all play a role in steroid hormone production 
and metabolism. Although acute attacks can occur during pregnancy 
(Brodie et al, 1977c) the outcome for both mother and child is 
good. Whereas Stein & Tschudy (1970) reported that pregnancy did 
not significantly affect the disease in 72 of 74 instances,
Brodie et al (1977c) found that 54% of 50 AIP women had an acute 
attack during pregnancy or the puerpurium. In the latter series 
there was only one recorded maternal death and foetal wastage was 
not increased. Despite the huge increase in serum concentrations 
of sex hormones in pregnancy, attacks are perhaps less frequent 
than expected because these steroids appear to be preferentially 
reduced to the 5c<-compounds instead of their 5p-analogues.
2.4.7 Diagnosis of AIP
During the acute attack, with the exception of homozygous ALA.D 
deficiency (Doss et al, 1982b), patients suffering from all types 
of acute hepatic porphyrias excrete excessive amounts of ALA and 
PBG in their urine. In those latent cases who are already 
excreting porphyrin precursors excessively, a further increase 
will occur during the exacerbations (Ackner et al, 1961). Urinary 
porphyrins will also be increased depending on the site of 
enzymatic block, but the presence of uroporphyrin may partly be 
due to its non—enzymatic formation from condensation of PBG. But 
since urinary porphyrins are predominantly of the III isomer 
series they are probably derived from the metabolism of porphyrin 
precursors in non—hepatic tissues such as the kidney (Day et al,
1981). In freshly voided urine PBG is a colourless compound, but
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upon exposure to light it turns to reddish-brown. This follows 
the spontaneous non-enzymatic conversion of PBG to porphyrins and 
other pigments such as porphobilin, a degradation product. 
Spontaneous oxidation of the porphyrinogens to porphyrins also 
contribute to this dark hue.
The presence of PBG can be rapidly tested by the Watson-Schwartz 
test. This is performed by first mixing equal volumes of urine 
and Ehrlich's aldehyde reagent -dimethylamino-benzaldehyde in 
hydrochloric acid). Sodium acetate is then added to pH4, followed 
by an extraction step with chloroform or butanol. If PBG is 
present, it forms a pink or red water-soluble complex. 
Urobilinogen also forms a red complex, but one which is soluble in 
the organic solvent following the extraction step (Watson & 
Schwartz, 1941). A less sensitive variation of the 
Watson-Schwartz test is the Hoesch test. It is performed by adding 
urine drop by drop to a large volume of acid Ehrlich's reagent.
If PBG chromogen is formed it becomes easily visible by its dark 
colour whereas urobilinogen fails to produce any significant 
colour change (Pierach et al, 1977a).
These simple bed-side tests remain very useful for diagnosing the 
disease during acute attacks.
If a positive Watson-Schwartz or Hoesch test is obtained 
quantitative measurement of PBG should be carried out.
In addition to urinary PBG the most useful method of confirming 
the diagnosis of AIP is by erythrocyte PBG.D activity assay (Sassa 
et al, 1974; Magnussen et al, 1974; Piepkorn et al, 1978). 
Unfortunately there is much overlap in the range of values for
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PBG.D (up to 30%) between normal and AIP individuals (McColl et 
alj 1982a; Bissell, 1982). Consequently some porphyric patients 
will fall within the low normal range. Since PBG.D activity is 
increased several-fold in newly produced reticulocytes and 
declines with ageing of the red cells (Anderson et al, 1977), 
interpretation of results must take these factors into account.
By combining the measurement of erythrocyte PBG.D and leucocyte 
ALA.S detection of the latent state in AIP can be increased to 90% 
(McColl et al, 1982a). Measurement of leucocyte ALA.S, however, 
is only available in few specialist laboratories.
2.4.8 Prognosis
With greater recognition and avoidance of porphyrinogenic drugs, 
and better supportive therapy for those in acute attacks the 
prognosis has greatly improved. In contrast to previously 
reported high mortality rates eg. 18 to 33% (Waldenstrom, 1957; 
Ridley, 1969; Sorensen & With, 1971), fatalities from an acute 
attack are now rare (Kramer, 1980; Ridley, 1984).
2.5 PORPHYRIA VARIEGATA (Variegate Porphyria)
2.5.1 Introduction
Porphyria Variegata (VP) is the name given by Dean & Barnes (1955) 
to a type of porphyria commonly seen in White South Africans of 
Afrikaan descent. It was first described by Van der bergh. The 
disease is inherited as an autosomal dominant trait. In a 
remarkable epidemiological study Dean (1971) traced back this 
familial disorder among White South Africans to an early Dutch 
settler who had married an orphan girl in Cape Town in 1688. VP
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has now been reported in many parts of the world. Its prevalence 
varies from country to country: in Finland it was estimated at 1,3 
per 100,000 population whereas in South African Whites it was 300 
per 100,000 (Mustajoki, 1978; Dean, 1971).
2.5.2 Underlying Biochemical Abnormality
Ferrochelatase activity was initially reported to be decreased by 
about 50% of normal in the fibroblasts and normoblasts of patients 
with the disease (Becker et al, 1977a). But other workers were 
unable to confirm this finding in leucocyte huffy coat 
preparations (Brodie et al, 1977a) and skeletal muscle (Pimstone 
et al, 1973). More recently Brenner and Bloomer (1980a) have 
measured the activity of ferrochelatase and protoporphyrinogen 
oxidase in cultured skin fibroblasts. Ferrochelatase activity was 
found to be normal whereas protoporphyrinogen oxidase was 
decreased to about 50% of normal, suggesting that 
protoporphyrinogen oxidase was the primary enzyme defect in VP. 
This observation has now been confirmed by others (Deyback et al,
1981). Nevertheless there is evidence in the South African cases 
of VP (and EPP) that a combined deficiency of protoporphyrinogen 
oxidase and ferrochelatase can exist (Viljoen et al, 1983). In an 
autopsy report Yamada et al (1984) described a patient with the 
porphyrin profile of VP and ferrochelatase deficiency, in whom 
PBG.D was also depressed. A family with homozygous VP in two 
siblings has recently been recognised by Korda et al (1984). Both 
children had photodermatosis and severe neurological disturbances 
from birth.
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The most characteristic biochemical finding in VP is a marked 
increase in faecal protoporphyrin IX accompanied to a lesser 
extent by an increase in coproporphyrin III (Elder, 1980; Bissell, 
1982).
There is also a considerable increase in some hydrophilic 
porphyrin-peptide conjugates called the X-porphyrin (Rimington et 
al, 1968). Indeed the excretory findings in VP are more 
consistent with protoporphyrinogen oxidase deficiency, causing an 
accumulation of protopophyrinogen which is rapidly oxidised to 
protoporphyrinogen in the stools. Intracellular oxidation of 
protoporphyrinogen in the presence of peptides with free-SH groups 
in the liver can account for the X-porphyrin.
As in the other acute hepatic porphyrias, excessive amounts of ALA 
and PGB are excreted in the urine during acute attacks.
2.5.3 Clinical features
The clinical features of the acute attack in VP are similar to 
those described for AIP regarding abdominal pain and 
neuropsychiatrie symptoms. In addition patients with VP can 
develop skin manifestations. In the absence of skin lesions it is 
often possible to obtain a family history of increased skin 
fragility (Mustajoki, 1978; Kramer, 1982).
2.5.4 Dermatological manifestations
Skin lesions can be the initial symptoms of the disease (Eales, 
1960). These occur on sun-exposed areas; namely the face, arms 
and back of hands. Most characteristic is the increased skin 
fragility which can be easily damaged by relatively minor trauma. 
Lesions usually start as erythematous patches and progress into
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vesicles and bullae. Haemorrhage can occur into these bullae 
which will eventually heal leaving scars. Development of milia is 
also typical: milia are small, yellowish-white, spherical
subepidermal papules varying from 1 to 5 mm in diameter. Other 
skin changes include hyperpigmentation, hirsutism, especially over 
the face and less commonly pseudo-sclerodermatous changes. A 
history of direct sensitivity to sunlight is somewhat uncommon, 
even though photosensitivity can be clearly demonstrated by light 
testing in the majority of these cases (Mustajoki & Koskelo,
1976). Histological examination of the skin typically shows the 
presence of an amorphous material around the smaller dermal 
vessels and capillaries. This substance which is strongly PAS 
positive is rich in 1:2 glycerol groups, as in neutral 
mucopolysaccharides or mucoproteins (Epstein et al, 1973).
2.6 HEREDITARY COPROPORPHYRIA
2.6.1 Introduction
Hereditary coproporphyria (HC) was described by Berger and 
Goldberg (1955) when they reported four cases in a Swiss family.
HC appears to be the least common type of the acute hepatic 
porphyrias in Britain. The exact prevalence is not yet known for 
any country. It is transmitted as an autosomal dominant trait, 
but recently a rare homozygous form of the disease with a more 
florid clinical expression has been recognised (Grandchamp et al, 
1980).
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2.6.2 Biochemical features
The primary enzyme defect in coproporphyrinogen oxidase activity 
can be demonstrated in the white cell huffy coat preparations 
(Brodie et al, 1977d), cultured skin fibroblasts (Elder et al, 
1976) and lymphocytes (Grandchamp et al, 1980). In the 
heterozygous form, enzyme activity is reduced to about 50% of 
normal and in the rare homozygous state to 2-3%. It is surprising 
that even with gross enzyme deficiency in the homozygous states 
haem formation seems normal whether the rate rather than the 
amount of haem formed is impaired remains to be seen. HC is 
characterised by an excessive urinary and faecal excretion of 
coproporphyria III. Urinary ALA and PBG excretion is also 
increased. In the latent phase, however, faecal coproporphyrins 
are much increased at a time when urinary porphyrin precursor 
excretion is often normal (Elder, 1980).
2.6.3 Clinical findings
The acute attacks with abdominal pain and neurodysfunction are 
similar to those described for AIP and VP; but they tend to be of 
milder severity (Brodie et al, 1977d). The skin manifestations 
resemble those of VP. Unlike VP, the skin lesions seldom occur 
without the other biochemical or clinical manifestations of an 
acute attack.
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SECTION I
CHAPTER 3
MANAGEMENT OF THE ACUTE ATTACK OF PORPHYRIA
3. MANAGEMENT OF THE ACUTE ATTACK OF PORPHYRIA
3.1 INTRODUCTION
The first step is to remove or correct any potential 
porphyrinogenic factor whenever possible. The most common 
precipitating factors are certain drugs (Moore & Disler, 1983; 
Goldberg et al, 1983), alcohol (Doss et al, 1982), fasting (Stein 
& Tschudy, 1970), hormonal influence (Welland et al, 1964; Paxton 
et al, 1974) and infection (Eales & Linder, 1972), A careful 
history is important in identifying a precipitating cause because 
exposure to the porphyrinogenic agent may be quite subtle as was 
the case in the surreptitious ingestion of a mouthwash preparation 
containing eucalyptol (Bickers et al, 1975).
There are two aspects to the treatment of the patient:
(I) to provide symptomatic and supportive therapy until the 
attack subsides spontaneously, as it does in the majority of 
cases within a few days;
(II) to modify the course of the disease so as to curtail the 
present attack or to prevent future attacks.
3.2 SYMPTOMATIC AND SUPPORTIVE THERAPY are directed at 
controlling pain, ensuring an adequate fluid and nutritional 
intake, providing appropriate physiotherapy, and last but not 
least, maintaining the patient's morale.
Pain control
For most patients, abdominal pain is the main problem. It often 
radiates to the back and is accompanied by pain in the limbs.
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Typical abdominal examination reveals few physical signs; the limb 
muscles may be tender to palpation.
Many patients are able to control their abdominal pain with simple 
analgesics such as paracetamol, aspirin or dihydrocodeine. But 
when the pain becomes more severe, opiate analgesics such as 
pethidine or morphine are needed. Buprenorphine, the long-acting 
synthetic opiate is also useful given sublingually or 
intramuscularly, but in our experience often worsens vomiting. In 
a prolonged attack the patient's response to the severe pain may 
change to the pattern of behaviour now recognised in other chronic 
pain situations (Sternbach, 1974). This is where the patient may 
not look particularly distressed while experiencing and 
complaining of great discomfort. In such instance, the lack of 
sympathomimetic features expected of severe acute pain can cause 
withdrawal of sympathy from inexperienced attending medical and 
nursing staff. Management of the patient can be very difficult 
for the clinician when he is confronted with increasing demands 
for opiate analgesics in a disease where psychological 
disturbances commonly occur, compounded by the failure to provide 
adequate pain relief with large doses of opiates. The constant 
request for analgesia often raises the suspicion of drug 
addiction. But this danger only exists for those few patients 
with frequent attacks requiring large doses of narcotic drugs 
outside hospital. It is therefore important that every attempt 
should be made to withdraw all opiate drugs during the remission 
periods. For a few unfortunate patients pain relief cannot be 
obtained during the waking hours despite administration of large
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doses of narcotic agents, even by intravenous infusion (Chapter 
9). The patient is therefore encouraged to sleep, undisturbed, 
but under constant supervision, in a quiet room. This can be 
achieved by combining standard dosage of opiates with a 
phenothiazine drug.
a^iis_ea and vomiting usually accompany the abdominal pain. In some 
cases it can be very severe, especially following the 
administration of opiate analgesics. These symptoms may be 
controlled with chlorpromazine, promazine or prochlorperazine. 
Metoclopramide is best avoided because of possible 
porphyrinogenicity (Doss et al, 1981). If vomiting is protracted 
the patient often becomes dehydrated and oliguric.
Constipation, a regular feature of the disease, is made worse by 
the reduction in food and fluid intake, correction of which often 
remedies the situation. If there is faecal impaction, "Bisacody” 
suppositories can be used, failing which a phosphate enema is 
indicated. Oral neostigmine is considered safe to combat the 
constipation, but is better avoided because of its other 
cholinergic side-effects.
Hyponatraemia and hypochloraemia commonly occur. These 
e.le.c^ r^o.lxte. disturbances are more frequently due to inadequate 
fluid and electrolyte replacement rather than to inappropriate 
anti-diuretic hormone (ADH) secretion. Differentiation between 
these two causes of hyponatraemia is important since inappropriate 
ADH secretion may require fluid restriction whereas hyponatraemia 
associated with volume—contracted states intravenous saline 
(Andreoli, 1985). It is desirable for the patient to have a
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urinary output of at least 1500 ml daily. Since better methods of 
nutritional support have become available a state of cachexia can 
be prevented in porphyric patients. Carbohydrate intake in the 
form of dextrose (Perlroth et al, 1968; Bonkowsky et al, 1976) or 
laevulose (Brodie et al, 1977b) has been shown to modify the acute 
attack both clinically and biochemically. It is recommended that 
at least 2500 Kcal should be given daily including a minimum of 
400 gram of carbohydrate. Should the patient feel nauseated or 
anorexic and cannot take an adequate carbohydrate intake by mouth, 
the supplements can be given with minimal discomfort via a 
fine-bore nasogastric tube. High content carbohydrate solution is 
conveniently available in proprietary preparations such as "Hycal" 
(Beecham products) or "Caloreen" (Roussel). For longer term 
treatment we have found "Clinifeed" (Roussel) which also contains 
protein and vitamin supplements to be particularly useful. In 
selected cases the patient has been successfully managed with 
naso-gastric feeding at home over a period of several weeks. The 
successful use of naso-gastric feeding has obviated the need for 
the parenteral administration of nutrients in many of our casesp 
(J^ à^ since a low-grade pyrexia is a common feature in the more 
severe attacks of acute porphyria (Waldenstrom, 1957; Goldberg, 
1959; Bales & Linder, 1962) an intravenous access with its risks 
of infection is to be avoided. Furthermore intravenous infusion 
of 2 litres of hypertonic solution containing 20% glucose, 
dextrose as laevulose daily necessitates its administration 
through a central venous line. Otherwise it has a thrombogenic 
effect on the peripheral veins. It has been our experience that
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the timely use of supplementary feeding aborts the onset of the 
paralytic phase.
Mu^ cJL.e__w^ alcne.s^  and limb paralysis require appropriate 
physiotherapy and splinting to prevent contractures and 
overstretching of tendons (Figures 9 and 10). Passive exercises 
should be started as early as possible during the acute phase 
proceeding to a programme of active movements until full recovery 
has taken place. Although muscle weakness can rapidly recover 
after the acute attack, in some cases it may take several months 
or years (Sorensen & With, 1971).
With the onset of muscle weakness lung function must be monitored 
to forestall the possibility of ^Âr^t_or% f^ all^ re,. The Wright
Peak flow rate meter provides a useful method of assessing the 
patient's ventilation sequentially. At the earliest signs of 
respiratory embarrassment, arterial blood gases must be checked, 
and assisted ventilation considered. Patients who have required 
intermittent positive pressure ventilation can eventually make a 
full neurologic recovery (Brezis et al, 1979).
The autonomic manifestations such as hypertension and _ta_ch%c^rdi^ 
can be controlled with B—adrenergic blockers, and much of the 
accumulated experience relates to propranolol (Beattie et al, 
1973a; Atsmon & Blum, 1970; Menewat et al, 1979). Recently the 
more selective B^—adrenergic blocker, atenolol, has been reported 
to be safe in AIP (Moore, 1985). Propranolol must be started at 
low dosage ie 10 mg tds because some patients appear to be unduly 
sensitive to its hypotensive effect (Bonkowsky et al, 1974). The 
high degree of first-pass hepatic metabolism for propranolol makes
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Figure 9 : Shows bilateral wrist-drop due to severe
weakness of the extensor muscles during 
an attack of AIP.
Figure 10: Physiotherapy and splinting are important
in preventing contractures. Movable 
finger splints as illustrated here are 
particularly useful.
prediction of B-blockade response particularly difficult. But 
large daily dosages of up to 168 mg intravenously and 960 mg 
orally have occasionally been employed to curtail an attack 
(Douer et al, 1978).
Of the psychological disturbances depression, often accompanied by 
insomnia and emotional lability, frequently plagues the patient. 
With good nursing care no specific drug treatment is usually 
required provided pain relief is adequate. Benzodiazepine drugs 
such as diazepam and chlordiazepoxide must be avoided whenever 
possible because of alleged porphyrinogenicity (Bonkowsky et al, 
1980). Chloral hydrate has been found useful in treating insomnia 
(Goldberg & Rimington, 1962; Bales & Linder, 1962). Less 
commonly, frank s^_ych,i_at_ric manifestations such as hypomania, 
hallucinations or an acute organic brain synchrome may necessitate 
the use of psychotropic agents like chlorpromazine. Phenothiazine 
drugs are also useful adjuncts to opiate analgesics but postural 
hypotension can complicate treatment, especially when combined 
with B-adrenergic blockers.
Seizure. c.ont^ o_l Anticonvulsant therapy is not necessary for 
treating the occasional seizure that occurs during an attack 
unless it is prolonged. Other causes such as water and 
electrolyte disturbances or coincidental meningitis must first be 
excluded before attributing seizure activity to the acute 
porphyria. Prolonged seizures can be stopped with intravenous 
diazepam. The established anticonvulsants like phenobarbitone, 
primidone, phenytoin and carbamazepine are all unsafe (Magnussen 
et al, 1975; Moore & Disler, 1983). Indeed before this danger was
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appreciated barbiturate use was the commonest precipitating factor 
that lead to fatal attacks (Hierons, 1957; Goldberg, 1959; Bales & 
Linder, 1962; Goldberg & Rimington, 1962). Paraldehyde (Goldberg 
& Rimington, 1962; Reynolds & Miska, 1981), intravenous magnesium 
sulphate (Taylor, 1981) and oral sodium bromide (Bonkowsky et al, 
1980) have all been employed for controlling seizure during the 
acute attack of AIP but long-term treatment with these agents is 
impractical and in the case of sodium bromide carries the risk of 
bromism. Although benzodiazepines and sodium valproate do not 
appear to induce the hepatic mixed-function mono-oxygenase system 
they exhibit some porphyrinogenic properties in experimental 
testing models (Shedlofsky & Bonkowsky, 1984). Thus maintenance 
anticonvulsant therapy in the porphyric patient who also suffers 
from epilepsy remains unsatisfactory. Use of any of the currently 
available drugs entails a calculated risk of porphyrinogenicity.
On balance, clonazepam (Larson et al, 1978) and sodium valproate 
(Biagini et al, 1979; Houston et al, 1977; Brodie & Goldberg,
1980) have been recommended as first—line drugs but these have not 
gained general support (Shedlofsky & Bonkowsky, 1984; Lai, 1981; 
Doss et al, 1981).
3.3 DISBASB-MODIFYING THBRAPY
Numerous remedies have previously been tried in an attempt to 
modify the course of the disease, but only two such treatments 
have been properly evaluated and found to be effective, high 
carbohydrate and haematin therapy. Hormonal manipulation, at 
present in the experimental state, promises to be useful in 
selected cases. Successful claims for the other treatments are
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based on anecdotal case reports and small, uncontrolled, often 
badly—documented studies; these remain unproven at best.
3.3.1 High Carbohydrate therapy
Following the observation that a high carbohydrate intake can 
reduce urinary porphyrin precursor excretion in experimental 
AIA-induced porphyria (Rose et al, 1961) it was shown that human 
AIP (Welland et al, 1964a; Felsher & Redeker, 1967) and VP 
(Perlroth et al, 1968) responded in a similar way to changes in 
diet. Refined carbohydrate in the form of glucose, dextrose 
(Bonkowsky et al, 1976) or laevulose (Brodie et al, 1977b) have 
been used therapeutically. A high dietary protein content 
(Welland et al, 1964a) and glycerol supplementation (Bonkowsky et 
al, 1976) have also been found to be effective but an increased 
dietary fat content (Bonkowsky et al, 1976) did not confer such 
benefit. Reduction in the urinary excretion of ALA and PBG by a 
high carbohydrate intake in acute porphyria is an example of the 
so-called "glucose effect" where glucose can inhibit the induction 
of certain hepatic enzymes, in this case ALA-synthase (Tschudy et 
al, 1964; Marver et al, 1966). The precise mechanism of the 
"glucose effect" remains speculative (Goldberg, 1974). The 
biochemical and clinical results of a high carbohydrate regime 
have ranged from a dramatic improvement to little or no effect on 
either (Bonkowsky et al, 1976; Dhar et al, 1975; Lamon et al,
1979). The factors governing this inter-individual response have 
not yet been identified.
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3.3.2 Haematin therapy
The interaction between haem and ALA was originally observed in 
bacteria by Lascelles (1960). Following the initial report that 
haematin administered intravenously to experimental animals 
repressed hepatic ALA-synthase (Waxman et al, 1966). Bonkowsky 
and his associates (1971) showed that the same effect could be 
obtained in an AIP patient treated for 2 days with haematin by 
causing a marked diminution of serum and urinary porphyrin 
precursors.
Haematin is prepared from haemin, a chloride derivative of 
haemoglobin extracted from out-dated hepatitis B-negative human 
blood (Pierach, 1982). The final haematin preparation must be 
sterile, and free from pyrogens and proteins. At present haematin 
can only be administered intravenously since early studies with 
oral preparations have been inconclusive (Lamon et al, 1979). 
Haematin therapy is given as repeated intravenous boluses. It has 
consistently lowered both plasma and urinary ALA and PBG in the 
majority of patients receiving it (Watson et al, 1977; Dhar et al, 
1975; Lamon et al, 1979; McColl et al, 1981).
A rebound elevation in the serum and urinary porphyrin precursors 
occurs after haematin therapy, but this does not appear to induce 
a clinical relapse. In contrast to the consistent biochemical 
improvement, clinical response has been more variable although 
generally considered to be favourable. Pierach(1982) reported 
clinical benefit following 91% of the haematin transfusions 
administered to 104 porphyric patients whereas McColl et al (1981) 
noted improvement in only 50% of their patients. The beneficial
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response has often been of a partial nature. Therefore in a 
disease like porphyria, characterised by spontaneous remissions 
and relapses, it may not be possible to assess the true result of 
therapy unless a controlled clinical trial is conducted. None has 
been carried out so far, and consequently enthusiasm for haematin 
therapy has varied amongst the centres treating these disorders. 
Undoubtedly, some severely ill patients can make a dramatic 
recovery following such treatment (Brezis et al, 1979; Menawat et 
al, 1979) but it does not always prevent a fatal outcome (Lamon et 
al, 1979). Two main reasons have been given to account for the 
failure to respond clinically to haematin infusions (Pierach,
1982). First haematin could have been given too late in the 
course of the attack. Once the neurones become structurally 
damaged any recovery will invariably be slow, thus masking the 
potential benefit of such short-term therapy. Second, haematin 
could have been administered in insufficient amounts or over too 
short a period of time. Earlier administration of haematin is now 
being advocated by some workers (Pierach, 1982) since the acute 
neurological features appear to respond better than the chronic 
neurological manifestations of the disease (Bosch et al, 1977; 
Lamon et al, 1979). Haemin has also been reported to promote 
neurite outgrowth from cultures of embryonic (Bonyhady et al,
1982) and neoplastic (ishii & Maniatis, 1978) nerve tissue from 
experimental animals. This neurotrophic property of haemin is 
unlikely to confer any immediate clinical benefit when used for 
only a few days, but given over longer term it could possibly 
fulfil this potential (See Chapter 7). The availability of an
53
oral preparation would be necessary for this purpose. In this 
context it is pertinent to note that haem has been found to 
stimulate formation and stabilisation of mitochondrial membranes 
in vitro (Gopalan et al, 1984).
Haematin solution has caused troublesome phlebitis in some studies 
(McColl et al, 1981; Lamon et al, 1979) but not in others 
(Pierach, 1982). It must therefore be administered with care via 
a large peripheral vein, or preferably through a central venous 
line. When given at the recommended dosage, 4 mg/kg B Wt/day at 
12 hourly intervals for a 4 to 7 day course, serious side-effects 
are infrequent (Pierach, 1982). Transitory acute renal failure 
has been reported in one case given relatively large doses of 
haematin (Dhar et al, 1978). A transient disturbance of
coagulation (Pierach, 1982; Morris et al, 1981) and a temporary
fall in platelets (Morris et al, 1981) have been encountered.
When examined in vitro haematin has been shown to aggregate 
platelets, inactivate thrombin and induce the release of serotonin
and adenosine triphosphate (Glueck et al, 1983). Experimental
studies have indicated that haemin binds to a variety of 
haemostatic proteins and inhibits their biological activities 
(Green et al, 1983). Haematin-induced haemolysis has been 
reported in a 32—year old woman (Petersen & Pierach, 1984) 
probably due to a direct effect on the erythrocytic membrane (Chou 
& Fitch, 1980). It can also promote DNA scission in vitro (Aft & 
Mueller, 1983) but to date no such reaction has been reported with 
human DNA.
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3.3.3 Phenothiazines
In 1956, Melby et al considered chlorpromazine and promazine to be 
the most effective drugs then available to alleviate the pain and 
other manifestations of acute porphyria, a view shared by other 
workers (Goldberg, 1959; Stein & Tschudy, 1970). Their mode of
action was attributed to their anti-cholinergic and
anti-adrenergic effects since they did not reduce the urinary 
excretion of porphyrin precursors (Melby et al, 1956). Monaco et 
al (1957) reported that chlorpromazine did not improve established 
paralysis although it provided good symptomatic relief. 
Paradoxically, neostigmine with its cholinergic activity, was also 
advocated with the belief that porphyrins might interfere with 
acetylcholine synthesis and function at the neuromuscular junction 
(Berg, 1945; Gordin, 1948). Ganglion-blocking drugs have also 
been used in an anecdotal fashion (Wehrmacher, 1952), but the 
ability of all these agents to modify the course of the disease
seems very dubious (Goldberg & Rimington, 1962).
3.3.4 Glucocorticosteroids
Urquhart (1898) originally thought of using suprarenal extract 
after adrenal disease had been seen in association with acute 
porphyria. Subsequently, corticotrophin and cortisone therapy 
have been reported to be of doubtful benefit (Goldberg &
Rimington, 1962; Eales & Linder, 1962). At present there is no 
rational basis for using glucocorticosteroids in porphyria 
although anecdotal claims of success are still appearing in the 
literature (Jusic et al, 1976; Sôstarko & Jusic, 1979).
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3.3.5 Vitamin E
Following the observation that the anaemia of vitamin E deficiency 
was related to a defect in haem biosynthesis (Porter & Fitch,
1966) Murty & Nair (1969) showed that Vitamin E could depress the 
urinary excretion of porphyrin precursors in AIA-induced 
experimental porphyria. In an uncontrolled study of four 
patients, Nair et al (1971) subsequently reported that a similar 
beneficial effect could be obtained in porphyric patients treated 
with vitamin E. Pre-treatment blood vitamin E levels in these 
patients were found to be sub-normal but other possible causes for 
this finding were not satisfactorily excluded. The neuropathy of 
vitamin E deficiency, only recently recognised, (Muller et al,
1983) is in fact different from that of acute porphyria being 
characterised by spinocerebellar degeneration and a sensory 
central-peripheral axonopathy.
3.3.6 Pyridoxal phosphate (Vitamin B5)
Pyridoxal phosphate is an essential co-factor for ALA.S and for 
tryptophan metabolism. Elder & Mengel (1966) studied a single AIP 
patient in remission whose urinary excretion of ALA and PBG fell 
significantly after being deprived of pyridoxal phosphate in her 
diet. Subsequent vitamin B5 replacement caused an increase in the 
urinary excretion of these porphyrin precursors. During the 
entire study she did not have any manifestations of porphyia, but 
the trial was stopped because she developed optic neuritis due to 
the deoxypyridoxine prescribed. The results of this experiment 
have not since been confirmed. (Chapter 4 for further discussion) 
Price et al (1959) reported that during the acute attack of
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porphyria abnormally high levels of copper and zinc are excreted 
in the urine accompanied by an increase in L-tryptophan 
metabolites. In the porphyric patients studied the disturbance of 
tryptophan metabolism could not be corrected by pyridoxine alone, 
but only when given in combination with chelating agents such as 
edetic acid. Cavanagh & Ridley (1967) have therefore proposed 
that in acute porphyria there might be a consumptive depletion of 
pyridoxal phosphate resulting from the abnormally high activity of 
ALA.S, This deficiency could then be responsible for the 
development of the neuropathy when combined with certain, as yet 
undefined, disturbance of polyvalent cations in the body.
Anaology is drawn between the neuropathological similarities in 
AIP and isoniazid-induced neuropathies in support to this 
hypothesis, especially since the latter can be prevented by 
pyridoxine supplementation (Cavanagh, 1967). This hypothesis has 
not since been properly tested clinically although the sparse 
published data relating to it have not been particularly 
encouraging (Price et al, 1959); Hamfelt & Wetterberg, 1968; 
Kosower & Rock, 1968; Bosch et al, 1977). Several patients with 
active AIP have recently been treated with large doses of 
pyridoxal phosphate supplements over a period of several months 
with no apparent response either to their acute attacks or in 
preventing further episodes (McColl, Personal communication).
3.3.7 B-adrenergic blockers
Schley et al (1970) found that urinary catecholamines were 
increased during attacks of porphyria. The possibility of a 
partial blockade in the re-uptake mechanism of catecholamines by
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the adrenergic neurones, as demonstrated in platelets of porphyric 
patients (Beal et al, 1977), could perhaps explain this 
observation and provide a rationale for the use of B-adrenergic 
blockers (Atuk et al, 1975). Several case reports have claimed 
both clinical and biochemical improvement with propranolol (Atsmon 
& Blum, 1970; Beattie et al, 1973a; Menawat et al, 1979). Atsmon 
and his group have produced some evidence in experimentally- 
induced porphyria which suggest that large doses of propranolol 
can decrease the activity of ALA-S and urinary excretion of ALA 
and PBG (Blum et al, 1973 ; Schoenfeld et al, 1976). Whereas 
propranolol can undoubtedly control the sympathomimetic features, 
often in relatively small doses (Menawat et al, 1979), solely by 
its B-adrenergic blocking action, the clinical benefit of higher 
dosage (Douer et al, 1978) remains uncertain.
Its putative disease-modifying effects have been attributed to its 
ability to inhibit aminoacid incorporation into protein 
(Schoenfeld & Atsmon, 1977) or increase free haem levels (Epstein 
et al, 1982), thereby reducing ALA.S activity.
3.3.8 Folic acid and specific enzyme replacement 
Folic acid and its pteroyl derivatives have been shown to activate 
PBG.D experimentally (Piper et al, 1976; 1979). Wider et al 
(1980) have subsequently claimed that folate supplementation can 
alter the clinical course of the disease but this remains 
unconfirmed. The same group of investigators have recently 
attempted to replace specific haem enzyme deficiency, as in the 
case of ALA-dehy dr as e deficiency in lead poisoning, by using 
erythrocyte ghosts as carriers of the missing enzyme (Bustos et 
al, 1983; Del C Battle et al, 1983).
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3.3.9 Hormonal therapy
Some patients suffer recurrent exacerbations of acute porphyria 
related to their menstrual cycles. Prevention of pre-menstrual 
attacks by hormonal manipulation is difficult because of the 
unpredictable and paradoxical effects that these steroids can 
have. Oral oestrogenic contraceptives, progestogens and androgens 
have been used in some patients without complications (Perlroth et 
al, 1965) but in others they have triggered acute attacks (Lamon 
et al, 1979b; Zimmerman et al, 1966). The reason why cyclically 
recurring attacks affect only a small percentage of female 
patients remains unknown. Anderson et al (1984) have recently 
reported that subcutaneous treatment of an AIP patient with a 
luteinizing hormone-releasing hormone (LH-RH) agonist successfully 
prevented her pre-menstrual attacks by abolishing the hormonal 
swings. The fact that LH-RH suppresses ovarian function by acting 
at the hypothalamic pituitary level indicates that gonadotrophin 
secretion or its secondary effects may be responsible for the 
acute manifestations of the disease. It is interesting to note 
that the clinical improvement was not accompanied by a concomitant 
decrease in the excretion of urinary porphyrin precursors. The 
future availability of an intranasal formulation for LH-RH 
analogues ("Buserelin") holds much promise not only in the 
prevention of menstrually—related attacks but also as a mode of 
contraception for these porphyric patients. Until the safety 
profile of long-term treatment with LH-RH agonists becomes known, 
use of these agents must necessarily be circumspect.
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Prevention of pre-menstrual attacks has also been achieved by 
timely intravenous haematin infusions (Lamon et al, 1978) but as 
previously discussed its place for regular long-term therapy is 
limited.
3.4 TREATMENT OF PHOTOSENSITIVITY
The photosensitizing lesions of HC and VP are best treated by 
measures aimed at shielding the patient from sunlight. Most 
commercial cream barriers are formulated to reduce exposure to 
light in the range of 290-320 nm, but for optimal screen in 
porphyria special preparations are required to exclude light 
within the wavelengths of 390-420 nm. These, unfortunately, 
contain zinc or titanium oxides which are not cosmetically 
pleasing because of their heavy consistency. Oral p-carotene, 
thought to act by quenching singlet oxygen radicals, may be 
useful. But it causes carotinaemia which sometimes may be 
converted to a more cosmetically pleasing brown tan by 
simultaneous oral administration of canthaxanthin (Eales, 1978).
3.5 PREVENTION OF ATTACKS
All patients identified as having acute porphyria should be 
carefully advised about the nature of the disease and instructed 
how to avoid known precipitating factors. They should be 
encouraged to take a regular diet, to avoid fasting and to abstain 
from alcohol. They should be warned about the dangers of 
porphyrinogenic drugs. It is helpful for the patient to be 
provided with a list of drugs which are considered safe or
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unsafe. The family doctor must also be informed about the type of 
the patient's porphyria and given advice about its future 
management. The patient should be reminded about informing any 
other medical attendant of their condition. As an additional 
precaution the patient should be encouraged to wear an 
identification bracelet or necklace indicating that he or she 
suffers from porphyria; this is to prevent the administration of 
dangerous anaesthetics or drugs in case of accident or emergency.
3.6 ANAESTHETICS
Surgery does not carry an increased risk of complications in 
porphyric patients provided the precautions outlined previously 
are taken. Safe anaesthetic agents must be carefully selected. 
Atropine or morphine can be used as premedication. Intravenous 
ketamine has been found to be a safe inducing agent and under no 
circumstances must thiopentone or barbiturate derivatives be 
used. Nitrous oxide is also a safe inhalational agent. 
Suxamethonium and d-tubocurarine are useful muscle relaxants. If 
a local anaesthetic is indicated, procaine is the agent of choice 
(Moore, 1983; De Verneuil et al, 1983). In order to prevent an 
attack induced by fasting an intravenous infusion of dextrose must 
be started prior to surgery and continued until a satisfactory 
oral intake is achieved.
3.7 PREGNANCY
Generally speaking, most porphyric patients have an uneventful 
pregnancy with no particular danger to the foetus (Stein &
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Tschudy, 1970; Brodie et al, 1977c). In some women however the 
hormonal changes during pregnancy or puerperium can trigger off an 
attack (Brodie et al, 1977c). Shared care between the 
obstetrician and a physician with an interest in porphyria is 
desirable. If vomiting is troublesome during early pregnancy, 
early administration of intravenous dextrose is indicated. 
Intravenous dextrose must also be given during labour.
If the patient has had frequent attacks of porphyria, it is our 
empirical practice to advise such patients against pregnancy until 
they have been free of symptomatic attacks for at least 18 
months. When attacks do occur during pregnancy, they are treated 
in the usual manner, and particular care is taken to control the 
blood pressure. Most attacks settle with adequate supportive 
therapy. As the teratogenic effects of haematin are unknown (Aft 
& Mueller, 1983), this treatment is better avoided if possible. 
Therapeutic abortion is rarely indicated unless the attack is 
uncontrollable and threatens the mother's life.
In cases where the woman decides to delay or avoid pregnancy, she 
should be warned against using the hormonal contraceptive pills 
and advised about other forms of contraceptions.
3.8 SCREENING OF RELATIVES
All the blood relatives of any new case of porphyria should be 
screened. Those with the genetic trait should then be counselled 
about the nature of their inherited disorder and advised about 
taking the necessary precautions. Careful counselling is 
important so as not to engender unnecessary fear or neuroticism
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since most of the identified cases will remain completely 
asymptomatic throughout their lives. Urinary measurement of 
porphyria precursors and porphyrins is an inadequate method of 
screening because only about one third of patients will be so 
identified. The measurement of erythrocytic PBG.D activity is now 
the standard method of screening AIP patients. But since there is 
some overlap between the values of PBG.D activity in normal 
subjects and patients with AIP, measurement of ALA.S in peripheral 
white cells can be helpful in borderline cases (McColl et al, 
1982).
For screening relatives of patients with HC and VP, faecal 
measurements of porphyhrins must be performed in addition to 
urinary assays (Mustajoki, 1978; Moore, 1983). But the most 
sensitive way of identifying the latent cases is by demonstrating 
reduced activity of the respective haem enzymes in their 
peripheral leucocytes (Brodie et al, 1977a).
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SECTION 1
CHAPTER4
PATHOGENESIS OF THE NEUROPATHY OF ACUTE PORPHYRIA
4. PATHOGENESIS OF THE NEUROPATHY OF ACUTE PORPHYRIA
4.1 INTRODUCTION
Although great strides have been made during the past 40 years in 
our understanding of the biochemistry and genetics of AIP the 
pathogenetic mechanism(s) of pain and neuropathy of this condition 
still remain controversial. Indeed a large amount of published 
information has already accumulated on this subject, but much of 
it is derived from animal and in vitro experiments, often under 
very contrived conditions, and from small uncontrolled clinical 
studies and anecdotal case reports. This chapter reviews the 
pathological and investigative data available as a prelude to the 
studies I have performed in an attempt to clarify the situation 
further.
4.2 Neuropathological features
The neurological complications of acute porphyria were originally 
described by Ranking and Parkington and by Harley in 1890. The 
earliest recorded case examined pathologically was in 1898 when 
Campbell failed to show any significant abnormality in the central 
nervous system. In 1903 Erbsloh first described features of 
axonal degeneration and patchy demyelination in the femoral nerve 
of a porphyric patient who died following treatment with 
sulphonal. Several case reports followed and the subject was 
comprehensively reviewed thirty years later by Mason, Courville 
and Ziskind (1933) when they sought the relationship between the
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clinical syndrome of porphyria and its pathological findings. 
Detailed histopathological examination of their own four autopsy 
cases revealed the most characteristic lesions to be in the 
nervous system particularly affecting the peripheral nerves and 
sympathetic ganglia. As previously reported by Courcoux et al 
(1929) and Bostroem (1920) marked degenerative changes were found 
in the spinal cord ganglion cells, especially of the anterior horn 
cells. In addition similar changes were present in the ganglia of 
the autonomic system. Other abnormalities recorded were extensive 
degeneration of the axis cylinders and myelin sheaths of the 
peripheral nerves, chromatolysis of the bulbar motor nuclei and 
Purkinje cells of the cerebellum. But the cerebrum appeared 
remarkably unscathed even when the patient displayed psychiatric 
manifestations during life. It was therefore concluded that the 
primary neurological damage was axonal degeneration followed by 
secondary demyelination.
Baker and Watson (1945) reported on the autopsy findings in a 24 
year old man who after being treated with a barbiturate developed 
flaccid quadriplegia and respiratory failure. Although no 
macroscopic changes were present in the nervous system, marked 
chromatolysis was noted within the facial and hypoglossal nuclei, 
and the dorsal nuclei of the vagus nerves. Similar microscopic 
changes were found in the spinal cord affecting the anterior horn 
cells but the myelin appeared normal. The spinal roots had 
remained intact. On the other hand the peripheral nerves, 
especially those of the lower limbs, were severely damaged with 
large segments of nerve tissue being totally destroyed. These
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pathological changes again supported axonal degeneration as the 
primary event but an additional demyelinating component could not 
be excluded. Likewise Denny-Brown & Sciarra (1945) laid stress on 
the chromatolytic changes in both dorsal and ventral horn cells of 
the entire spinal cord after finding that the white matter was 
unaffected. Patchy areas of demyelination were observed along the 
posterior tibial nerves whereas sections of the sural cutaneous 
phrenic and vagus nerves had remained intact. Although these 
authors concluded that the neurological damage could possibly be 
explained on the basis of a myelin defect due to 
vasoconstriction-induced ischaemia, the histological features 
characterising the marked chromatolysis were more supportive of a 
primary axonal degeneration. Nevertheless the proposal that 
porphyric neuropathy could be due to segmental demyelination 
instead of axonal degeneration gained ground (Garvin and Lapresle, 
1950; Gibson and Goldberg, 1956).
In their neuro-pathological study of 5 fatal AIP cases Gibson and 
Goldberg (1956) reported widespread patchy demyelination of the 
peripheral and autonomic nerves, but axonal damage and Wallerian 
changes were also noted. In addition they observed marked 
chromatolysis in the anterior horn cells of the spinal cord and 
the nerve cells of the medullary nuclei, the dorsal vagal nuclei 
being particularly affected. Other histological features 
described were cytoplasmic vacuolar changes and small perivascular 
haemorrhages. These workers believed that the chromatolytic 
changes were due to the demyelination of the dependent nerve 
fibres. And contrary to Denny-Brown and Sciarra (1945) they could
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find no evidence for these histopathological changes po be> ' ■ 
ischaemic in nature. Hierons' (1957) description of the 
post-mortem findings in five AIP patients was not dissimilar from 
that of Gibson and Goldberg (1956). Again chromatolysis of nerve 
cells was a prominent feature of the disease, as was the 
vacuolated appearance of the affected neuronal cells for which the 
author could find no satisfactory explanation. Gross 
demyelination was found in the spinal cord of one of the five 
cases but meaningful interpretation was hindered by the following 
atypical features:
(1) the development of bilateral pyrimidal signs;
(2) an elevated cerebrospinal fluid protein level;
(3) focal lymphocytic infiltration of the meninges;
(4) marked post-mortem autolysis with poor histological quality 
of the axon preparations.
In the single case with good nerve preparations the changes of a 
primary axonal degeneration was supported by the loss of the large 
myelinated fibre population with relative preservation of the 
small myelinated and unmyelinated fibres, indicative of 
regenerative attempts.
In a review of nine autopsy cases of acute porphyria. Ten Eyck et 
al (1961) reported neuropathological changes very similar to those 
described by Mason et al (1933): predominant neuronal degeneration 
with patchy demyelination. But they stressed on the fact that all 
these patients had other severe complications unrelated to the 
porphyria which contributed to their deaths and that could have 
produced secondary histological changes in the brain.
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Analogy has been drawn between the neuropathy of acute porphyria 
and that of lead intoxication not only because of their striking 
clinical similarities but also because of their effects on the 
haem biosynthetic pathway (Dagg et al, 1964). In both conditions 
there is an excessive accumulation and excretion of the porphyrin 
precursors, believed by some (Becker & Kramer, 1977b) to be of 
pathogenetic importance. In chronic lead intoxication both axonal 
degeneration with nerve loss and demyelination occur in the human 
peripheral nerves (Buchtal and Behse, 1979) but there is marked 
species difference in the predominance of these changes in other 
experimental animals (Dyck et al, 1977). In the rat lead 
intoxication provide a good model of primary segmental 
demyelination (Windebank & Dyck, 1984). It is interesting to note 
that in primary demyelinating disorders such as multiple sclerosis 
chromatolysis is not a prominent finding despite widespread 
destruction of the myelin.
Cavanagh and Mellick (1965) provided strong support in favour of 
axonal degeneration as being the primary lesion in acute porphyria 
by describing Wallerian-type degeneration and failing to find any 
demyelination in the peripheral nerves of five fatal cases.
Axonal degeneration of the motor nerves was extensive and 
proceeded as far proximally as the ventral roots, characteristic 
of the dying-back phenomenon (Cavanagh, 1979). The sensory nerve 
fibres were less severely affected than their motor counterparts. 
But an intriguing observation was the sparing of the 
large-diameter primary sensory fibres from the muscle spindles 
when the muscles concerned were almost completely depleted of
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other types of innervation. Unlike the neuropathy of 
organo-phosphorus poisoning where the distal muscles with the 
largest fibres are affected earliest and most severely (Cavanagh, 
1954), the dying-back process in porphyric neuropathy occurred 
irrespective of the distance of the muscle from the spinal cord. 
Cavanagh & Mellick (1965) also shared the view (nierons, 1957; 
Mason et al, 1933) that the neurones of the spinal cord and 
ganglia seldom underwent necrosis although they became 
chromatolytic. Cavanagh and Ridley (1967) described axonal 
degeneration with collateral sprouting in muscles, indicative of 
previous cycles of nerve degeneration and regeneration, even in 
those cases where the neuropathy had clinically been of brief 
duration. They therefore envisaged that porphyric neuropathy was 
due to a relatively acute and massive "dying-back" degeneration 
superimposed upon a background of pre-existing subclinical 
denervation. The dose similarity in the type of denervation 
between porphyric and isoniazid-induced neuropathies has been 
highlighted (Cavanagh & Ridley, 1967; Jacobs et al, 1979). And 
since isoniazid seems to exert its neurotoxic effect by 
interfering with pyridoxal phosphate formation it was postulated 
that tissue depletion of this cofactor for ALA synthase might be 
responsible for the porphyric neuropathy (Cavanagh, 1967).
In a detailed case study, Sweeney et al (1970) again confirmed the 
presence of axonal degeneration and central chromatolysis with the 
absence of segmental demyelination. Nerve fibres supplying both 
proximal and distal muscles were found to be equally affected, 
supporting the dying—back hypothesis of Cavanagh & Ridley (1967).
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A characteristic feature of acute porphyria is proximal muscle 
weakness. This was explained on the basis that neurones supplying 
the proximal anti-gravity muscles might be more vulnerable 
metabolically because of their larger motor units (Ridley, 1969). 
And the development of weakness in a limb that was subject to 
unaccustomed exercise supports this possibility (Ridley & 
Cavanagh, 1972).
It must be emphasized that several workers have also recorded 
minimal morphological changes in the nervous system of porphyric 
patients who died during an acute attack, especially if death had 
occurred within a short time of the onset of paralysis (Mason et 
al, 1933; Denny-Brown & Sciarra, 1945; Hierons, 1957). This 
observation is indicative of a functional block resulting from 
some biochemical disturbance, with the development of structural 
changes arising from other considerations such as the severity, 
duration and frequency of the acute attack(s) (Chapter 10).
Indeed some patients can make strikingly rapid and complete 
neurological recovery from virtually complete paralysis (Ridley, 
1969; Menawat et al, 1979; Brezis et al, 1979). In such cases the 
degree of axonal damage must have been comparatively small. Yet 
in others in whom nerve degeneration has extended far proximally, 
recovery may not be complete even after several years (Sorensen & 
With, 1971; Ridley, 1969). For the same reason, the distal limb 
muscles take longer to recover than the proximal muscles even 
though the latter may be more severely affected clinically 
(Ridley, 1969).
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Following the work of Cavanagh, Mellick & Ridley on the 
neuropathological changes in AIP only sporadic case reports of 
peripheral nerve or muscle biopsies have been published (Masuja, 
1969; Nagler, 1971; Thomas, 1971; Wakayama et al, 1975; Anzil and 
Dozic, 1978; Thorner et al, 1981), They all support the concept 
of axonal degeneration but some workers (Thomas, 1971; Wakayama et 
al, 1975; Anzil & Dozac, 1978) have also described the presence of 
mild segmental demyelination in sural nerve biopsies which could 
not be attributed to axonal degeneration.
C.oncJji^ ion
The histopathological data available support the hypothesis that 
the neuropathy of acute porphyria is caused by a metabolic 
disturbance which interferes with nerve cell function. Depending 
on considerations such as severity, duration and frequency of 
attacks and other as yet unidentified factors the metabolic 
disturbance can cause a neuronopathy with axonal degeneration of 
the "dying-back" type. The brunt of the damage is borne by the 
anterior horn cells of the spinal cord and brain stem ganglia, 
with relative sparing of the brain cells. Severe axonal 
degeneration can eventually cause some secondary demyelination.
It also appears that the Schwann cells could be directly damaged 
in an acute attack accounting partly for the demyelination but 
this is unlikely to be clinically relevant.
4.3 ELECTRODIAGNOSTIC FINDINGS
4.3.1 Motor nerve conduction studies
From the earliest studies it was recognised that even in the 
presence of severe muscle weakness motor conduction velocity (MCV)
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is often normal or only mildly impaired in acute porphyria 
(Simpson, 1962; Stein & Tschudy, 1970; Maythem & Eales, 1971; 
Nagler, 1971). This observation has been amply confirmed in 
larger and more detailed investigations (Flugel & Druschky, 1977; 
Wochnik-Dyjas et al, 1978; Albers et al, 1978). It favours the 
concept of primary axonal degeneration since primary demyelination 
would be expected to cause more marked reduction in conduction 
velocity. Following an acute attack the impaired MCV can rapidly 
return to normal in accordance with the speedy removal of a 
transient functional block. Nagler (1971) suggested that this 
transient neurological dysfunction could be due to the neurotoxic 
effects of the porphyrin precursors.
Flugel and Druschky (1977) reported the results of nerve 
conduction studies on 16 AIP patients, six of whom had no 
neurological abnormality, four with neuropathy and the remaining 
six with tetraplegia. The single patient studied during the acute 
attack had absent or low-amplitude motor responses except in one 
nerve with moderate slowing of conduction. Patients studied three 
to ten years after the acute attack displayed slowing of 
conduction velocity proportional to amplitude reduction and the 
presence of fibrillation. The authors concluded that their 
findings were best explained by an axonal neuropathy. A similar 
view was reached by Albers et al (1978) after recording normal MCV 
in eight of eleven AIP patients previously affected by 
tetraparesis.
Mustajoki and Seppalainen (1975) used the technique of partial 
antidromal blocking to differentiate between the fast and slow
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motor fibres. Patients with AIP and VP were found to have a 
significant reduction in the conduction velocity of their slow 
motor fibres and sensory fibres, years after recovery from the 
acute attacks. Of note similar findings were found in latent 
cases who have always remained asymptomatic. These results 
suggest that subclinical neuropathy may be more frequent than 
clinically suspected - a situation reminiscent of lead neuropathy 
(Seppalainen & Hernberg, 1972). Since conduction velocity of the 
slow motor fibres was diminished even in patients with normal 
urinary porphyrin precursor excretion the neurotoxic role of ALA 
and PBG becomes questionable.
4.3.2 Sensory nerve conduction studies have been few. In the 
three patients studied late after recovery from tetraplegia, 
slowing was noted in one whereas the two others were normal. 
Albers et al (1978) reported normal measurements in four of six 
AIP patients with quadriparesis whereas in the remaining two 
patients sensory-nerve action potentials were absent or of low 
amplitude with normal latencies. Therefore these findings as for 
the motor nerve conduction studies are consistent with an axonal 
neuropathy.
4.3.3 Electromyographic (EMG) Findings
In the early stages of porphyric neuropathy profuse fibrillation 
potentials have been recorded, and after six to eight weeks 
polyphasic motor unit potentials characteristic of re—innervation 
appeared and subsequently increased in amplitude (Nagler, 1971). 
EMG recordings have conclusively shown that motor nerve fibre 
degeneration takes place and that the ensuing regenerative
73
attempts may or may not proceed to completion (Ridley, 1967; Stein 
& Tschudy, 1970; Maythem & Eales, 1971; Flugel & Druschky, 1977; 
Wochnik-Dyjas et al, 1978; Albers et al, 1978), The near-normal 
MCV accompanied by low amplitude compound muscle action potentials 
is characteristic of an axonal neuropathy. The low amplitude 
compound muscle action potential reflect loss of axons and 
subsequent muscle atrophy; the normal or slightly abnormal 
conduction velocities indicate that the remaining axons are 
conducting normally. The early predominance of fibrillation 
potentials in the proximal muscles suggested to Albers et al 
(1978) that the major insult occurred at root or cord level, or 
that the nerve cells with the larger motor units were more 
vulnerable to damage. The latter possibility supports the 
hypothesis of Cavanagh & Ridley (1967).
Wochnik-Dyjas et al (1978) reported that after an acute attack 
rapid reversibility of EMG changes took place in some patients 
whereas subclinical disturbances persisted long afterwards in 
others. They also found that tetanic stimulation tests of 
neuromuscular function resulted in potentiation rather than 
fatigue. This was interpreted as suggesting that in porphyric 
neuropathy there might be a block of neurotransmission at the 
cholinergic nerve endings reminiscent of botulinum poisoning. No 
confirmatory report has yet appeared in favour of this intriguing 
proposal, but in view of the possible pharmacological effects of 
ALA on neurotransmission it must be further explored.
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4.4 PATHOGENESIS OF_THE ACUTE ATTACKS
Although the clinical features of acute porphyria can be explained 
on the basis of a widespread neurological dysfunction (Goldberg, 
1959) uncertainty still surrounds its pathogenesis. The 
relationship between the biochemical abnormalities, predominantly 
studied in the liver, and the clinical manifestations remains 
conjectural. Over the past 30 years several hypotheses have been 
advanced, and as yet there is no conclusive proof for any 
particular postulate. These postulates are however not mutually 
exclusive. Unfortunately most of them have been inadequately 
tested, having been formulated on anecdotal or limited clinical 
information.
4.4.1 Hypothesis 1
"The neurological manifestations are caused by the depletion of 
essential substrates or co-factors arising from the haem 
biosynthetic pathway defect."
Depletion of pyridoxal phosphate (Vitamin Bg)
Pyridoxal phosphate is an essential cofactor for ALA synthase, the 
rate-limiting enzyme of the haem biosynthetic pathway. It has 
been suggested that during an acute attack increased ALA synthase 
activity correspondingly augments the demand and consumption of 
pyridoxal phosphate with consequent deprivation to the nervous 
tissues (Price et al, 1959; Cavanagh & Ridley, 1967). Indeed 
plasma pyridoxal phosphate concentration has been found to be 
decreased in some AIP patients as compared to normal controls 
(Hamfelt & Wetterberg, 1968). Unfortunately no details were given 
about the nutritional status of these porphyric patients who often
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take an inadequate diet. Believing that AIP was a disease caused 
primarily by ALA.S overproduction Elder and Mengel (1966) 
attempted to reduce ALA.S activity by inducing pyridoxal phosphate 
deficiency artificially in a patient in remission. This patient 
seemingly had pre-existing vitamin B5 deficiency at the outset 
with abnormal tryptophan metabolism. Following further vitamin 
deprivation her urinary porphyrin precursors fell significantly. 
The authors subscribed to the view that a lack of pyridoxal 
phosphate was responsible for the clinical manifestations of the 
disease. And from their interpretation the patient ought to have 
developed porphyric symptoms when her urinary porphyrin precursors 
fell - and she did not. The belief behind this expected outcome 
is in fact not supported by current knowledge. Cavanagh (1967) 
has drawn attention to the close neurohistopathological 
similarities between porphyric neuropathy and that of vitamin B5 
deficiency; but other differences not seen in porphyria such as 
demyelination of the posterior column fibres (Follis & Wintrobe, 
1945; Swank & Adams, 1948) and swelling of the Betz cells in the 
motor cortex (Victor & Adams, 1956) have been recorded in 
experimental animals. The main objection to the pyridoxal 
phosphate deficiency hypothesis is that the clinical picture of 
these two conditions is quite different. The neuropathy of 
vitamin B5 deficiency is a distal, symmetrical, predominantly 
sensory polyneuropathy affecting the lower limbs (Vilter et al, 
1953; Evans et al, 1960) whereas porphyric neuropathy is primarily 
motor chiefly affecting the upper limbs (Ridley, 1969). Moreover, 
Hamfelt & Wetterberg (1968) have pointed out that patients without
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porphyria who had the same degree of vitamin deficiency as 
those AIP patients with neuropathy showed no evidence of 
neurological involvement. Pyridoxine supplementation was found 
not to cause any clinical improvement in the neuropathy despite 
normalisation of the low vitamin B^ levels (Hamfelt & Wetterberg, 
1968; Price et al, 1959). This, however, could conceivably be due 
to the advanced stage of nerve damage in so far as any beneficial 
effect of short-term therapy would not become evident against the 
background of slow regenerative capacity of the damaged nerve 
fibres. Cavanagh & Ridley (1967) have advocated the prophylactic 
use of pyridoxal phosphate to forestall future attacks of 
porphyria, but doubts have been expressed about this suggestion 
because pyridoxal phosphate requirement for ALA synthase is 
probably quite small compared to the other enzymes also dependent 
on this cofactor (Bonkowsky & Schady, 1982).
e^£.l e.tion o^f_Z_inç.
Patients with porphyria have an increased urinary excretion of 
zinc on account of the chelating properties of porphyrins for 
divalent ions (Peters et al, 1974). Depletion of zinc is unlikely 
to explain the porphyric neuropathy for the following reasons. 
First, the clinical features of zinc deficiency syndromes are 
totally different from those of acute porphyria. Second, it fails 
to explain the absence of neurological manifestations in the 
chronic porphyrias such as PCT and erythropoietic protoporphyria 
where zinc excretion often exceeds that in AIP (Peters et al,
1974). Third, zinc sulphate supplementation has not shown 
clinical benefit.
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Dep.le.tion o^f glycine
Glycine is a natural substrate for ALA.S which has a high Km. De 
Matteis & Rimington (1962) have suggested that when ALA.S activity 
is induced the increased glycine flux into the haem biosynthetic 
pathway could deplete the supply of this substrate for other 
important pathways such as that for acetylcholine synthesis - 
hence causing the neurological manifestations. But in acute 
porphyria there is no evidence for an acquired deficiency of 
glycine availability or of acetylcholine synthesis. Sodium 
benzoate is conjugated with glycine by mitochondrial glycine 
acyl-transferase to form hippurate which is rapidly excreted in 
the urine. Piper et al (1973) have reported that diversion of 
glycine from the haem to the hippurate biosynthetic pathway is 
theoretically possible. Administration of sodium benzoate to rats 
with experimentally-induced porphyria led to a decrease in the 
excretion of ALA and PBG. Contrary to previous suggestion (De 
Matteis & Rimington, 1962) these results would suggest that 
limitation in the supply of glycine for ALA.S might blunt the 
biochemical manifestations of porphyria. But this potential 
therapeutic use of sodium benzoate in acute porphyria (Becker & 
Kramer, 1977), has not received confirmation.
4.4.2 Hypothesis 2
The neuropathy is due to the abnormal products derived from the 
porphyrin precursors.
Irvine and his associates (1961, 1969, 1974) identified a pyrrole 
compound in the urine of AIP patients, which had previously been 
found in the urine of patients with certain psychoses, namely
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schizophrenia. Initially the compound was thought to be 
kryptopyrrole (2,4-dimethy1-3-ethyl pyrrole), and it exhibited a 
mauve colour when reacted with Ehrlich's reagent - hence the term 
'mauve factor'. This material was shown to have neurotoxic 
properties (Irvine et al, 1969). Subsequent studies (Gendler et 
al, 1978) revealed that the natural compound in porphyric urine 
was in fact hydroxyhaemopyrrolin-2-one, which under certain 
conditions was converted to kryptopyrrole and related 
monopyrroles. Gorchein (1980) failed to find any qualitative or 
quantitative relationship between the urinary concentrations of 
hydroxyhaemopyrrolin-2-one and the clinical manifestations of 
AIP. It is now generally believed that these pyrroles, thought to 
be mainly derived from PBG, play an insignificant role in the 
pathogenesis of the disease.
Porphobilin, a dipyrrylmethane derivative of PBG can be found in 
the urine of porphyric patients after it has been exposed to 
light. Using a rat phrenic-nerve hemidiaphragm preparation 
Feldman et al (1971) reported that porphobilin at low 
concentrations could cause pre-synaptic neuromuscular inhibition. 
Porphobilin was much more potent than PBG or ALA in this respect. 
However its role in the pathogenesis of acute porphyria is 
doubtful since this compound has not been detected in either urine 
or tissues of porphyric patients. Moreover patients with 
ALA-dehydratase deficiency would not be expected to make the 
compound, and yet they exhibit clinical features similar to the 
other types of acute porphyria (Doss et al, 1980b). Pierach et al 
(1977b) have also reported that rats given large amounts of
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porphobilin displayed no abnormality in blood pressure, pulse or 
behaviour.
4.4.3 Hypothesis 3
The neuropathy is the result of neurotoxicity from an accumulation 
of the porphyrin precursors, ALA and/or PBG.
All the types of acute porphyria have in common the excessive 
production and urinary excretion of ALA. PBG is also increased 
except in homozygous ALA-dehydrase deficiency. The pathogenetic 
role of PBG is doubtful since patients with homozygous 
ALA-dehydratase deficiency can only produce large amounts of ALA 
without PBG, yet they display the neurological manifestations seen 
in the other types of acute porphyria (Doss et al, 1979, 1982b). 
The liver is considered to be the main site of ALA and PBG 
production. It therefore follows that these precursors must cross 
the blood brain barrier to exert their neurotoxic effect. 
Experimental studies in normal rats have shown that the 
blood-brain barrier is weakly permeable to ALA and PBG. For 
instance, after intraperitoneal administration the maximal ALA 
concentration attained in brain ranged from 4% (Shanley et al,
1975) to 12% (McGillion et al, 1975) of maximal blood levels. 
McGillion et al (1975) have also shown that brain tissue 
concentrations of ALA remained elevated after the blood 
concentrations had returned to normal. More significantly, during 
the acute attacks of porphyria, ALA and PBG can be detected in the 
cerebro-spinal fluid where they are not normally present. The 
concentrations of ALA and PBG in the cerebrospinal fluid of 
patients with AIP (Sweeney et al, 1970, Bonkowsky et al, 1971) and
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VP (Percy & Shanley, 1977) (10  ^ to 10""^  M) were reported to be 
much lower than in the blood (10”  ^ to 10”  ^m) in keeping with the 
experimental observations made in the rat. Becker et al (1974) 
have demonstrated that brain slices can actively concentrate ALA 
from the surrounding medium with the implication that the neuronal 
concentration may be much higher than that in the cerebrospinal 
fluid.
The present hypothesis particularly holds for ALA and is supported 
by the following:
1. Acute attacks only occur when excretion of the porphyrin 
precursors is increased. Although some patients can have elevated 
serum ALA and PBG levels during remission, the onset of symptoms 
is always accompanied by an even higher excretion of these 
compounds (Becker & Kramer, 1977b). But the excretion of 
porphyrin precursors does not correlate well with the clinical 
severity of the disease (Ackner et al, 1961) (Chapter 9). This is 
perhaps because different patients display varying degrees of 
susceptibility to the effects of ALA on account of genetic or 
other interacting factors. A recent exciting development has been 
the recognition of molecular heterogeneity in PBG.D accounting for 
different enzymatic activities (Anderson et al, 1981; Mustajoki & 
Desnick, 1985); this observation could explain why certain 
porphyric families seem to suffer from their disease more than 
others.
2. Acute administration of ALA either intraperitoneally to mice 
(McGillion et al, 1975) or into the cerebral ventricles of rats 
(Shanley et al, 1975) produced transient excitatory effects.
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When mice were treated with ALA no morphological changes occurred 
in the nerves but nerve conduction was transiently impaired (Sima 
et al, 1981), However a number of studies involving oral or 
parenteral administration of ALA and PBG have produced no evidence 
of any pharmacological effects except for some skin sensitivity 
(Berlin et al, 1956; Meyer et al, 1972). These experimental 
situations merely constitute brief exposures to the effects of the 
porphyrin precursors, and are clearly not comparable to the more 
prolonged exposure prevailing during the acute attacks in man.
3. There are two other diseases, one acquired and the other 
inherited, in which large amounts of ALA are produced and excreted 
in the urine; lead poisoning and hereditary tyrosinaemia. In both 
conditions patients can develop clinical features resembling these 
of the acute attack of porphyria with abdominal pain, motor 
weakness, tachycardia and hypertension (Dagg et al, 1964; Gentz et 
al, 1969; Strife et al, 1977). In lead poisoning, the alterations 
in porphyrin metabolism are mainly due to inhibition of ALA 
dehydrase and ferrochelatase although other enzymes may also be 
affected (Tephly et al, 1978). Consequently plasma ALA 
concentration is increased with brain ALA levels increasing 
as much as four-fold as compared to controls (Dagg et al,
1964).
Hereditary tyrosinaemia is an inborn error of metabolism, 
transmitted as autosomal recessive, which is due to a deficiency 
of 4—fumarylacetate hydrolase (Lindblad et al, 1977). As a result 
succinylacetone (4 ,6—dioxoheptanoic acid), an abnormal metabolite, 
accumulates. Succinylacetone is an extremely potent competitive
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inhibitor of ALA dehydrase (Sassa & Kappas, 1983), and in 
hereditary tyrosinaemia, both plasma concentration and urinary 
excretion of ALA are increased while PBG level remains unchanged. 
The occurrence of an AlP-like syndrome in certain patients with 
hereditary tyrosinaemia (Gentz et al, 1969; Strife et al, 1977) 
suggests, as in genetically-determined homozygous ALA dehydratase 
deficiency (Doss et al, 1979, 1982b) that PBG or its 
derivative porphobilin are unlikely to be the cause of the 
neurotoxicity.
Whereas clinical and in vivo experimental evidence for porphyrin 
precursor toxicity has been unimpressive much information is now 
available to show that ALA and PBG can exert a variety of 
pharmacological effects in vitro. These in vitro experiments have 
employed tissues from different animal species including 
invertebrates and amphibians (Loots et al, 1975; Nicholl, 1976). 
High concentrations of ALA have also had to be used, often 
100-1000 fold higher than those observed in the patient's serum 
(Sweeney et al, 1970; Miyagi et al, 1971; Percy & Shanley, 1977). 
Therefore extrapolation of results from such studies to man must 
be tempered with utmost caution.
Direct effects of ALA
Using isolated rabbit duodenum. Cutler et al (1980) have shown 
that even after blocking nerve transmission by tetradotoxin ALA 
(0.2 to 8 X 10"3 M) can inhibit muscle tone and both spontaneous 
and induced contractions. These results indicate that ALA can 
have a direct effect on rabbit gut smooth muscle. On the other 
hand, no such effect was observed by Mcgillion (1974) in
83
guinea-pig ileum, thus highlighting the inter-species variation. 
Cutler et al (1978) have also previously reported that ALA can 
inhibit frog gastrocnemius muscle contraction to direct electrical 
stimulation.
^f jfec.t^  o f^_ALA_on, neuro transmit ter release
Experiments using rat phrenic nerve-hemidiaphragm preparations 
have shown that ALA inhibits K'*' augmented spontaneous release of 
acetylcholine (Feldman et al, 1968) and the release of 
acetylcholine evoked by nerve impulses (Bornstein et al, 1979) at 
concentrations of 7.4 x 10”  ^M and 0.6 to 18 x 10“  ^M 
respectively. ALA (10~^ to 10"^ M) has also been found to depress 
electrically-stimulated (Nicholl, 1976) and spontaneous (Loots et 
al, 1975) dorsal root potentials in isolated hemisected frog 
spinal cord preparations. Becker et al (1975) have reported that 
ALA and PBG can depolarise frog muscle fibres. These observations 
suggest that ALA and/or PBG might have a clinically significant 
effect at the synaptic level.
ALA a,nd_ Garam^-^mj^nobiitxric_ac.i^ X.GABA) .
ALA is structurally similar to GABA and glutamic acid.
Chemical structures of ALA and amino acid neurotransmitters.
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GABA is an inhibitory neurotransmitter in both spinal cord and 
cerebral cortex whereas glutamic acid exerts an excitatory effect 
(Krnjevic & Schwartz, 1967; Walker, 1983; Fonnum, 1984). GABA 
seems to act at two receptor sites. At the post-synaptic GABA A 
receptor GABA increases conductivity through chloride ion channels 
to cause hyperpolarisation of the post—synaptic neurones 
(Krnjevic, 1976), thus inhibiting nerve activity. GABA can also 
bind to GABA B receptors located on the pre-synaptic membrane. 
Pre-synaptic inhibition mediated by the GABA—B receptor blocks the 
release of neurotransmitters in both central and autonomic nervous 
system. ALA selectively competes with GABA for GABA receptor 
sites on rat brain synaptosomes (Muller & Snyder, 1977; Brennan et 
al, 1980). Dichter et al (1977) have shown that ALA can mimic 
GABA A action by increasing chloride ion conductance in the 
crayfish stretch receptor neurones. At relatively high 
concentrations (100 uM) ALA can release both GABA and glutamic 
acid from unstimulated brain cortex synaptosomes, but at lower 
concentrations (0-5 uM), it can only liberate ALA (Becker et al,
1976). ALA has also been shown to impede Na+, K"*" - ATPase activity 
in rabbit brain preparations (Becker et al, 1971). Since 
inhibition of NA"^ , K"*" -ATPase can influence neuromuscular 
transmission by increasing neurotransmitter release ALA seems to 
act as a GABA agonist. The situation is more complex because 
depending on the experimental circumstances ALA can be shown to 
have opposite effects. Thus at higher concentrations (10 ^ —
10"”^  M), ALA can paradoxically inhibit K^ stimulated release of 
GABA from preloaded synaptosomes (Brennan & Cantrill, 1979). GABA
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activity is terminated through a re-uptake mechanism using a 
high-affinity transport system in both nerve and glial cells (Mao 
and Costa, 1978). ALA has been shown to inhibit GABA uptake by 
brain synaptosomes at high concentrations (1 mm) (Brennan & 
Cantrill, 1979) but not at lower concentrations (Percy et al, 
1981).
Ne^r(01ox_ic_itx of ALA
Percy et al (1981) have reported that ALA (10 uM) was neuro toxic 
to both neuronal and glial components of brain cell cultures from 
the chick embryo « Such a concentration could possibly occur in 
porphyric patients since a CSF level of 21 nM has been recorded 
(Sweeney et al, 1970). Other workers, however, have measured much 
lower levels: 2.9 uM (Bonkowsky et al, 1971) and 0.3 uM (Percy and 
Shanley, 1977). ALA neurotoxicity certainly offers an explanation 
for the histopathological changes seen in acute porphyria; but 
results obtained with avian cells in vitro does not necessarily 
reflect the in vivo human situation where cells may be more 
resistant to toxic agents.
ALA being a small molecule freely crosses the placenta; thus 
during pregnancy the foetus will be exposed to the high levels of 
ALA prevailing in the mother's blood. It is remarkable that no 
porphyria—related teratogenic effects or neurological 
complications have yet been reported in any of the newborn of 
women suffering from acute attacks during their pregnancies 
(Brodie et al, 1977c; Stein & Tschudy, 1970; Kappas et al, 1983). 
This would seem to indicate that porphyrin precursors are not 
neurotoxic unless foetal nerve tissue is particularly resistant to
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their detrimental effects or unless these complications have 
passed unnoticed.
^f f.ec.tx of PBG
Earlier studies have indicated that parenterally administered PBG 
produced no evident toxic effects in rats or rabbits (Goldberg & 
Rimington, 1954; Jarrett et al, 1956). Feldman et al (1971) found 
that PBG at relatively low concentrations (2.4 uM) could inhibit 
neuromuscular transmission in a rat hemi—d iaphr agm preparation. 
Paradoxically only weak inhibitory effects were observed on the 
spontaneous (Nicholl, 1976) and electrically-stimulated (Loots et 
al, 1975) activity on the frog spinal cord.
4.4.4 Hypothesis 4
The neurological manifestations are due to a deficiency of haem in 
neural tissues.
Brain tissue contains ALA.S and other enzymes of the haem 
biosynthetic pathway (Barnes et al, 1971; Paternini et al, 1978). 
The activities of these enzymes in the rat brain are 
quantitatively much lower than those in the liver with 
corresponding ratios ranging from 0.002 to 12.5 (Percy & Shanley, 
1979). Sassa et al (1979) have also reported that isolated dorsal 
root ganglia in culture were able to synthesise a wide spectrum of 
porphyrins from ALA. Although brain tissue contains low levels of 
ALA, PBG, total porphyrins, haem and cytochrome P450 it can 
perform certain haemoprotein—dependent mixed—function oxidase 
activities (Cohn et al, 1977; Paul et al, 1977).
In considering this hypothesis two key questions need be 
answered. First, does haem deficiency occur in neural tissues of
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patients with acute porphyria? If so, does it fluctuate with the 
activity of the disease?
Until now direct measurement of the intracellular "haem pool" has 
not been made possible, its existence being based on much indirect 
evidence (Muller-Eberhard & Vincent, 1985). As previously 
discussed (Chapter 1) the "free haem pool" is currently believed 
to be the regulatory component of total haem in the liver. 
Deficiency of hepatic haem, however, does not necessarily entail a 
similar state of depletion in neural tissues unless both organs 
share a common control mechanism for haem biosynthesis. Earlier 
studies have reported that brain ALA.S could not be induced in 
rats after either dietary starvation or treatment with known 
potent inducers of hepatic ALA.S such as phénobarbital, ethanol, 
AIA and other allyl compounds (Paternini et al, 1978; Percy & 
Shanley, 1979). Maines (1984) also found that unlike the liver 
inhibition of rat brain ALA-synthase by manganese ions was not 
accompanied by a reciprocal increase in haem oxygenase activity. 
Both these findings therefore suggested that the brain is perhaps 
endowed with a different regulatory mechanism for its haem 
pathway. In contrast. De Matteis et al (1981b, 1982) have 
provided evidence to indicate that regulation of rat brain ALA.S 
may after all be affected by haem through a negative feed-back. 
They have shown that ALA.S could alter its activity during the 
neonatal period in parallel with the physiological haem 
requirements of brain tissue and become depressed after 
intravenous injections of ALA. Inhibition of cerebellar haem 
biosynthesis by succinylacetone, a specific inhibitor of
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ALA-dehydrase, also led to ALA.S induction whereas 
intra-ventricular injection of haematin caused a depression of its 
activity. At present there is no satisfactory explanation to 
account for the discrepancy between these two sets of observations 
in the control of brain haem synthesis.
Contraction of the haem pool, as may occur in the acute 
porphyrias, induces ALA.S activity whereas expansion of the haem 
pool leads to an increase in haem oxygenase (Bissell & Hammaker,
1977) and an accumulation of haem in tryptophan pyrrolase 
(Al-Badawy & Evans, 1975). Studies in which the fate of ^^C-ALA 
was followed after intra-ventricular injection in the rat brain 
have supported the existence of a "haem pool" in that organ (Percy 
& Shanley, 1980; De Matteis & Ray, 1982).
In the human liver at least there is some indirect evidence in 
favour of the present hypothesis. Most of the haem synthesized in 
the liver is used up as the prosthetic group for microsomal 
cytochromes P450. The functional capacity of the 
cytochrome-P450-dependent mixed-function oxidase system, as 
assessed by antipyrine clearance, was significantly depressed in 
patients with AIP (Anderson et al, 1976), HC and VP (Ostrowski et 
al, 1983). This depression was more marked during the acute 
exacerbations (Anderson et al, 1976) and in some patients in 
remission with higher excretion levels of ALA and PBG (Ostrowski 
et al, 1983). Only certain types of cytochromes-P450 seemed to be 
affected. Song et al (1974) have reported that AIP patients had 
decreased rate of metabolism for salicylamide, a salicylic acid 
derivative that depends on the cytochrome P450 system for its
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oxidation. Unfortunately the lack of clinical details on these 
patients make meaningful interpretation of these results 
difficult.
As a consequence of intracellular haem deficiency other metabolic 
disturbances can be expected to arise in those pathways dependent 
on haem proteins. Labbe (1967) put forward the hypothesis that in 
the porphyrias the primary defect could be due to inhibition of 
the mitochondrial terminal electron-transport system, thereby 
impairing energy production. This proposal was based on studies 
performed in vitro (Cowger & Labbe, 1967) and in experimental 
porphyria (De Matteis & Rimington, 1962; Gajdos & Gajdos-Torok, 
1969). For instance, several chemical porphyrinogens were shown 
to impair mitochondrial reduced nicotinamide adenine dinucleotide 
(NADH) oxidation (Cowger & Labbe, 1967; Gajdos & Gajdos-Torok, 
1963) and to deplete hepatic ATP (De Matteis & Rimington, 1962).
A wide variety of clinically important porphyrinogenic drugs such 
as barbiturates and anticonvulsants were also found to increase 
lactate production in cultured mouse fibroblast cells, presumably 
by increasing glycolysis (Cowger & Labbe, 1967). Bonkowsky et al 
(1975) have subsequently reported that mitochondrial NADH 
oxidation was impaired in fibroblast cultures from AIP patients as 
compared to controls, in keeping with the in vitro results. But 
no direct evidence is yet available to show that porphyrinogenic 
agents either inhibit NADH oxidation or ATP production in human 
nervous tissue. It is interesting however that some AIP patients 
have been noted to have an abnormal pyruvate tolerance test 
(Goldberg, 1959; Stein & Tschudy, 1970; Ridley, 1969; Nagler,
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1972). Unfortunately no nutritional documentation of these cases 
was provided and other factors such as thiamine deficiency which 
could possibly have given an abnormal pyruvate tolerance test were 
not excluded (Chapter 6).
The concept that the acute porphyrias constitute a group of "haem 
deficiency states" (Watson et al, 1977) gained considered support 
following the successful therapeutic use of parenterally 
administered haematin in exacerbations of the disease (Bonkowsky 
et al, 1971; Dhar et al, 1978; Watson et al, 1977; Lamon et al, 
1979; McColl et al, 1981). Haematin had been shown to repress 
hepatic ALA.S activity both in vitro and in experimental animals 
(Granick, 1966; Waxman et al, 1966; Burnham & Lescelles, 1963). 
Administration of haematin to porphyric patients consistently 
reduced the elevated concentrations of ALA and PBG in plasma and 
urine (Lamon et al, 1979; McColl et al, 1981; Pierach, 1982). 
Despite these defined effects on the haem pathway the precise mode 
of action of haematin in relieving the symptomatology of acute 
porphyria remains unclear.
The transfer of haematin across the blood brain barrier has not 
been adequately investigated. But of two AIP patients treated 
with intravenous boluses of haematin, none of it could be measured 
in the CSF (Lamon et al, 1979). Although this finding has been 
construed as evidence against the haem deficiency hypothesis in 
neural tissue (Bonkowsky & Schady, 1982) an alternative 
explanation is possible. Farrell & Correia (1980) have shown that 
liver cells can use exogenous haem directly to restitute any haem 
deficiency and there is no reason to believe that neural tissue
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cannot do the same. Since the porphyrin content of brain tissue 
is normally very low (Percy & Shanley, 1980) only a small amount 
of exogenous haem may be necessary for restoration of cellular 
function, without being accompanied by any significant increase in 
CSF level. The ability of neural cells to utilize haem or 
porphyrins synthesised extraneurally is supported by the findings 
that the total porphyrin content of different brain regions does 
not vary substantially and does not follow the pattern of ALA.S 
activity (Maines, 1980).
Should the therapeutic effectiveness of haematin not depend on its 
uptake by the neural tissues for direct use, two further 
explanations must be considered. First, haematin could simply be 
repressing ALA.S, thereby stemming hepatic overproduction of the 
neurotoxic porphyrin precursors. Second, deficiency of haem in 
the liver could conceivably impair its ability to detoxify some 
unidentified neurotoxic material or depress the production of some 
essential factor needed by neural tissues. In that respect it is 
noteworthy that subtle microscopic abnormalities have recently 
been described in the liver of porphyric patients whose bile salt 
and antipyrine clearances were found to be impaired (Ostrowski et 
al, 1983).
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SECTION II
CHAPTER 5
AUTONOMIC NEUROPATHY IN AIP
5. AUTONOMIC NEUROPATHY IN AIP
5.1 INTRODUCTION
The clinical manifestations of AIP have been attributed to a 
widespread neurological dysfunction caused by the block in haem 
biosynthesis (Gibson & Goldberg, 1956; Becker & Kramer, 1977b).
The abdominal pain has been explained on the basis of splanchnic 
autonomic dysfunction, providing a mechanism for the intestinal 
dilatation and stasis occasionally noted radiologically and at 
laparotomy in patients suffering from an acute attack (Berlin & 
Cotton, 1950). Indeed many of the accompanying features of an 
acute attack are suggestive of autonomic neuropathy; namely, the 
inappropriate sinus tachycardia, labile hypertension, postural 
hypotension, excessive sweating, severe vomiting, constipation and 
occasional diarrhoea and sphincteric bladder problems. Ridley et 
al (1968) have reported that tachycardia invariably preceded the 
development of peripheral neuropathy and respiratory paralysis, 
and they postulated that the tachycardia of porphyria might be due 
to autonomic cardioneuropathy. The transient and labile 
hypertension which commonly accompanies the acute attack has also 
been given a neurogenic explanation following damage to the vagal 
nerves from the underlying disease (Chapter 4).
The development of simple non-invasive tests of cardiovascular 
reflex function has enabled objective assessment of autonomic 
neuropathy to be made in a more systematic way than hitherto 
possible (Ewing, 1978 and 1984). I have therefore studied
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autonomie function in patients with AIP by using three tests that 
reflect cardiac parasympathetic integrity and two tests which give 
abnormal results with sympathetic nerve dysfunction.
5.2 PATIENTS AND METHODS
Four groups of subjects were studied, the individuals selected 
being less than 45 years of age. Group I consisted of 28 normal 
healthy subjects, age- and sex-matched with patients with AIP in 
groups II, III and IV, Group II comprised eight patients admitted 
to hospital during an acute attack of AIP prior to receiving any 
form of drug treatment. Six of these patients were subsequently 
retested while in remission and were also included in group III.
In group III there were 14 asymptomatic patients with AIP in 
remission, their last attack having occurred at least six months 
prior to autonomic testing (range 6 months - 10 years). Group IV 
had ten latent cases of AIP identified after screening relatives 
of known symptomatic cases. The latent cases denied ever having 
had any symptoms of acute porphyria, and they belonged to 
different kindreds. None of the subjects tested were taking any 
drugs that are known to interfere with autonomic tests. They all 
had a normal haemoglobin, random blood sugar and blood lead levels. 
In all symptomatic cases the diagnosis of AIP was made on the 
basis of excess urinary excretion of ALA, PEG and uroporphyrins, 
and confirmed by the measurement of the haem enzymes ALA.S and 
PBG.D in the peripheral leucocytes and erythrocytes respectively.
In latent cases in whom urinary excretion of porphyrin precursors 
and porphyrins were not necessarily elevated the diagnosis
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depended on the measurements of ALA.S and PBG.D activity (McColl 
et al, 1982b). Urinary ALA, PBG and porphyrins; and activities of 
ALA.S and PBG.D were measured according to the methods described 
by Moore (1983) and Moore et al (1978) respectively.
The three parasympathetic tests performed consisted of heart rate 
responses to the Valsalva manoeuvre and to standing from a lying 
position, and beat-to-beat variation in heart-rate with 
respiration. The two tests of sympathetic function were blood 
pressure response to sustained isometric hand-grip and postural 
drop in blood pressure upon standing (Ewing, 1984).
1. Valsalva manoeuvre (Ewing, 1984): The subjects were asked 
to blow into a tube connected to an aneroid manometer (Cape 
Engineering Co Ltd., Warwick, England) with their nostrils closed 
and to hold their breath at a pressure of 50 mmHg for 15 seconds 
while a continuous electrocardiogram was recorded. The Valsalva 
ratio was calculated from the ratio of the longest R-R interval 
after the manoeuvre (reflecting the rebound bradycardia) to the 
shortest R-R interval during the manoeuvre (reflecting the 
tachycardia during strain).
2. Heart-rate response to standing (Ewing et al, 1980a): After 
lying down in a relaxed state for five minutes, the subject was 
asked to stand up gently unaided and to remain standing for a 
further two minutes. A continuous ECG tracing was recorded for 
the period starting a few beats before until about 60 beats after 
standing. The R-R intervals were then measured with a ruler. The 
heart-rate response was expressed as the ratio of the longest R-R 
interval around the 30th beat to the shortest R-R interval around 
the 15th beat after standing (the 30 : 15 ratio).
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3. Heart rate variation during deep breathing (Hilsted &
Jensen, 1979). The patient, resting supine, was instructed to 
breathe deeply at the rate of six breaths per minute (timed 5 
seconds in and 5 seconds out) while an electrocardiogram was 
recorded. The minimum and maximum R-R intervals during each 
breathing cycle was measured with a ruler and converted to the 
equivalent number of beats per minute. The final result was taken 
as the mean of the difference between the maximal and minimal 
heart rates for three breathing cycles.
4. Sustained hand-grip test (Ewing, 1984): First the maximum
voluntary contraction (MVC) for the dominant hand was determined 
using a handgrip dynamometer (Tephcotronics Ltd., Edinburgh). The 
subject was then encouraged to maintain his handgrip steadily at 
only 30% of that MVC for as long as possible up to a maximum of 
five minutes. Blood pressure was measured by means of a London 
School of Tropical Medicine Sphygmomanometer (Rose-Box) on the 
non-exercising arm with recordings made three times at rest and at 
one-minute intervals during applied grip. The response to the 
test was taken as the difference in diastolic blood pressure 
(phase 5) between the mean of the three resting measurements and 
the last reading before release of handgrip.
5. Postural drop in blood pressure (Ewing, 1984): The blood
pressure of the subject was recorded after ten minutes rest while 
lying down and again, within 30 to 60 seconds, after standing up. 
The difference between the systolic blood pressure measured when 
lying and when standing was taken as the postural fall in blood 
pressure.
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a.tj,s_ti£^ a 1^ analysis 
The significance of differences between the mean values obtained 
in groups I, II, III and IV was examined by Analysis of Variance. 
When this was found to be significant, differences between 
individual group means were examined, in a standard manner, by 
follow-up t-tests.
5.3 RESULTS
Table 3 gives the clinical details of patients in group II who 
were in an acute attack at the time of autonomic testing. They 
all had severe abdominal pain. Six of the eight patients had 
detectable motor weakness affecting the limbs, especially the 
extensor muscles of the wrists. Those with motor involvement had 
a higher basal heart rate (range 84-119 beats/min) than normal 
(range 64-78).
All the subjects managed to perform the autonomic tests 
satisfactorily except for four of the eight patients in group II 
who had difficulty in sustaining the handgrip (test 4) as 
described. The test was accordingly modified in that these four 
patients were encouraged to sustain near maximum handgrip for at 
least 15 seconds before their blood pressure was measured.
The mean values (j^  SD) for the five tests of autonomic function 
are presented in Table 4. The three tests of parasympathetic 
cardiovascular reflex: Valsalva manoeuvre, heart-rate response to
standing and heart-rate variation during deep breathing, and one 
of the two tests of sympathetic function, the blood pressure 
response to sustained hand-grip were abnormal for group II as 
compared to normal controls (group I). The differences during the
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acute attacks were most marked in the heart-rate response to 
standing (30 : 15 ratio) and the blood pressure response to 
sustained handgrip (Figs 11 and 12). It is interesting to note 
that all these abnormal tests improved on subsequent re-testing 
during remission.
The Valsalva manoeuvre and heart-rate variation during deep 
breathing were also significantly reduced for the latent 
porphyries (group IV) and those in remission (group III) 
respectively.
5.4 DISCUSSION
The battery of cardiovascular reflex tests used in our study has 
already proven to be useful in the overall assessment of the 
autonomic system in diabetic patients towards a better 
understanding of the natural history and prognosis of that disease 
(Ewing et al, 1980b, 1980c). These tests have now provided 
objective evidence for the common occurrence of both 
parasympathetic and sympathetic dysfunction during the severe 
acute attacks of AIP as manifested clinically.
In contrast to diabetic neuropathy in which neurological damage 
tends to persist once detectable (Ewing et al, 1980b; Watkins & 
Edmonds, 1984) the autonomic disturbance in the acute attack of 
porphyria appears to be mostly reversible. Interestingly one of 
the patients in group II experienced a prolonged attack lasting 
several months and her autonomic tests were repeatedly found to be 
grossly abnormal. Undoubtedly persistent peripheral nerve damage 
can occur in porphyric neuropathy, even after a single severe
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Figure 11: Results of (a) Valsalva manoeuvre; (b) 30 : 15 ratio
and (c) heart rate variation during respiration in 
different groups:
(l) young normal subjects; (ll) AIP in acute 
attack; (ill) AIP in remission; and (IV) latent 
AIP. Each line represents individual patients tested 
during an acute attack and during remission.
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Figure 12: Results of blood pressure response to (d) sustained
muscular exercise and (e) posture in groups I to IV.
acute attack (Ridley, 1969; Sorensen & With, 1972). But the 
reversible nature of the abnormal tests supports the possibility 
of a transient functional autonomic blockade either resulting from 
impaired haem biosynthesis within the nerve cells or an 
accumulation of porphyrin precursors or their derivatives in the 
body. The actual operative mechanism however remains speculative 
(Chapter 4).
The Valsalva manoeuvre has previously been reported to be a good 
indicator of parasympathetic dysfunction in diabetic patients, and 
in this present study it was found to be abnormal in latent AIP. 
This observation is in keeping with the subclinical sensorimotor 
neuropathy often present in these latent AIP cases as detected by 
nerve conduction studies (Mustajoki & Seppalainen, 1975). Yet the 
Valsalva manoeuvre remained normal in the AIP patients in 
remission whereas heart-rate variation during deep breathing was 
significantly reduced. The discrepancy between these two tests of 
parasympathetic function could perhaps be accounted for by the 
relatively small number of patients studied since heart-rate 
variation during deep breathing is reputedly another sensitive 
index of parasympathetic nerve damage in diabetic patients, often 
preceding the manifestation of autonomic symptoms for years 
(Mackay et al, 1980). Recently Gupta et al (1983) reported that 
the 30 : 15 ratio was also abnormal in asymptomatic Indian 
subjects with AIP, but they did not measure other parameters of 
autonomic function. Nevertheless with cardiac autonomic 
involvement these studies have shown that in AIP, as in diabetes, 
the parasympathetic tests become abnormal earlier and more
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frequently so than the sympathetic tests (Bennett et al, 1978; 
Ewing et al, 1980c).
Although the results of the autonomic tests in the groups of 
porphyric subjects were statistically different from the control 
group, few individual values were in the unequivocally abnormal 
range of values published by Ewing et al (Ewing, 1978 & 1984) on 
the basis of their work in diabetic patients. The reason for this 
is not clear. A higher hasal heart rate, as noted in AIP patients 
in an acute attack, is presumably not the predominant causative 
factor since the beat-to-beat variation in heart rate with 
respiration has at least been shown to be independent of basal 
heart rate (Ewing et al, 1981). Care was taken in excluding older 
subjects from the study since increasing age affects sinus 
arrhythmia (Heilman & Stacy, 1976) postural blood pressure (Caird 
et al, 1973) and heart-rate response to the Valsalva manoeuvre 
(Kalbfleisch et al, 1978). The complete absence of symptoms in 
the latent cases with early parasympathetic damage, and the lack 
of other autonomic clinical manifestations in a number of AIP 
patients with severe abdominal pain suggest that the abdominal 
pain is not entirely due to autonomic dysfunction. Until 
splanchnic autonomic function can be measured by more direct and 
sensitive methods in porphyric patients its relationship to 
abdominal pain will remain conjectural.
It is conceivable that the pain might be causally related to local 
vasoconstrictor (Denny-Brown & Sciarra, 1945) or spasmodic effects 
(Cutler et al,1980) of porphyrin precursors (or derivatives) on 
the gut. The experience of pain by some patients with autonomic
102
SECTION II
CHAPTER 6
A STUDY OF CYTOCHROME OXIDASE ACTIVITY IN 
MUSCLE BIOPSIES FROM PATIENTS WITH AIP 
AND OTHER DISEASES
6. A STUDY OF CYTOCHROME OXIDASE ACTIVITY IN MUSCLE 
BIOPSIES FROM PATIENTS WITH AIP AND OTHER DISEASES
6.1 INTRODUCTION
The hypothesis that the clinical manifestations of AIP are due to 
intraneuronal haem deficiency has been difficult to substantiate 
because of the present limitations in measuring the "free haem" 
pool. During an acute attack of porphyria, in addition to 
abdominal pain, the patient often complains of limb pain, hitherto 
attributed to the neuropathy. Accompanying muscle tenderness can 
be quite troublesome (Goldberg, 1959; Ridley, 1969) but there is 
no elevation of serum muscle enzymes (Stein & Tschudy, 1970, 
Personal observations). The possibility of a myopathic component 
contributing to the muscle weakness in acute porphyria is 
supported by the observation that peripheral reflexes are often 
preserved in the presence of severe limb paralysis (Ridley, 1969). 
Labbe's group (Labbe, 1967; Cowger & Labbe, 1967) have reported 
that a wide variety of porphyrinogenic drugs could inhibit 
mitochondrial terminal oxidation leading to enhanced glycolysis in 
vitro. The increased glycolysis, as reflected in lactate 
concentration, was attributed to the Pasteur effect - accelerated 
glycolysis resulting from impairment of terminal oxidation. 
Bonkowsky et al (1973) subsequently showed that fibroblast 
cultures from AIP patients had a defect in mitochondrial 
oxidation. Indeed energy production in muscles greatly depends on
104
phosphorylative oxidation which uses many haem-containing 
cytochromes. This present study was undertaken to determine if 
cytochrome oxidase activity was impaired in AIP.
6.2 PATIENTS
The following patients were studied:
1. Fourteen AIP patients in an acute attack requiring hospital 
admission and one latent case of AIP. Their clinical and 
biochemical findings are summarised in Tables 5, 6 and 7.
2. Two patients with peripheral neuropathy caused by proven 
chronic lead poisoning.
3. Seven patients with denervation states due to lateral 
popliteal nerve damage (1), chronic alcohol abuse (2) and 
diabetes.
4. Two with autoimmune polymyositis.
5. Twelve with post-viral fatigue syndrome, all being
sero-positive for Coxsackie B antibody (Behan & Behan, 1980)
6. Ten "normal" controls undergoing hip surgery for
degenerative joint disease and rheumatoid arthritis.
6.3 METHODS
Five of the AIP patients underwent an open muscle biopsy under 
local anaesthesia, and tissue was obtained from the "normal" 
controls at the time they had their operation. The remaining 
patients had a needle biopsy performed under local anaesthesia 
with lignocaine (Edwards et al, 1980). The muscle tissue was 
immediately snap-frozen in liquid nitrogen before being processed
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at the Regional Neuropathology Centre, Institute of Neurological 
Sciences, Glasgow. Tissue sections were stained histochemically 
for cytochrome oxidase, succinate dehydrogenase, muscle 
phosphorylase, myosin ATPase and monoadenylate deaminase. 
Cytochrome oxidase activity was assessed by using the modified 
Burstone and G-NADI methods.
6.3.1 Histochemical methods 
Cytochrome oxidase
(1) Modified Burstone method (Burstone, 1960)
The tissue sections were incubated for periods varying from 10 to 
40 minutes at 37°C in Tris-buffered solution containing 
p-aminodiphenylamine (base) and 8 amino- 1, 2, 3, 4 tetraquinoline 
at pH 7.4. After the incubation period they were transferred into 
10% cobaltous acetate in 10% formalin (PH 5.2) for one hour. The 
slides were then washed under running water and mounted in 
glycerin jelly.
(2) Graff^s NADI method (Pearse, 1972)
The section were incubated for periods varying from 10 to 40 
minutes at 37°C in NADI reagent solution (PH 7.5) containing 
alpha-naphtol and the oxidase reagent, dimethyl-p-phenylene 
diamine hydrochloride. After incubation the sections were washed 
with normal saline and mounted in 20% potassium acetate. The 
coverslips were ringed with paraffin wax and examined within 24 
hours since these preparations are not permanent.
Both cytochrome oxidase methods were used with and without 
cytochrome C in the incubation medium as an enhancing agent.
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u^ç.cijia,t^  dehydrogenase, a mitochondrial enzyme catalysing the 
conversion of succinate to fumarate in the Kreb's cycle, was 
stained histochemically by the method of Pearse (1972),
Muscle phosphorylase, a regulatory enzyme for the conversion of 
glycogen into glucose residues, was assessed according to the 
method of Meijer (1968).
Mpiio^denxl^te^ ^ eamjjias^, a cytosolic enzyme whose deficiency is a 
recognised cause of myopathy, was stained histochemically by the 
method of Fishbein et al (1980).
Myo.sjji_AXPa,se. staining (Padykulla & Herman, 1955) permitted the 
differentiation of muscle fibre types. At pH 9.4, the type II 
fibres stained dark and the type I fibres were light-reacting 
(Swash & Schwartz, 1984).
6.3.2 Methods of histochemical assessment 
1. .Çy t.o^ hxome_ox i^ a^ e_ac.t iyitx
The sections were examined after the shortest time interval at 
which the reaction product became detectable histochemically i.e. 
10 minutes, and then at 10 minute intervals till 40 minutes. The 
sets of sections were coded and always examined with control 
sections previously shown to stain strongly for cytochrome 
oxidase. They were examined by an experienced 
neuro-histopathologist (Dr D Doyle) under light microscopy and 
scored subjectively for the presence or absence of the reaction 
products (Fig 13). The following scoring system was adopted:
110
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Figure 13: Histochemical staining of muscle sections
by the Burstone method. On the left is a 
strongly positive reaction (graded 3 )
from a normal control; the middle picture 
shows a medium reaction graded 3 ; and on 
the right is a negative reaction (graded 
(0 ) from an active AIP patient.
(Courtesy of Dr D Doyle)
Numerical Scale Activity
0 No demonstrable activity evident
1 Only few muscle fibres showed slight activity
2 All fibres showed activity but not sufficient 
to allow type fibre differentiation
3 Type fibre differentiation was present but 
weak
4 Type fibre differentiation was moderate
5 Type fibre differentiation was strong.
After the first reading the activities were checked again before 
final scores were given. This method of assessment was validated 
after obtaining similar results with the same sections stained and 
reassessed at a later date.
2. The activities of the other enzymes studied were graded 
either normal or reduced as compared to the control muscle 
sections.
Pyriiva^e_To^l^r^nc^e_Te^s^ (PTT) was performed in six of the active 
AIP patients, each matched for age and sex with two normal healthy 
controls. The patients were given at least 2500 Kcals daily for a 
minimum period of one week before the test was carried out. After 
an overnight 12 h fast a baseline venous blood sample was taken 
and the subject was given 50 gram of glucose dissolved in 300 ml 
of water. This was followed by a further 50 gram of glucose 30 
minutes later. Blood samples were removed at 60 and 90 minutes 
after the first glucose load. Blood for pyruvate and lactate 
levels was immediately transferred into ice-cold 10/ 
trichloroacetic acid solution. Pyruvate and lactate were assayed 
by the methods of Hadjivassiliou & Reider (1968).
Ill
6.4 RESULTS
All 14 patients with active AIP showed some depression of 
cytochrome oxidase activity by both histochemical tests whereas 
the latent case and the normal controls had good enzymatic 
activity (Tables 8 and 9). Fewer cases were stained by the 
Burstone method because of its later development as a routine 
staining. There was good correlation between the results of the 
two cytochrome oxidase methods. The 12 AIP patients in whom the 
activity was more markedly depressed showed virtually no reaction 
product at the lowest incubation time at 10 minutes. But by 
increasing the incubation time the activity became perceptible in 
six and remained undetectable in the others. With the addition of 
cytochrome C as an enhancing agent, there was a detectable product 
at 40 minutes in all cases, although the reaction was still 
weaker. One patient (EL) had two muscle biopsies: the first being 
an open biopsy and the second a needle biopsy performed 18 months 
later. On both occasions she had similar staining results. The 
latent AIP gave a detectable reaction at 10 minutes proceeding to 
a strong staining of well-defined fibre types at 40 minutes, even 
without addition of cytochrome C.
The two patients with lead poisoning also showed severe depression 
of cytochrome oxidase activity. In the non-porphyric groups 
cytochrome oxidase activity was more variable but generally much 
stronger than in the AIP patients. Six of the seven patients with 
peripheral denervation states expressed reduced cytochrome oxidase 
activity but most developed a reaction short of type 
differentiation after 40 minutes. Cytochrome oxidase was also
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impaired in the two cases of polymyositis, particularly in the 
damaged fibre staining at 40 minutes but addition of cytochrome C 
led to clear distinction of fibre types.
Of the five AIP patients who had an open muscle biopsy, 
histological changes of denervation were present in three and two 
of these showed marked features of reinnervation as well. Muscle 
histology in the remaining two patients was entirely normal 
although cytochrome oxidase activity was reduced in both. No 
obvious difference was discernible between the biopsies of those 
with and those without denervation/reinnervation.
Succinate dehydrogenase and muscle phosphorylase activities were 
reduced in seven of ten active AIP cases studied, and normal in 
the latent case. Monoadenylate deaminase staining appeared 
normal. Myosin ATPase showed a mild predominance of type II 
fibres in several of the AIP cases, but depression of cytochrome 
oxidase activity involved both types of muscle fibres.
The pyruvate tolerance test results are shown in Fig 14, Blood 
lactate levels measured simultaneously during these tests, 
together with the fasting blood glucose and erythrocyte 
transketolase activities are given in Table 10, The normal 
erythrocyte transketolase activities excluded thiamine deficiency 
as a possible cause of the abnormal pyruvate tolerance test 
observed in four of the six AIP patients studied. The fasting 
blood lactate concentrations were normal in the porphyric patients 
and did not rise significantly after glucose loading.
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PYRUVATE TOLERANCE TEST IN ACUTE
INTERMITTENT PORPHYRIA
B L O O D  
P Y R U V A T E  ( w m o l / O
300-
200-
C O N T R O L S
( M e a n i S . D . )
p < 0.05
100-
P A R E T I C
SOg50g
0 - - 0  N O N - P A R E T I C
G L U C O S E
0 60 9030
T I M E  ( m i n u t e s )
Figure 14: Shaded area represents mean ± S.D.
for 12 controls age- and sex- 
matched with the AIP patients.
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6.5 DISCUSSION
Cytochrome oxidase is a complex functional unit which forms part 
of the inner mitochondrial membrane (Fuller et al, 1979( (Fig 
15). It consists of two types of haem proteins, cytochromes a and 
a3 , and it requires copper ions for its activity (Malmstrom, 1979; 
Wainio, 1983). Its fundamental role is to transfer electrons 
along the terminal oxidative phosphorylation pathway from 
cytochrome C^ to molecular oxygen (Azzi, 1980) (Fig 16).
Cytochrome oxidase thus catalyses the final step in a series of 
redox reactions involved in cellular respiration for ATP 
synthesis.
Using two different staining techniques cytochrome oxidase 
activity was found to be markedly depressed in muscle from 
patients with active AIP and chronic lead poisoning.
Interestingly, both tests were normal for the latent case of AIP, 
who was the father of one of the AIP patients (EL) with severe 
enzymatic depression. The reduction in cytochrome oxidase 
activity involved muscle fibres of both types I and II (a and b), 
although, as is characteristic of neuropathies in general (Swash & 
Schwartz, 1984), there was a mild predominance of type II fibres 
in the presence of denervation changes.
Six of the 14 AIP patients studied had evidence of muscle atrophy, 
partly contributed by disuse and partly by the underlying 
disease. The remaining eight AIP patients had normal muscle bulk 
and were fully mobile. Several workers have shown both 
experimentally (Rifenberick et al, 1973; Nemeth et al, 1980) and 
in man (Astrom et al, 1976) that although muscle disuse caused
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CYTOCHROME C
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MEMBRANE
CYTOCHOME-C 
OXIDASE MITOCHONDRION
Figure 13; Diagrammatic representation of the
cytochrome oxidase molecule within the 
mitochondrial membrane. Each molecule 
reguires two iron and two copper ions 
for activity.
Cyt c + 2 Cyt a (Fe )
I
Cyt C + 3 /  ^ Cyt a (Fe ■^)
C Y T O C H R O M E  C OXIDASE
& 0.
Figure 16: The last stage of the electron transport
chain where cytochrome oxidase (i.e. 
cytochrome aa,) transfers electrons from 
cytochrome C to molecular oxygen with the 
generation of A T P
atrophy it did not affect the activities of several mitochondrial 
enzymes including cytochrome oxidase. On the other hand, muscle 
denervation in animals led to a marked decline in metabolic rates 
and enzyme activities, suggesting possible neural regulation of 
mitochondrial enzymes in type 1 muscle (Nemeth et al, 1980), This 
explanation might account for the mild depression of cytochrome 
oxidase activity seen in patients with the other types of 
denervation states.
It is important to note that cytochrome oxidase activity was 
depressed in AIP patients even in the absence of clinically 
evident peripheral neuropathy or denervation changes 
histologically although it was more markedly so in the presence of 
these findings. Astrom et al (1976) have reported that muscle 
mitochondrial enzyme activities also became depressed during viral 
and mycoplasma infections and slowly rose towards normal in the 
convalescent period. This might explain the reduced cytochrome 
oxidase activity observed in patients with the post-viral fatigue 
syndrome. At present little is known about the genesis of the 
post-viral fatigue syndrome other than its strong association with 
Coxsackie B infections and a lack of any consistent physical, 
biochemical or histological findings (Behan & Behan, 1980).
Certain immunological abnormalities have recently been found 
(Behan, 1983) but, interestingly, Arnold et al (1984) have also 
discovered a defect in the energy-producing mechanism of such a 
patient by ^^P-nuclear magnetic resonance spectroscopy.
In view of the subjective element inherent in the histochemical 
methods used the excellent correlation between the results of the
118
Burstone and G-NADI techniques, performed over a study period of 
five years, strongly supports our conclusions about the cytochrome 
oxidase activity. There is indeed some evidence to suggest that 
cytochrome P450 deficiency exists in the liver of patients with 
the acute hepatic porphyrias. Anderson et al (1976) have shown 
that hepatic oxidative drug metabolism, as measured by antipyrine 
half-lives, was significantly depressed during the active phase of 
AIP. Ostrowski et al (1983) who have reported that antipyrine 
clearance was impaired even during the remission phase. Indeed, 
antipyrine clearance has been found to be a good measure of the 
activity of the cytochrome-dependent microsomal mixed-function 
oxygenase system (Hepner & Vessell, 1975).
Gross impairment of cytochrome oxidase would be expected to cause 
an accumulation of pyruvate and lactate (Fig 17), as has been 
reported in cases with congenital deficiency of this enzyme (Di 
Mauro et al, 1980; Minchom et al, 1983; Sengers et al, 1984). The 
abnormal pyruvate tolerance test found in four of the six AIP 
patients studied can be explained in the same manner. These four 
patients had more severe attacks with limb weakness whereas the 
two patients with normal pyruvate tolerance test only complained 
of abdominal pain. Blood lactate levels, however, were not 
significantly raised in any of the five AIP patients, three of 
whom also had an abnormal pyruvate tolerance test. In McArdle's 
disease where there is a congenital deficiency of muscle 
phosphorylase blood lactate fails to increase after exercise 
(Howell, 1978). Exercising the patients might well have caused 
an abnormal elevation of blood lactate but it was not possible 
to exercise these patients because of their clinical 
condition.
Oxidative Catabolism
Glucose
Lactate.
Glycolysis
A
Pyruvate }} 
U
Acetyl CoA
Citric
Acid
Cycle
CO2
e
\  Cytochrome 
Oxidase electron transport chain
3 ATPI I
Figure 17; Schematic representation of the effects of 
cytochrome oxidase deficiency on 
oxidative catabolism.
The presence of cytochrome oxidase has been demonstrated in both 
nerve cells and neuroglia of the cerebral cortex (A1 Ali & 
Robinson, 1979). A deficiency of cytochrome oxidase activity in 
AIP would lend support to the concept of a functional neuronal 
block operating in the genesis of the clinical manifestations.
This would account for the absence of histopathological changes in 
the fatal case of AIP whose illness, lasting for several years, 
was complicated by marked quadriparesis and ultimately led to 
respiratory failure (Chapter 7). Such observation has previously 
been made by other workers (Mason et al, 1933; Hierons, 1957). It 
is conceivable that a more severe or prolonged depression of 
cytochrome oxidase activity could cause the nerve cells to 
degenerate. Since mitochondria are located within the perikaryon 
of the nerve cells the distal part of the axons would be the most 
vulnerable, irrespective of their length. This could explain 
Cavanagh's observation (1967) that the dying-back type of 
neuropathy in acute porphyria is "not typical of that seen with 
organo-phosphorus poisoning" where cells with the longest fibres 
are affected first, but where fibres of neurones with the largest 
metabolic requirements are also involved.
Furthermore the brain is metabolically one of the most active 
organs in the body with relatively enormous rate of oxygen 
consumption. For a 70 kg man, it is estimated that the brain 
requires about 40 ml oxygen/min as compared to 250ml oxygen/min 
for his whole body (Smith & Sokoloff, 1981). The oxygen is used 
for glucose metabolism upon which the brain almost entirely 
depends. Not only does it utilize oxygen at a rapid rate but it
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is dependent on uninterrupted oxidative metabolism for maintaining 
its structural integrity and functional activities (Klatzo &
Spatz, 1981). This high sensitivity of neuronal cells to oxygen 
deprivation could account for the nervous system to be the primary 
organ affected in acute porphyrias.
The potent inhibitory effect of lead on the haem enzymes, 
especially ALA.D (Moore et al, 1980a) could adequately explain the 
severe depression of muscle cytochrome oxidase activity in the two 
patients with chronic lead intoxication.
If cytochrome oxidase deficiency could account for the 
pathogenesis of the acute types of porphyria the absence of 
neurological complications in the non-acute types such as 
porphyria cutanea tarda or erythropoietic porphyria would require 
further explanation. As previously discussed (Chapter 1) evidence 
is accumulating for the existence of different control mechanisms 
operating on the haem pathway in different tissues of the body 
(Kappas et al, 1983; Maines, 1984). Moreover congenital 
cytochrome oxidase deficiency is not uniformly present in all 
tissues. For instance Stansbie et al (1982) described a patient 
with selective cytochrome oxidase deficiency in skeletal muscle 
whereas the cases reported by Di Mauro et al (1980) and Van 
Biervliet et al (1977) also had kidney involvement. In two 
further cases, the biochemical abnormality was reversible in one 
(Di Mauro et al, 1983) and was probably a coincidental finding in 
the other (Rimoldi et al, 1982). Patients with oculo-cranial- 
somatic syndrome (Versmold et al, 1977; Mitsumoto et al, 1981) are 
also lacking in cytochrome oxidase but the deficiency in the
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muscles is only partial, affecting a proportion of muscle fibres 
of both types I and II (Johnson et al, 1983). Muscle cytochrome 
oxidase deficiency has also been reported in association with 
Leigh's encephalomyelopathy (Willems et al, 1977) and progressive 
poliodystrophy (Alper's disease) (Prick et al, 1983).
These various phenotypic expressions could conceivably result from 
mutations involving different cytochrome oxidase isoenzymes in 
different tissues. The specific block in the haem biosynthetic 
pathway imposed by the type of porphyria could provide a further 
mechanism by which the synthesis or functional activity of 
particular cytochrome oxidase isoenzymes could be regulated. 
Indeed, Arrese et al (1982) have shown that an abnormal 
uroporphyrinogen decarboxylase isoenzyme was specifically involved 
in haem "a" production in a yeast mutant resulting in marked 
cytochrome oxidase deficiency.
Other specific defects of the respiratory chain affecting 
cytochromes b and c^ or NADH.CoQ reductase complex (Morgan-Hughes 
et al, 1977; Morgan-Hughes, 1983) have been described. All these 
patients suffered from mild weakness, severe exercise intolerance 
and a fluctuating acidosis which was either induced or made worse 
by exercise. None, however, had central nervous manifestations. 
Recently it has become possible to observe non-invasively the 
energy metabolism of human muscle in vivo by using phosphorus 
nuclear magnetic resonance measurements (Ross et al, 1981; Gadian 
& Radda, 1981). Application of this technique in acute porphyria 
to measure intracellular pH and phosphorylated high energy 
compounds such as ATP would be most helpful in confirming the
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existence of a myopathie component due to cytochrome oxidase 
deficiency. But more precise quantitative measurements of the 
various types of cytochromes in neural tissue will be required to 
ascertain their role in porphyric neuropathy.
On the basis of the results presented, it is suggested that a 
deficiency of cytochrome oxidase, affecting the nerve cells in 
particular, could link the biochemical, clinical and 
neuropathological findings in AIP.
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SECTION II
CHAPTER 7
CLINICO-PATHOLOGICAL DISCUSSION ON A FATAL CASE OF AIP
7. CLINICO-PATHOLOGICAL DISCUSSION ON A FATAL CASE OF AIP
7.1 INTRODUCTION
As stated in the review (Chapter 4) some controversy still exists
as to what part axonal degeneration and segmental demyelination
play in the pathogenesis of AIP. The correct assessment and 
interpretation of the neuropathological changes is indeed an 
important prerequisite for understanding the mechanism of the 
neuropathy. Although pharmacological and degenerative processes 
must be considered separately a unitary explanation must be sought 
in the final solution. In this chapter, the detailed 
neuropathological studies undertaken in a well-documented case of 
AIP who died of the disease are presented.
7.2 CASE REPORT
This 31-year old woman was diagnosed as having AIP in 1971 at the
age of 22. Until May 1978 she had already been admitted to 
hospital on 12 occasions because of severe abdominal pain, 
constipation and vomiting. Three of these attacks were 
complicated by mild quadriparesis from which she subsequently 
recovered. Her attacks were inconstantly related to menstruation 
and no other precipitating factors could be identified. On most 
previous admissions she had received parenteral administration of 
20% laevulose intravenously in addition to symptomatic treatment 
with pethidine and chlorpromazine.
124
4-1
•H
>
■H
4J 0
o 4-1
CD u G
•H U
CD w CD
CO 0
CD a i  c*-
«—4 O
4-1 CD
C C
>\ CD
CO ü
"O 0
< C
- J ra
< 0
0
CD 4-1 ■O
CD 0
>> ü CGI
a C
a 2 Q
a G 1—4
3 f—4 G
CD Ci- (-1
Cl
Ds:
c: CD JT
a 0 4-1
Q . ■H
2
>>
C
CD O 0
4J E5 ra G
CD ü 2
•H
CXTD
CO
o 0 O
IL, 1
CO (4
CD 0 0
CO C 0 •H
'r-l o >> |4
3 -H 1 > \
O 4-1 rC.
ü 0 n CL
(-1 C-i
0 0 c O
0 X •H G.
C4 0
0 4-1
< c 4-1 c
_ l C 0
u_ < 0 4-1
o s 4-1
>N 0 •H
P4 t4 E
ü CD u
0 C G 0
Ci_ •H G" 4-1
I-I 0 C
w G C-i
3
en
Is
4-1
•H
>
•H4-J 0
Ü 44ro O 3
•H Ü
0 0 0
0 0
0 cn 0-
_C 1— 1 O4-J 0c C
>, 0
0 uXJ 0
< c 44
_1 0 44
< 0
0
0 4->~a4-4 0 0
>\ P4 Ql
o co 2 oo o 1— 1D 1— 1o
0 Q- f41— 1 Q_
c 0 JCo 0 44a.■Hc s•H >%4-> f4 c0 O 0
E 4-> E0 0 O0 (4 sJZ •Ha.T3U- 0 rH
O 0 of4 1
0 f4
0 0 0
0 c 0 •H
Ü4 o >> f4D •H 1
O 44Ü 0 Q.f4 (4
0 o c O
0 X •H Q.
f4 0
0 44
44 44 C
_l c 0
(+- < 0 44
O E 44
>> 0 •H
4-) f4 f4 E
Ü 0 •H f4
0 c 3 0
0- •H CT44
l4- f4 0 o
LiJ D •H
CO
0A
3
cn•H
On O^ c_to^ e_r _9,_1_97^  she was given a fifth course of haematin for an 
attack complicated by severe hypertension (210/125 mm Hg) and 
tachycardia (160/min). On that occasion, she developed a 
hypertensive exudative retinopathy (Fig 8), The hypertension and 
accompanying fundal changes settled with propranolol and two weeks 
later she was discharged home.
Seven months later on Max 2 0 1 9 8 0  she was readmitted with severe 
abdominal pain, hypertension, tachycardia and marked muscle 
weakness. Her temperature was mildly elevated (38.5°C) in the 
absence of detectable infection. Nevertheless she was treated 
with parenteral broad-spectrum antibiotics. She also had three 
generalised tonic-clonic seizures which did not require specific 
treatment. Administration of a sixth 2-day course of haematin 
failed to produce any beneficial effect. On iun,e_5j_ 1980 the 
patient was transferred to the intensive care unit. The following 
day she suddenly went into asystole from which she was 
successfully resuscitated. Apart from a mild hyponatraemia (Na: 
128 mM/L) and hypochloraemia (Cl: 92 mM/L) no other biochemical 
abnormalities were present at the time. Her arterial blood gases 
which had been monitored closely were deemed satisfactory. The 
asystole was considered to be a possible manifestation of the 
widespread autonomic neuropathy. Although the patient did not 
appear to have sustained any cerebral damage from her cardiac 
arrest, she required artificial ventilatory support for the 
subsequent ten weeks because of severe motor paralysis.
On Au£uxt_12»_1980. she was weaned off the ventilator. She still 
experienced constant abdominal pain despite regular administration
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of narcotic analgesics. Her hands were deformed showing a 
claw-like deformity; the muscles of her lower limbs were wasted 
but no fasciculation was present. Her peripheral reflexes were 
absent and both plantar reflexes were flexor. Sensory modalities 
were clinically unimpaired. Her state of nutrition was otherwise 
remarkably good following the parenteral nutrition she had been 
receiving. On ^e2.tember_ 1980 she had another episode of 
asystole in the ward and died despite resuscitative 
measures.
Autopsy was performed ten hours after the time of death by 
Professor David Graham from the Department of Neuropathology, 
Institute of Neurological Sciences, Glasgow with the specific 
purpose of correlating the histopathological findings with the 
clinical features. The histopathological findings were initially 
reported by Professor Graham and later reviewed by Dr David Doyle, 
Consultant Neuropathologist.
7.3 NEUROPATHOLOGY
7.3.1 Gross features
The brain weighed 1220 grams and no external abnormality was 
noted. The meninges were normal with no evidence of tentorial or 
tonsillar herniation. The hypothalamic structures and oculomotor 
nerves were normal. The basal vessels were fully patent and free 
of congenital anomaly.
Coronal sections; No abnormalities were seen in serial sections 
of cortex, white matter, basal ganglia, thalami and hypothamus 
including the mamillary bodies. The ventricles were of normal 
size and there was no shift of the midline structures. Each
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medial occipital cortex was also normal. The stems and branches 
of cerebral arteries were thin-walled and patent. The cerebellum 
and brain stem were entirely normal externally and at multiple 
representative cross-sectional levels. The spinal cord was 
likewise normal externally and at multiple representative levels 
throughout its length.
7.3.2 Histological findings
Sections were routinely stained by haematoxylin and eosin, Van 
Giesen, Luxol fast blue counterstained with cresyl violet and 
silver impregnation after Palmgrin staining.
Multiple representative sections were taken from both right and 
left cerebral and cerebellar hemispheres. The only abnormality 
noted was focal loss of nerve cells within the Sommer sector of 
the hypothalamus. These minor changes were fairly recent in that 
there was considerable microglial cell reaction to the loss of the 
nerve cells. Otherwise there were no other abnormalities - in 
particular no evidence of demyelination.
The sections of hypothalamus and brain stem were completely 
normal. Particular attention was paid to the vagal nuclei. 
Similarly sections of the spinal cord taken at multiple levels 
showed no evidence of demyelination, especially within the 
ascending fibre systems of the posterior columns. Chromatolytic 
changes were not seen either in the anterior or posterior horn 
cells.
Posterior root and autonomic ganglia were completely normal. The 
posterior roots showed no features of demyelination or axonal loss. 
Multiple transverse sections of the ulnar.,_sc.iAtic_and_suraLl
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nerves showed preservation of normal axonal types with no features 
of demyelination or Wallerian degeneration. No teased fibre 
preparations were available for examination.
7.4 DISCUSSION
It is now widely accepted that axonal degeneration, and not 
demyelination, is the main histopathological lesion that 
characterises the peripheral neuropathy of acute porphyrin (Mason 
et al, 1933; Sweeney et al, 1970; Cavanagh & Mellick, 1965). This 
finding is supported by electrophysiological studies which have 
often shown normal or only minimal impairment of motor conduction 
velocities in the presence of severe muscle weakenss (Nagler,
1971; Flugel & Druschky, 1977; Albers et al, 1978; Wocknik-Dyjas 
et al, 1978), Earlier reports have also noted the absence of any 
morphological changes in the nervous system of some porphyric 
patients who died of the disease, but incomplete documentation has 
made meaningful interpretation difficult (Mason et al, 1933; 
Denny-Brown & Sciarra, 1945; Hierons, 1957). Following the 
detailed neuro-histopathological study of five fatal AIP cases by 
Cavanagh & Mellick (1965), highlighting the neuropathy of acute 
porphyria as an example of dying-back axonopathy, only sporadic 
reports have been published, usually of peripheral nerve biopsies 
(Nagler, 1971; Thomas, 1971; Wakayama et al, 1975; Anzil & Dozic, 
1978; Thorner et al, 1981). Apart from few reservations 
concerning the possible contribution of demyelination in the 
pathogenesis of the disease (Thomas, 1971; Wakayama et al, 1975; 
Anzil & Dozor, 1978) axonal degeneration has consistently been
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emphasised as the hallmark of porphyric neuropathy. In the 
autopsy cases whenever axonal changes were found in peripheral 
nerves chromatolysis was invariably present in the anterior horn 
cells, vagal and autonomic nuclei (Bostroem, 1920; Mason et al, 
1933; Baker & Watson, 1945; Denny-Brown & Sciarra, 1945;
Gibson & Goldberg, 1956; Ten Dyck et al, 1961; Sweeney et al, 
1970).
The present case is remarkable because of the singular lack of 
morphological changes, previously described in such cases in both 
central and peripheral nervous system. This is despite well 
documented evidence of active disease over a period exceeding 
eight years during which the patient developed all the severe 
complications attributed to a widespread neuropathy (Goldberg, 
1959). During the later phase of her illness she suffered from 
constant abdominal pain and had marked tetraparesis. Wasting of 
the extensor muscles of the upper extremities was particularly 
evident resulting in claw-like deformity of her fingers. Without 
examination of teased fibre preparations, more subtle changes of 
demyelination or Wallerian degeneration in the peripheral nerves 
could not be excluded. But there were certainly no abnormalities 
to be found in the multiple cross-sections obtained from the 
autonomic nerves, and peripheral nerves supplying the severely 
affected limbs.
Whether haematin therapy could have had a protective effect on the 
development of morphological changes in the nerve cells remains 
speculative. In vitro experiments have shown that haematin can 
promote neurite growth (ishii & Maniatis, 1978; Bonyhady et al.
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1982). The relatively small quantity of haematin administered and 
the short time course of these treatments could cast some doubt on 
this possible mode of action. Nevertheless, this matter is 
undoubtedly of considerable therapeutic importance because earlier 
and more frequent administration of haematin than hitherto 
employed may well prevent the chronic sequelae of the acute 
porphyric attack.
The findings of this case support the concept that porphyric 
neuropathy is primarily due to a functional block within the nerve 
cells, possibly arising from a deficiency of haem containing 
compounds (Meyer, 1973) such as cytochrome oxidase (Chapter 6).
If the cellular dysfunction becomes unduly severe or prolonged the 
recognised morphological changes could ensue and cause permanent 
damage. The mechanism can also explain why the "dying back" type 
of porphyric neuropathy is not of the classical type seen in 
organo-phosphorous poisoning, where the distal portions of the 
longest nerve fibres are affected first (Cavanagh, 1979) but where 
neurones with shorter axons (Cavanagh & Ridley, 1967,; Hierons, 
1957) and higher metabolic requirements (Ridley, 1969; Ridley & 
Cavanagh, 1972) are also involved. It is interesting to note that 
Spencer et al (1979) had proposed a similar hypothesis to explain 
certain other types of peripheral neuropathies.
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SECTION II
CHAPTER 8
EARLY-ONSET CHRONIC RENAL FAILURE AS A COMPLICATION OF AIP
8 EARLY ONSET CHRONIC RENAL FAILURE AS A COMPLICATION 
OF ACUTE INTERMITTENT PORPHYRIA
8.1 INTRODUCTION
Oliguria is frequently encountered during the acute attacks of 
AIP. Although it can often be attributed to inadequate fluid 
intake due to abdominal pain and vomiting, it can persist despite 
restoration of fluid volume. The transient renal impairment has 
been noted previously (Day et al, 1981) but permanent renal damage 
has not been recognised to occur. This chapter describes the 
close association between early onset chronic renal failure (CRF) 
that is, renal failure occurring under the age of 65, and AIP.
The possible pathogenetic mechanisms involved are also discussed.
8.2 PATIENTS AND METHODS
The records of the six cases presented were retrieved from the 
files of the Porphyria Research Unit at Glasgow Western 
Infirmary. These files store information on the majority of 
symptomatic AIP cases diagnosed in the West of Scotland over the 
past 20 years. In all six cases, acute intermittent porphyria was 
diagnosed on the basis of excess urinary excretion of ALA, PEG, 
and uroporphyrin following clinical presentation. In three cases 
the diagnosis was further confirmed by measurement of ALA.S and 
PBG.D in peripheral blood. Urinary ALA, PEG and porphyrins were 
assayed according to the methods of Moore et al (1978). Renal 
function was assessed by the measurement of blood urea and serum
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creatinine, and whenever possible by 24 hr urinary creatinine 
clearance and intravenous pyelography (IVP), In three of the four 
fatal cases, gross and histological examination of the kidneys was 
possible at autopsy.
A summary of the clinical details, and available laboratory amd 
autopsy data are given in Tables 11 and 12 respectively.
Since no association has been established hitherto between AIP and 
CRF the probability of these two conditions occuring together by 
chance were determined by applying the binomial distribution test.
8.3 RESULTS
In all six patients, none of whom were related, the cause of CRF 
was attributed to end-stage renal disease accompanied by 
hypertension (Table 12). No other primary cause could account for 
the CRF; in particular, there was no underlying infection, 
diabetes, gout or auto-immune disease. These cases occurred in a 
population of 65 patients with AIP in remission; that is those 
patients known to have had an acute attack previously and 
excluding those latent for the disease. The prevalence of 
early-onset CRF in subjects under 65 years of age in Scotland is 
estimated at about 52 per million population (Pendreigh et al, 
1972), a figure comparable to that in other parts of the United 
Kingdom (Dombey et al, 1975). Since the prevalence of symptomatic 
AIP cases, estimated at about 1.9 per 100 000 (Beattie, 1973b), 
has not altered in Scotland over the period of observation a 
highly significant association was found to exist between AIP and 
early onset CRF (p < 0.001). In fact this prevalence is likely to 
be an underestimate of the exact figure because many cases of AIP
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Case
no.
Sex
Age (yiears) when Analgesic history from
First
attack
AIP
Last 
known 
normal BP
Sustained CRF 
hypertension noted 
diagnosed*
Patient Relatives
Outcome 
(age - 
years)
1 M 37 N.K. 37 37 No N.K. Died - 43
2 M 24 26 27 27 No N.K. Died - 35
3 F 21** 23 35 35 No N.K. Died - 37
4 F 36** 44 52 52 No No Died - 55
5 F 14** 28 37 37 No No Alive - 45
6 F 22** 25 32 32 No No Alive - 34
N.K, = not known 
* Hypertension = diastolic > 100 mmHg 
** Transient hypertension noted during acute attacks
Table 11: Clinical features
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Figure 19: Renal histopathology in AIP patient with
early-onset chronic renal failure (Case 1). 
Section shows prominent tubular loss with 
atrophy and dilatation of remaining tubules, 
A number of sclerotic glomeruli are evident 
and protein casts are easily seen.
(Masson stain x 100 magnification)
Figure 2 0 ; Renal histopathology of Case 3.
Ischaemic renal cortex. Majority of 
glomeruli are totally obsolescent with 
marked sclerosis and hyalinosis.
Changes are evident within the 
glomerular tufts. Features are 
compatible with end-stage renal failure, 
(Masson stain x 100 magnification)
a.2 
«-4 SO 
I - I  CO CO <U W p <U 04
o
r-4
o
CO
•p»
o
p
U
.3
pOi
p
<
a
p
i
o
0
or-t qq q q M 
P q 0) (U 
P 04
43 S*
q
u
'd  ^q q
q P 
P q 
q q
M q
q o u a
43 q o
P q 'p
•P 00 <P q 43
> 1 q q o P1— 4 43 q 00 p q q q p •P q
q P > q P q jq q > 43 > o
q •P •p •p q Ip q q Or o p •p CJ 1 cp •p
q q q q q •p q >4 q O q O P q
p q • P o o (3 p 43 q q >4 q q r-4 • P q q
q q q  q q a.•p q q > 00 q rP q op o P q 2 qo P p q 43 q q p P q •p >4 •p q q 43 p q p q 0 P
•p q p 00 P o •P •p 43 q q p q • P P p q P 00 00 P
q rP q q o •p rq rq rq CJ q P (3 q q q q q a 43 q •p q
o •P q. q > q q rP q o q q 1 q q Or 1 o Or q Orp q >443 o 43 p o •P •p u q p rq •P O >. 73 rH q 43 2cp 43 u a O 04 CJ a q 73 Or 43 0 00 q U a 43
U •s M w
<p
O
73
>4 •P
43 O
Or q
o •p
p p + p
q p + 43
rP p q •P
q q •p ip
CJ Or rq
q >4 q O
3 43 a a
a
q
p
CJ q
•P P«4 P
q p p
o o ip
+ p p •P
43 q •p
q CJ q•p •p
q rP q
o q rP rP
p CJ «P
43 O q q
•P p4 •p CJ
Pm
p
q
rP
3
43
3 73
P q >4 q +
q 43 •p +
q Or q q
P q O p p
q q P o q
> o P p q
q rP q Or CJ
ca
>4
rP
iP
q
p 9
o o
p 43 CJ
73 q •p
q q 00 a
3 q q q q q
O O P •p q 00
P P q >4 43 q
q 43 43 P CJ 8
a •P P q q q
3 cp O !> •P 73
a
q q
Or o CM q q
•P q 73 O •P
P CM q q > 43
P P N q 8 q
q P 3 •P o >4 q
q q rP •p 43 Or P
q >4 rP q p CJ 2^4 rP 3 P p CJ q rP a
3 •P q q q 3 q q q
q q q p q 73 p q p
Or q p 3 q q q q q
q q o O o p Or Or 3
U
00
q
73 •p
Ip q 00 00 p
q q q p
p > 4 0 o q
q rP q 00 o
p rP a q q
q q p 73 II II
rP a •p •P O
•P q <p 4«S Or r0 a
p
tp CJ o q CMO •p
p q •S O00 q •P q fp 00 q
q a q •p q 3 •p 73
•p q O p >4 •p P 73 q P
q q fp •p 43 q q q •p q q q q
q q rP 3 P q q ip O q q q ip
•P Or CJ q >,xs P q q 00 p q
CJ 73 q p 43 CJ q q •p q u q q
•p q O q p CJ •p CM q p q •p CM q
43 a a > q p 43 CM q 43 43 43 CM q
H q P q > •p o q >
•}« Or Or
CJ >4 q
•p q CJ P o
p p •p o •p
>4 q q p p
u P o q q
o p p P
43 fp 43 p
Or •p CJ q fp
a CM •P
P>4 q "3 CM CM
•p fp q q
•P •p •p
a
q.
0
1 +
Cd CO 
CO
u  ocd I—* r-4
| i
1-4 T3
a -H
C  0  <P p
o o qq 0 r-4
00 q  q 
>4 q q p 
r-4 o 00 q q 
q  Æ q  a .0
00 P  q O u
P i-t .q r-4 o
q q cj 00 "r-4
10
T3
q
N•P >"«
r-4 j q
q Or
P o 
q P
q -4J 
q q 
o
q q 
q o 
q -H 
p  P
q 00 q 
H q q 
g Tj *H
q r-4
00 q
•a-
P cp
q o 
>
>41—4
q
p
q
I— 4
a * 0  
o q 
o q
q p
§:3
q <P
•H q 
p  P
>4 q
CJ P  
O  p
0  1-4
01 'r-4
T3 1 
q q
N
q Pu
p  o  q
q p q
q p  o
q q r-4
Ü
• 0rq 0) 
q -H 
>4 q w-4 p p
•P  p  1—4
P q q
O rP CJ 
•»“l CJ o 
q q pp rq
3S
CJ
• p
OO 00
q CM q q
43 o • p • p
P q > X
P q O fp q
O q P o p
1 a q CJ > p
1 q P q q o
q q q • p CJ
X
fp rP .
q q q
P >4 p >4
q rP q q q
p fp q p q
q q 73 q q 73
fp a •P a • p
• p q rUS • p q
P3 n
q
p
p 3
q rP
q •P
a qp CM
q
q
p q
p q
q
q P
p
o CJ
CM •p
q q
43 o
p
o 43
CJ
CM
o o
vO
73
q
I •p
73
Or
PQ O
43
73 >
q
q Or
tP
fp <4
q
a 43
p P
o •P
q >
u q
p
04 q
E> q
M •p
p
q q
q Or
43
3 q
q
43 P
P 43
q P
q
73 q
o
q
P q
O 00
CM q
q •p
43 •3
q
q •p
P CM
q
q fp
>4 q
q
X q
•p p
q
fp
73 q
q CJ
a •p
p 00
o o
CM
p o
q 43
Or P
q
>4 Or
q
Or
o
•p
43 on
q q
q
q 43
p q
H
CM
o
>4
00
o
o
p
q
• P
X*
137
HEPATIC HAEM BIOSYNTHETIC PATHWAY
Condensation
reactions
Glycine + Succinyl CoA
Sequential 
decarboxylation 
and oxidation
Final
product
Delta aminolaevulinic acid 
\
PorphobilinogenI
Hydroxymethylbilane
Uroporphyrinogen III
*
Coproporphyrinogen III
Protoporphyrinogen IX
\
Protoporphyrin IX 
Fe++
HAEM
ENZYMES
ALA synthase*
ALA dehydratase**
PBG deaminase**
/L Uroporphyrinogen III** 
Co-synthetase
Uroporphyrinogen**
decarboxylase
Coproporphyrinogen* 
Nr* oxidase
Æ Protoporphyrinogen* 
Vj”  oxidase
^IFerrochelatase *
* mitochondrial 
** cytosolic
The rate of haem biosynthesis is regulated by the initial 
enzyme of the pathway ALA.synthase which is under negative 
feedback control by haem (broken line).
Figure 3
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analgesic nephropathy has previously been reported to be 
relatively high in Glasgow (Murray, 1978). As patients with 
analgesic nephropathy frequently minimise or even deny their 
analgesic consumption, interview of their close relatives often 
provides a more accurate estimate of their analgesic intake 
(Murray, 1978). Although drug information for three of the 
deceased patients was limited to what was available from their 
case-notes, careful interview of the two living patients and the 
relatives of the decreased patients failed to disclose any history 
of chronic analgesic abuse. In fact, none of the six cases 
fulfilled the criteria by which the diagnosis of analgesic 
nephropathy is made (Nanra et al, 1978; Lindvall, 1978), namely, a 
history of analgesic abuse and the demonstration of renal 
papillary necrosis either radiologically or at autopsy. It is 
relevant to note that a higher prevalence of analgesic nephropathy 
has been reported in hotter climates (Nanra et al, 1970). 
Conpeivabiy/^therefore conceivable that the state of dehydration
—  _     ti
that frequently accompanies the recurrent attacks of porphyria 
might constitute a similar risk even in the absence of excessive 
analgesic intake. But cases nos 4 and 6 had only one documented 
acute attack of porphyria.
As the diagnosis of sustained hypertension was made in all six 
cases at a time when renal damage was already present, the 
question arises as to whether it preceded or followed the 
development of CRF. Transient and labile hypertension is a 
well-recognised feature of the acute attacks of AIP, its frequency 
ranging from 35-55% in different series (Waldenstrom, 1957; 
Goldberg, 1959; Stein & Tschudy, 1970). Even though blood pressure
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returns to normal soon after the acute attack, the hypertension 
can reach levels high enough to cause an exudative retinopathy as 
was recently seen in a fatal case (Fig 8). Transient hypertension 
can also arise from a variety of situations causing stress, 
probably due to adrenergic dysfunction (Frohlich, 1977). But to 
date no systematic study has been reported on the relationship 
between the development of acute hypertension and the severity of 
abdominal pain during the acute attacks.
The central nervous system has an important role in the 
physiological regulation of the circulation. The brain maintains 
relatively steady-state conditions within the circulatory system 
by constantly monitoring the signals received from the 
cardiovascular mechanoreceptors. Arterial baroreceptor fibres 
from the aortic depressor regions and carotid sinus are carried by 
the aortic nerve, a branch of the vagus, and the carotid sinus 
nerve, a branch of the glossopharyngeal nerve respectively. These 
then enter the brain-stem before travelling in the tractus 
solitarius to synapse within the nucleus tractus solitarii (NTS) 
(Fig 22). The NTS provides one effective locus for regulating 
autonomic activity since it acts as the primary relay centre of 
the baroreceptor reflex arc connecting with the hypothalamus and 
cerebral cortex (Palkovits & Zaborsky, 1977). By sustaining a 
continuous tonic discharge, dependent on the balanced actions of a 
"vasopressor" and opposing "vasodepressor" systems in the brain 
stem, the sympathetic neurones maintain a state of partial 
vasoconstriction which provides resistance to blood flow and keeps 
blood pressure in the normal range (Reis & Talman, 1984).
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CARDIOVASCULAR CONTROL 
MECHANISMS
Afferent Efferent
Cortex
Hypothalamus f \\
Pons — 
Medula-^
Thoracic^ 
cord
Figure 2 2 ; Schematic representation of the
anatomical pathways from the arterial 
baroreceptors via the vagus and 
glossopharyngeal nerves to the nucleus 
tractus solitarii in the brain-stem.
Baroreceptor reflexes would therefore appear to stabilise and 
restrain blood pressure control constantly.
Removal of the baroreceptor input to the CNS produces a sharp 
increase in arterial pressure, which, if sustained is referred to 
as "neurogenic" hypertension. Several investigations have shown 
in different animal species that blood pressure rises when the 
afferent arm of the baroreceptor reflex arc is interrupted either 
surgically or pharmacologically (Kumazama et al, 1969; Ferrario et 
al, 1969; Bustyl et al, 1972; Chalmers & Reid, 1972) ie by 
sino-aortic de-afferentation. This induced hypertension is 
characteristically labile (Reis & Talman, 1984) and is accompanied 
by increased levels of catecholamines (Versteeg et al, 1984).
In fact, Kezdi (1954) has already postulated a similar neurogenic 
cause for the hypertension of acute porphyria following damage to 
the vagal and glossopharyngeal nerves from the underlying disease 
- in the single patient studied neither the blood pressure nor the 
pulse rate increased following paralysis of the carotid sinus 
receptors with a local anaesthetic agent. Analogy is drawn to the 
transient "neurogenic" hypertension (McDowell & Plum, 1954) 
commonly seen in acute paralytic poliomyelitis and less frequently 
in Guillain-Barre polyneuritis. It is noteworthy that in a study 
of four patients with AIP, Schley et al (1970) found an increased 
24 hr urinary catecholamine excretion during the acute attacks, 
the maximal excretion being ten times normal in one patient - 
somewhat analogous to the excessive production catecholamine 
production by phaeochromocytoma. Interestingly, brain-stem 
dysfunction caused by lesions around the floor of the fourth
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cerebral ventricle has been reported to cause paroxysmal systemic 
hypertension and markedly elevated urinary catecholamine excretion 
in man (Evans et al, 1977),
Vickers (1940) originally reported that 25% of young adults 
previously affected by paralytic poliomyelitis eventually 
developed sustained hypertension. This observation suggested that 
neurogenic hypertension might not be as transient as commonly 
believed. Indeed structural damage to the hypothalamus and 
brain-stem nuclei has been described in patients dying of 
poliomyelitis (Baker et al, 1950; McDowell & Plum, 1954) and AIP 
(Gibson & Goldberg, 1956). In poliomyelitis the encephalitis can 
damage the NTS in addition to the other centres for respiratory 
and cardiovascular control, ultimately leading to respiratory and 
cardiovascular arrest. Prolonged survival however, has been 
reported to occur in patients who developed hypertension following 
damage to the NTS as a result of syringobulbia and ischaemic 
lesions of the brain-stem (Montgomery, 1961; Magnus et al, 1977). 
Although bilateral lesions of the NTS can cause a lethal form of 
hypertension in rats (Doha & Reis, 1973), other animal studies 
have also shown that discrete experimentally-induced lesions in 
and around the nucleus of the tractus solitarius can cause 
specific changes in baroreceptor function capable of producing 
amore sustained hypertension (Krieger, 1964; Schmitt & Lamb ie, 
1979; Talman et al, 1980; Coleman, 1980). Only partial 
denervation of the sino-aortic areas was sufficient to produce the 
hypertension (Schmitt & Lambie, 1979), and interestingly, the 
chronic type of hypertension caused by NTS lesions was not
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particularly labile (Zandberg et al, 1978) Neurogenic 
hypertension, whether produced by NTS lesions or by sino-aortic 
deafferentation, arises from the removal of inhibitory 
baroreceptor influence on sympatho-excitatory centres in the 
brain. Since NTS neural projection radiate to mid-brain and 
fore-brain structures as well as to brain-stem vasomotor areas, it 
is possible that the neural circuit necessary for the full 
expression of neurogenic hypertension is spread over a wide area 
(Brody et al, 1984). It is interesting to note that neurogenic 
hypertension has been found to occur in association with 
increased levels of plasma vasopressin (Alexander & Morris, 1982), 
another well-recognised feature of the acute effects of 
porphyria.
The experimental data support Beattie & Goldberg's original 
observation (1975) that AIP predisposes to chronic hypertension. 
After a 20 year follow-up study of 38 AIP patients presenting in 
an acute attack during early adulthood, about 50% of the surviving 
patients had a random diastolic blood pressure exceeding 100 
mmHg. Six patients had died: one of early onset CRF and
malignant hypertension, three of complications of hypertension and 
two of non-accidental premature deaths at 40 and 42 years, the 
exact cause of which was unknown. Unfortunately tests of renal 
function were not carried out in that study and no further 
up-to-date information is available on this complication.
Apart from these neurogenic mechanisms AlP-associated hypertension 
could arise from disturbances of the nerve supply to the kidneys 
since the efferent pathway to the neurogenic control of renin
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release is in the sympathetic nervous system. Renin activates the 
formation of angiotensin I which in turn is converted to 
angiotensin II. Angiotensin II acts directly as a potent 
arteriolar constrictor agent. In addition it causes the release 
of noradrenaline from the adrenergic nerves and acts on specific 
brain receptors which affect sympathetic nerve outflow (Brody et 
al, 1984). Indeed high-renin hypertension is a well-established 
entity both experimentally and in certain clinical states. 
Elevation of blood pressure in the carotid and aortic 
baroreceptors can induce a reflex inhibition of renal nerve 
activity (Ninomoya and Irisawa, 1969), whereas complete 
baroreceptor denervation can lead to increased renal sympathetic 
activity (Niijima, 1976), thereby increasing renin release from 
the renal juxtaglomerular cells. Thus it is possible that 
activation of the renal neuroendocrine system might be involved in 
the pathogenesis of the AlP-associated hypertension. In this 
context it is relevant to mention the case of an 11-year old girl 
who developed renal failure during an acute attack of porphyria 
for no apparent reason, the renal impairment then persisting 
although blood pressure remained normal (Whitelaw, 1974). 
Furthermore, spasm of retinal (Denny Brown & Sciarra, 1945; De 
Francisco et al, 1979) and coronary arteries (Eliaser & Kondo, 
1942) have also been recorded during an acute attack. 
Alternatively, as the kidneys are exposed to a relatively high 
concentration of porphyrins and their precursors, partly 
synthesised locally (Day et al, 1981) and partly derived from 
other organs such as the liver, these compounds could possibly
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exert a pharmacological effect in reducing renal function either 
by a cytotoxic or a vasospastic action on renal vessels 
(Denny-Brown & Sciarra, 1945).
The pathogenesis of early onset CRF in AIP is probably 
multifactorial. The highly significant association between these 
two conditions clearly indicates that further studies are needed 
to define the relative roles of the three factors discussed: 
porphyria-induced neurogenic hypertension, nephrotoxic effects of 
porphyrins and precursors, and enhanced susceptibility to 
analgesic nephropathy. Of these, neurogenic hypertension appears 
to be the most important. Of note, the renal function of both our 
living patients has remained stable over the past four years 
following satisfactory control of their blood pressure with a 
combination of p-adrenergic blockers and diuretics.
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SECTION II
CHAPTER 9
TREATMENT OF PAIN IN THE ACUTE ATTACK OF AIP • 
A STUDY OF THE RESPONSE TO OPIATE ANALGESICS
9. TREATMENT OF PAIN IN THE ACUTE ATTACK OF AIP - 
A STUDY OF THE RESPONSE TO OPIATE ANALGESICS
9.1 INTRODUCTION
Abdominal pain is the commonest symptom of acute porphyria 
occurring in more than 90% of cases (Waldenstrom, 1957; Goldberg & 
Rimington, 1962; Eales, 1962; Stein & Tschudy, 1970). When the 
pain is mild simple analgesics seem effective in providing relief, 
but for more severe attacks narcotic drugs such as pethidine and 
morphine are required. An acute attack usually lasts a few days 
but in some cases it can linger for weeks and months.
Most porphyric patients suffering from recurrent attacks learn how 
to cope with their disease without recourse to hospital 
treatment. Those who do represent a selected group with more 
severe attacks, often complicated by protracted vomiting, 
neuropathy and seizures. It has been our experience that a number 
of these patients do not appear to respond to opiate analgesics. 
Administration of narcotic drugs in large amounts without any 
resulting benefit and the constant demand for still more analgesia 
inevitably raise the suspicion of drug addiction in some 
instances. This is particularly so in a disease where 
psychological and psychiatric disturbances are recognised. Yet 
these patients display the biochemical manifestations of active 
porphyria and a stereotype pattern of behaviour which is not that 
expected of a drug addict. The purpose of this study was to 
investigate whether opiate resistance occurs in acute porphyria.
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9.2 STUDY I
9.2.1 Patient selection
Between June 1981 and March 1984 10 AIP patients admitted to the 
Porphyria Unit were included in this study after they had 
satisfied the following criteria:
1. The onset of the attack was less than one week prior to 
entering hospital.
2. No narcotic analgesics were used during that period of time
(but simple analgesics, paracetamol or aspirin-like drugs,
were allowed).
3. The patient was well-adjusted to his or her social
environment in between attacks.
4. The patient had no other painful conditions requiring
treatment.
5. The patient had not been taking any medication that could
affect pain response; namely, psychotropic agents.
The clinical details of the patients studied and referred to by 
their initials are given in Tables 5 and 6. Informed consent was 
obtained before inclusion in the study.
9.2.2 Pain measurement - Visual Analogue Scale (VAS)
Intensity of abdominal pain was rated according to a visual 
analogue scale (Scott & Huskisson, 1976).
The scale consisted of a 15 cm line scored into 10 unlabelled 
segments except at the two ends. One end of the line was marked 
"0" representing no pain whereas the other end marked "10" 
indicated the worst pain imaginable: "the sort of pain that would 
drive one to end it all if it lasted for too long". In the
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initial explanation of the pain rating system, the patient was 
additionally informed that the first third of the line from "0" 
was equivalent to mild pain; the middle third, moderate pain; and 
the last third, severe pain.
Pain rating was carried out regularly at 4 hourly intervals unless 
the patient was asleep. The patient was requested to point with a 
pencil on the line, and a numerical conversion on the 0 to 10 
scale was immediately recorded on a separate chart. When 
injections were given assessment of pain was carried out before 
and 5 to 10 minutes after the drug was administered. Correct 
usage of the VAS by the patient and nursing staff was checked 
daily by the Principal Investigator.
9.2.3 Diet
On admission, a detailed dietary assessment was carried out by the 
Hospital Dietitian. If the calorie intake was less than 2500 
Kcal/day a fine nasogastric tube was passed to supply at least 
that amount containing a minimum of 300 gms of carbohydrate. Two 
of the patients studied could not tolerate a nasogastric tube, and 
intravenous glucose had to be administered initially. An adequate 
calorie intake was maintained throughout the study period.
9.2.4 Drugs were obtained from the hospital pharmacy and used in 
their standard formulation.
Opiate analgesics :
1. Pethidine hydrochloride
2. Morphine sulphage
3. Diamorphine hydrochloride
4. Buprenorphine ("Temgesic" - Reckitt & Colman) 
Opi.at.e_antago.nlst.:
1. Naloxone ("Narcan" - Du Pont)
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Aatieme.ti,c.s
1. Prochlorperazine ("Sternetil" - May & Baker)
2, Cyclizine
Prochlorperazine was always administered with the narcotic 
analgesics in a dose of 12.5 mg twice to four times daily as an 
antimetic. In two cases cyclizine 50 mg was used instead.
Hygnotlcls^d^tlye^ 1. Oral diazepam was prescribed to six of 
the patients.
Antihvnertensive 1. Oral propranolol ("Inderal" - ICI) was 
required to control hypertension and tachycardia in three patients 
(e l , RR and JMcM) in a dose ranging from 40 to 160 mg daily.
9.2.5 Analgesic regimens
I Because of its proven safety in porphyric patients pethidine 
was used as the first-line analgesic (Moore & Disler, 1983; De 
Verneuil et al, 1983). It was initially administered in a dose of 
100 mg intramuscularly at regular four hourly intervals. The dose 
was usually increased to 150 mg if required.
In three patients the dosage was further increased stepwise to a 
maximum of 1800 mg daily. In two patients failure of pain control 
necessitated a trial with diamorphine. The starting dose of 
diamorphine was 5 mg four hourly and increased stepwise to a 
maximal dose of 20 mg.
II Three patients were given buprenorphine intramuscularly 
first instead of pethidine. The initial dose of 1.2 mg daily was 
increased stepwise to 4.8 mg/day. Two of these patients 
subsequently received pethidine because of failure to control the 
pain.
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Ill Two patients receiving narcotic analgesics were additionally 
treated with nitrous oxide inhalation analgesia. A gaseous 
mixture containing 50% nitrous oxide and 50% oxygen - "Entonox" 
was self-administered through a rebreathing face mask. The 
patient was instructed to use the "Entonox" mixture only when the 
pain was most severe.
The ward staff in our Research Unit nursed and monitored all 
porphyric patients as for routine "post-operative" management. 
Blood pressure and pulse were recorded four-hourly except when 
patient was asleep. The respiratory rate and peak flow expiratory 
rate were also checked regularly.
9.2.6 Haem enzyme and porphyrin measurements 
Erythrocyte URO.S, leucocyte ALA.S and 24 h urinary porphyrin 
precursor excretion were assayed on the same days.
9.2.7 Results
Pain ratings assessed before and after the intramuscular 
injections correlated very well with each other.
Ana,lg.es.ic_ reg.imeii %: Five of the 10 patients studied obtained
satisfactory pain relief (ie more than 50% reduction in daily mean 
pain score) with intramuscular administration of pethidine alone. 
Pain relief was complete in only a single patient whereas in the 
others it was only partial. The mean duration of the acute 
attacks was 8.4 days (range 5 to 12 days). Pain benefit coincided 
with the expected pharmacological effect of pethidine in three of 
the five patients. In the other two patients reduction in pain 
intensity was not evident for at least two days after pethidine 
had been given at maximal dosages; this is illustrated for patient
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RR in Figure 23. This same patient had a recurrent attack during 
which little benefit was obtained with high-dose pethidine, either 
as intramuscular injections or intravenous infusion (Fig 24).
The course of three separate attacks for patient JMcM is shown in 
Figures 25 and 26. In the first attack (Fig 25) she stayed in 
hospital for six weeks and pethidine given intramuscularly failed 
to control the pain. At the time of discharge the pain was still 
rated at 3-4. It persisted for another week before disappearing. 
During the second attack (Fig 26, A & B) inadequacy of pain relief 
with pethidine (maximal dose = 1500 mg daily) led to a trial with 
diamorphine; this was also ineffective in achieving pain control. 
This lack of response raised the possibility of drug addiction in 
the patient and the drug was tailed off. When she went home she 
regularly took oral dihydrocodeine, diazepam and chlorpromazine. 
The second attack lasted another 17 days before her symptoms 
settled and all medication was stopped. She suffered a third 
attack two weeks later just before her menstrual period (Fig 26 
C). Pethidine was again found to be ineffective in large doses. 
This attack lasted for nearly five weeks. Interestingly the 
patient did not have another attack requiring narcotic analgesics 
for several months thereafter.
In both patients (RR and JMcM) pethidine did not appear to cause 
any significant increase in haem enzyme activities or excretion of 
porphyrin precursors.
Ana,lg.es.ic. ieg.imen, 11 Buprenorphine failed to provide adequate 
pain relief to the first three patients in the study who received 
that drug (Figs 27, 28 and 29). In one case (Fig 29) the daily
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Figure 2 3 : Patient R.R.
Pain ratings during treatment with IM 
pethidine. Solid line represents ratings 
recorded before each injection, and dotted 
line represents re-assessment values 
obtained 5 to 10 minutes after injection 
was administered. Urinary porphyrin 
precursors were measured at intervals.
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Figure 2 4 ; Patient R.R.
Pain ratings following IM and IV administration 
of pethidine during a recurrent attack. Haem 
enzyme activities and urinary porphyria 
precursors were measured at intervals.
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Figure 2 5 : Patient J.McM.
Pain ratings during treatment with 
IM pethidine in an attack which lasted 
for more than 6 weeks. Patient still 
suffered from abdominal pain when she 
left hospital.
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Figure 2 6 : Patient J.McM.
Response to opiate analgesics in two 
successive attacks. During the first 
(A & B) neither pethidine nor 
diamorphine provided any significant 
relief. In the second attack (C), 
pethidine was again ineffective. On 
both occasions attacks settled after 
2-3 weeks folowing hospital discharge.
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Figure 27: Patient C.M.
Pain ratings while receiving IM 
buprenorphine. Haem enzyme 
activities and urinary porphyrin 
precursors were measured at intervals.
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Figure 2 8 ; Patient M.S.
Pain ratings with IM buprenorphine 
during an acute attack of AIP.
Haem enzyme activities and urinary 
porphyrin precursors were assayed 
to follow the course of treatment.
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Figure 2 9 : Patient J.C.
Pain ratings during treatment with 
buprenorphine followed by pethidine 
administered IM. Supplementary 
inhalation nitrous oxide analgesia 
was also provided. Haem enzyme 
activities and urinary porphyrin 
precursors were measured at intervals
dosage was maximally increased to 16.8 mg with no apparent 
benefit. this very high dose, careful monitoring of the 
patient's blood pressure, pulse and respiratory rate showed no 
significant effect. But she experienced excessive drowsiness and 
a strong feeling of depersonalisation. These psychotomimetic 
symptoms disappeared with stoppage of buprenorphine. A change to 
pethidine made no difference to the pain ratings. Buprenorphine 
did not cause any significant increase in haem enzyme activities 
or porphyrin precursor excretions.
^^l^e^ic^ %e^ime^ %I_I : The value of supplementary nitrous
oxide inhalation analgesia was assessed in two AIP patients whose 
pain was resistant to narcotic drugs. In only one case did it 
seem to provide a mild beneficial effect (Fig 30); no such 
response was obtained in the other (Fig 29). Both patients 
overused the nitrous oxide mixture beyond what was recommended.
It seemed to induce sleep and a state of "relaxation". Nitrous 
oxide did not significantly increase haem enzyme activities or 
urinary excretion of porphyrin precursors.
9.3 STUDY II
9.3.1 Patients
Three patients were studied: two in a severe attack of AIP and a 
third patient suffering from chronic abdominal pain of unknown 
cause suspected of being addicted to pethidine.
Case 1 : Mrs EL was a 30-year old woman admitted to the Western
Infirmary on 29 May 1981 with severe abdominal pain, tachycardia, 
hypertension and motor weakness. She has had several attacks 
during the previous six years. On that occasion, her tachycardia
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Figure 3 0 : Patient E.L.
Response to treatment with IM pethidine 
supplemented with inhalation nitrous 
oxide analgesia.
(108/min) and hypertension (160/112) were controlled with 
propranolol but large doses of opiates failed to alleviate the 
pain. On the same evening her unstable condition necessitated her 
transfer to the intensive care unit (ITU).
On 31 May 1981 the patient was discovered to have received 90 mg 
of morphine intravenously in less than one hour when that amount 
was intended for administration over a longer period -she was 
suspected of having tampered with the sage pump. Naloxone was 
immediately administered in a dose of 0.4 mg intravenously to 
prevent respiratory depression. No opiate withdrawal reaction 
ensued. Surprisingly, by the next morning the abdominal pain had 
nearly disappeared. Two days later she was discharged home 
without any analgesics. When she was reviewed as an out-patient 
two weeks afterwards she was noted to have remained nearly 
pain-free since her discharge home.
On 8 October 1982 the patient was readmitted with another severe 
attack. Her pain response to sequential intravenous infusions of 
pethidine, normal saline as placebo, morphine and naloxone was 
therefore studied in the hope of repeating the previous favourable 
outcome.
Case 2; Miss JC was a 26-year old nurse who had experienced her 
first symptoms of AIP at the age of 20. During the previous year 
she had suffered from five attacks, precipitated by alcohol on two 
occasions.
On 25 June 1981 she was admitted to hospital with severe abdominal 
pain and vomiting. She was initially treated with intramuscular 
buprenorphine without benefit. After the dosage of buprenorphine 
had been increased stepwise to 3.6 mg/day over a period of six
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days without apparent benefit, she was entered into this present 
study. Buprenorphine was reduced to 0.6 mg/day for two days, 
before all subsequent analgesic therapy was administered 
intravenously.
Case 3; Mrs PJ was a 38-year old woman who had been 
complaining of constant severe upper abdominal pain for 11 years. 
She has already had numerous investigations with negative results, 
including pancreatic function tests, endoscopic retrograde 
cholangiopancreatography (ERCP), total body CAT scanning and an 
extensive metabolic screen for rare causes of abdominal pain. She 
had also been attending the pain clinic in Edinburgh where a 
coeliac ganglion block was performed without any benefit. She was 
referred to the Western Infirmary in March 1984 for exclusion of 
porphyria.
The patient claimed that pethidine, which she could 
self-administer, was the only drug that could relieve her pain.
Any slight suggestion of drug addiction was met with strong 
protest. But during this admission she consented to see a 
Consultant Psychiatrist with a special interest in drug abuse.
When she was informed that she was suffering from drug dependence 
on pethidine she refused further psychiatric help. It was 
discovered that a year previously she was discharged from her post 
as a high-ranking Nursing Officer after being suspected of 
securing pethidine fraudulently. Throughout her stay in hospital, 
her pain ratings were high and her requirements for opiate 
analgesics showed no abatement. She was keen to undergo further 
physical tests, and she readily consented to take part in the 
study.
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Case 2
Daily Agent Syringe Amount Syringe Amount Syringe Amouni
Coding Code No . of drug Code No. of drug Code No. of dri
A Buprenorphine Al 0.6mg A2 1.2mg A3 2.4mg
B Saline (Placebo) Bl - B2 - B3 -
C Saline (Placebo) Cl - C2 - C3 -
D Pethidine Dl 200mg D2 400mg D3 SOOmg
E Saline (Placebo) El - E2 - E3 -
F Saline (Placebo) El - E2 - E3 -
G Naloxone Gl O.Smg G2 1.6mg G3 3.2mg
H Saline (Placebo) Hi - H2 - H3 -
I Diamorphine II lOmg l2 20mg I3 40mg
J Saline (Placebo) - l2 - I3 -
Case 3
A Pethidine Al lOOmg A2 150mg A3 200mg
B Saline (Placebo) Bl - B2 - B3 -
C Diamorphine Cl lOmg C2 15mg C3 20mg
D Placebo Hi - D2 - D3 -
E Placebo El - E2 - E3 -
F Placebo El - E2 - E3 -
G Placebo Gl - G2 - G3 -
H Naloxone Hi O.Smg H2 1.6mg H3 3.2mg
I Placebo II - l2 - I3 -
J Buprenorphine II 0.6mg l2 1. 2mg I3 2.4mg
Table 14: Scheme of drug and placebo administration by
intravenous infusions to cases 2 and 3 in 
Pain Study II
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9.3.2 Scheme of drug administration for cases 2 and 3 
Following a base-line period during which the patients received 
relatively low daily dosage of analgesics intramuscularly, the 
drugs to be tested were administered intravenously by a sage 
pump. Three externally identical coded syringes containing 
incremental concentrations of the same agent were prepared for 
each 24 hour period in the hospital pharmacy. Each syringe 
contained enough material for an eight hour infusion. The coding 
scheme, amount and order of drugs administered are shown in Table 
14. After use, the empty syringes were returned to the pharmacy 
and checked for the total amount of drug administered. With the 
exception of the principal investigator and the pharmacist no 
other medical, nursing or paramedical staff knew the drug coding. 
The daily progress of the trial was closely monitored by the 
principal investigator who was available for immediate 
consultation in case of emergency; but he did not play an active 
role in the recording of data.
The patients were informed that they would be receiving various 
types of potent narcotic analgesics but were not specifically told 
about the inclusion of placebo.
9.3.3 Results
Case 1: Both pethidine and morphine, increased to a maximal
dose of 1600 mg and 100 mg/24 h respectively, failed to provide 
any significant pain relief. Response to placebo was similar to 
that obtained with the two opiate agonists (Fig 31). A mild 
reduction in blood pressure was noted during morphine 
administration, but concomitant treatment with propranolol and
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Figure 31 ; Patient E.L. (Case 1)
Pain ratings during intravenous 
infusions of pethidine, saline as 
placebo and morphine followed by 
naloxone. Note that pain did not 
increase when the specific opioid 
antagonist naloxone was administered,
prochlorperazine could have contributed to that effect.
Respiratory rate was not depressed, and arterial blood gases 
remained normal during maximal morphine infusion.
Naxolone was initially administered cautiously by intravenous 
boluses in the event that she might develop opiate withdrawal 
syndrome. Following the third naloxone injection, the patient 
yawned excessively but her pain rating did not increase and other 
withdrawal symptoms did not develop. Continuation of naloxone 
infusion was in fact accompanied by favourable pain ratings, yet 
the dramatic recovery previously experienced did not occur. 
Following naloxone infusion, administration of buprenorphine did 
not help the pain.
Case 2; Pain rating apparently improved after initiation of 
pethidine and diamorphine therapy, but this was not maintained at 
higher drug dosage (Fig 32). Since a similar transient reduction 
in pain rating was seen during the second placebo phase it was 
concluded that these opiate agonists were not particularly 
effective in relieving pain. Neither was there any significant 
benefit from buprenorphine or naloxone therapy.
Case 3 : In contrast to case 2, the pattern of pain response in
this case is different altogether (Fig 33). Whereas pain ratings 
showed no improvement with low-dose diamorphine or pethidine, an 
apparent improvement was seen at the higher dosages. But the most 
remarkable feature was the dramatic swings in pain ratings 
encountered during the placebo periods.
Administration of a single IV bolus of naloxone (0.4 mg) induced 
no reaction but infusion of the antagonist at higher dosage caused
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Figure 3 2 : Patient J.C. (Case 2)
Pain ratings during sequential intravenous 
infusions of buprenorphine (bupren), 
pethidine (peth), naloxone (nalox) and 
diamorphine (diamorph) with intervening 
periods of saline infusions as placebo.
All treatments were coded and 
administered blind.
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Figure 3 3 ; Patient P.J. (Case 3).
Pain rating during sequential IV infusions 
of pethidine, diamorphine, naloxone and 
buprenorphine, given blind and coded.
A test-dose of naloxone was given during 
placego period G without the patient 
developing any opiate withdrawal reactions, 
Solid and dotted lines represent sets of 
ratings assessed within 10-15 minutes 
of each other.
a worsening of abdominal pain accompanied by increasing 
restlessness and aggressiveness. Yet no other manifestations of 
the opiate withdrawal syndrome emerged.
The erratic pattern of pain ratings to the blind infusion of 
different opiates and to placebo supports the clinical diagnosis 
of psychic dependence on narcotic drugs, ie addiction. Failure of 
withdrawal symptoms to appear following high-dose naloxone is in 
keeping with the absence of physical dependence.
9.4 DISCUSSION
Pain is an abstract concept which was recently defined by the 
International Association for the Study of Pain as (Merskey, 1979) 
"an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such 
damage". Such a definition raises as many questions as it seems 
to answer (Wall, 1985) but it serves a useful purpose in 
emphasising the two equally important components of the pain 
experience: the sensory and emotional elements.
The abdominal pain of AIP is typically that of the acute type 
associated with the generalised activation state referred to as 
"flight and fight reaction". Although it can retain such 
characteristics for a few days, it may acquire features of a 
chronic pain state if it persists for weeks or months. The 
development of a chronic pain state will cause the disappearance 
of the sympathomimetic effects of acute pain and the emergence of 
what Sternback (1981) has called the "vegetative signs"; namely, 
social withdrawal, psychomotor retardation, agitated depression, 
abnormal illness behaviour and associated hypochondriasis. Thus
157
the manifestations of a chronic pain state in AIP may be readily 
mistaken as part of the psychological and psychiatric disturbances 
that can also occur in porphyria (Waldenstrom, 1937; Ackner et al, 
1961).
The measurement of pain adopted in this study needs some
consideration. The patient with pain conveys his or her distress
to others through verbal and non-verbal behaviour. Since there 
are no direct objective measures of pain observation of this 
behaviour is the only way towards understanding the patient's 
private experience. Physiological measures have not been found to 
be reliable indicators of pain. The methods of brain-evoked
potentials (Gracely et al, 1978) and signal detection theory (Chen
et al, 1979) are potentially more objective indicators of the 
subjective experience of pain but are quite cumbersome to 
perform. To date subjective pain responses have been assessed by 
language analysis (Melzack, 1975; Leavitt et al, 1977), pain 
category rating (Gracely et al, 1978), pain estimates (Sternback, 
1974) and visual analogue scales (Revill et al, 1976; Scott & 
Huskisson, 1978). Of these specific descriptive methods which 
have contributed to a more precise measurement of pain intensity, 
the visual analogue is considered to be the best for measuring 
pain clinically (Church, 1979; Rutter et al, 1980; Catling et al,
1980; Swanson & Maruta, 1980) - hence its use in this study.
To validate this technique of VAS, pain ratings were recorded 
twice at each four—hourly time point ie before and 5 to 10 minutes 
after the intramuscular injections. And indeed the results 
obtained with these two sets of pain ratings correlated very well
with each other for all patients studied.
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Pethidine is the recommended standard narcotic analgesic in acute 
porphyria because of its proven safety record (Moore & Disler,
1983). But in patients requiring large doses of this drug, it 
often induces muscle hardening at the injection sites, in part 
accounting for its variable absorption kinetics (Austin et al, 
1980). Therefore the high solubility of diamorphine with twice 
the potency of morphine, provided an advantage in its 
administration. An alternative to pethidine and morphine was also 
sought because of the rapid development of tolerance to and 
dependency on these opiates (Bond, 1984). Moreover repeated 
pethidine administration can cause central nervous system 
hyper-irritability due to an accumulation of the active toxic 
metabolite, norpethidine (Kaiko et al, 1983).
Buprenorphine, a newly developed mixed agonist-antagonist opiate 
(Appendix IV) (Harcus et al, 1974; Houde, 1979), was used in the 
study after it was shown to be clinically as effective as morphine 
and pethidine (Hayes et al, 1979; Harmer et al, 1983) without 
producing troublesome psychotomimetic effects. In addition it is 
reputed to be less addictive than the other opiates (Robbie, 1979; 
Ventafridda et al, 1983). Like other synthetic opiates it can 
cause some degree of respiratory depression, but a ceiling-effeet 
seems to be reached at about 1.2 mg in normal volunteers. It has 
been given in a dose of up to 7.0 mg (equivalent to 200 mg 
morphine) post—operatively without causing any significant 
respiratory depression (Orwin, 1977). Furthermore at high dosage 
its effects on the cardiovascular system are relatively minor 
compared to morphine and pethidine (Malcolm & Coltart, 1977).
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In this study the drugs were administered on a regular basis with 
the pharmacological objective of maintaining plasma drug level 
above a minimal effective concentration for pain relief. When a 
switch was made from the intramuscular route to continuous 
intravenous infusion the starting dose was calculated as the 
equivalent for a 24-hour period (Foley, 1982).
Three of the ten porphyric patients studied seemed to have had a 
pharmacological response to the opiate drugs. Although pethidine 
was used as our first-line narcotic analgesic, diamorphine and 
buprenorphine were subsequently found to be as effective in some 
patients. It is interesting to note however that a beneficial 
placebo response can be expected to occur in about a third of 
patients treated for other painful conditions irrespective of the 
methods employed (Beecher, 1959). And this placebo effect, 
mediated by the release of endogenous opioids, has been reported 
to be more marked for moderate to severe pain than for mild pain 
(Levine et al, 1978). While placebo has been advocated as a 
therapeutic measure for some categories of pain it may cause 
considerable harm if the patient finds out the stratagem. This 
can lead to severe loss of confidence in any further treatment and 
worse in the clinician. That is why it has been difficult to 
withhold narcotic drugs from porphyric patients in acute attacks 
when they complained of severe pain.
In some patients who received large amounts of opiates pain relief 
was not apparent for at least two to three days after the maximal 
dosage was reached. This beneficial effect is more likely due to 
the "glucose effect" induced by the high calorie carbohydrate-rich 
diet than the analgesic drugs.
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Pi^Gvious studies have shown that intravenous administration of 
pethidine at a median rate of 25 mg/h/Bwt (Chakravarty et al, 
1979), buprenorphine at a median rate of 0.048 mg/h/Bwt
(Chakravarty et al, 1979) or morphine in the range of 1.5 to 3
mg/h/BWt (Rutter et al, 1980; Catling et al, 1980; Gourlay &
Cousins, 1980; Orr et al, 1981) provided effective analgesia to
patients undergoing major abdominal and thoracic surgery. The 
pain of thoracotomy, reputedly one of the most painful operations, 
was successfully managed with morphine infusion at a rate of less 
than 1.5 mg/h/BWt. Yet three of the porphyric patients failed to 
obtain any pain relief following the intravenous administration of 
pethidine (67 mg/h/BWt), morphine (4.16 mg/h/BWt), diamorphine 
(2.9 mg/h/BWt) or buprenorphine (0.17 mg/h/BWt). In one instance, 
buprenorphine was given intramuscularly to a maximal daily dose of 
16.8 mg and was completely ineffective. The pain ratings with 
placebo were similar to those obtained with the different 
opiates.
The possibility of tachyphylaxis was avoided by selecting patients 
who have not had narcotic drugs before the study and by rapidly 
increasing the dosage to a maximum level compatible with safety. 
Changing from morphine to pethidine, or vice versa, made no
difference to the pain ratings. Neither did the pain get worse
when buprenorphine followed either morphine or pethidine. These 
results thus confirm that the abdominal pain of acute porphyria
can be truly resistant to opiate analgesics.
Nitrous oxide analgesia appears to act by a non—opioid dependent 
mechanism since it is not reversed by naloxone. It has been 
successfully used in terminally ill patients with refractory pain
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(Fosberg & Crone, 1979). But only one of the two porphyric
patients showed a mild but definite response. Unfortunately the
risk of developing megaloblastic anaemia with this agent further 
limits its usefulness. However nitrous oxide did not exhibit any 
porphyrinogenic tendency.
Other methods of pain control that might interfere with the 
peripheral nervous system, spinal circuits and ascending pathways 
have been considered (Levine, 1984). For instance, peripheral 
acting analgesics like paracetamol and non-steroidal 
anti-inflammatory drugs ie aspirin, ibuprofen, flurbiprofen and
indomethacin have been used on many occasions, alone or in
combination with opiates without any benefit.
Transcutaneous electrical nerve stimulation is a form of 
counter-irritation that activates both opioid and non-opioid 
pain-inhibitory mechanisms (Meyer & Watkins, 1984). Attempt at 
interrupting the transmission of nociceptive impulses by this 
method has also failed to relieve the abdominal pain. One 
patient, JC, was trained in self-induced hypnosis in an attempt to 
modify her pain experience, but after an initial favourable 
response the patient gave it up.
9.5 ABNORMAL OPIATE RECEPTOR RESPONSE IN AIP
Failure to control the abdominal pain of AIP with large amounts of 
opiate analgesics implied an abnormal opioid receptor response.
The pharmacological basis for this phenomenon was further 
investigated.
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9.5.1 Case history
In October 1981 in the course of a severe attack the pupils of a 
porphyric patient (EL, Case 1 in the previous study) were noted to 
be of normal size despite intravenous administration of large 
doses of morphine (100 mg/24 h). The pupillary responses to 
accommodation and to light, both direct and consensual, remained 
normal.
After the acute attack had settled, a complete ophthalmological 
examination was carried out in the Eye Department on 19 November 
1981. No abnormality was detected. The pupillary diameter was
3.5 mm on the right and 4 mm on the left. Fifteen milligrams of 
morphine was administered intravenously and the pupillary 
responses reassessed 45 minutes later. The size and 
responsiveness of the pupils remained unaltered.
Since 1981 the patient has had chronic abdominal pain and 
persistent quadriparesis with biochemical evidence of active 
porphyria. She was last admitted to hospital in September 1985 
with a severe attack. Diamorphine was given without much benefit 
and it was stopped on 11 September 1985. On 14 September 1985, 
the pupillary responses were again examined before and after 
administration of diamorphine. Fifteen milligrams of diamorphine 
were initially given intramuscularly with close monitoring of the 
patient's pulse, blood pressure and respiratory rate. Pain 
ratings were also recorded. When no significant effect occurred 
one hour after the injection, a further dose of 30 mg diamorphine 
was administered and observations were continued for another four 
hours.
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9.5.2 RESULTS
Before the administration of diamorphine both pupils were equal in 
size and reacted briskly to accommodation and to light, both 
directly and consensually. Diamorphine in a dose of 45 mg failed 
to induce miosis (Table 15) and the pupillary responses remained 
unaltered (Fig 34). Pain ratings were minimally improved after 
the second injection. There was a mild reduction in pulse rate 
and blood pressure but respiratory rate remained unaffected.
Two hours after the 30 mg morphine injection the patient felt 
nauseated and vomited once. But she remained remarkably alert and 
denied any feelings of drowsiness. Her only complaint was that 
her nose felt unduly itchy.
9.5.3 DISCUSSION
Innervation of the iris is exclusively autonomic. Parasympathetic 
supply to the pupillary constrictor muscles of the iris is carried 
by the third cranial nerve via the ciliary ganglion and short 
ciliary nerves. Sympathetic innervation of the pupillary dilator 
muscles is provided by the long ciliary nerve, a branch of the 
trigeminal nerve (Fig 35). The light and accommodation reflexes 
depend on the preservation of both parasympathetic and sympathetic 
pathways as well as the optic nerve pathways.
Opioid receptors have been described in the inner plexiform and 
ganglion layers of the retina (Wamsley et al, 1979). They are 
also found in high concentrations in the pre-optic areas of the 
mid—brain tectum which receive afferents from the retina. Since 
section of the optic nerve abolishes morphine-induced miosis while
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Figure 3 4 : Pupillary responses of AIR patient E.L. after
IM administration of 45 mg diamorphine.
Patient was comfortable seated at a Haag-Streit 
slip lamp and photographs of the right pupil 
were taken successively at the same 
magnification in one sitting.
(a) in ordinary room-lighting.
(b) after about 10 seconds in complete 
darkness, showing rapid pupillary 
dilatation.
(c) responding consensually and briskly to 
light shone into the left eye.
AUTONOMIC NERVE SUPPLY TO THE IRIS 
Superior Colliculus
Pretectal nucleus 
Lateral
geniculate body yf 
Optic tract
Optic nerve
Eldinger-Westphal nucleus 
nird Nerve nucleus
,Yth c.n.
/  Nasociliary
nerve
long ciliary 
nerve
Cüiary ganglion
short ciliary 
nerve
sympathetic pathway 
parasympathetic pathway
Figure 35: Schematic representation of visual
pathways to the mid-brain and 
autonomic innervation of the iris. 
Normal pupillary responses to light 
and accommodation indicate that 
these pathways are intact.
the consensual light response in the same eye is still preserved 
(McCrea et al, 1942; Duke-Elder, 1962) local activation of these 
opioid receptors rather than direct central stimulation would seem 
to play an important role in its mechanism (Atweh & Kuhar, 1983). 
Tress and El-Sorby (1979) have shown that although tolerance 
develops to the miotic effects of diamorphine in drug addicts, 
miosis can still be induced with a fraction of the daily dose on 
which they are dependent. Not only was the dose used in the 
present study much larger than what the patient had been receiving 
before, but she had no other features to suggest drug dependence. 
Previously she had been given naloxone without having any 
withdrawal reactions, and following discharge from hospital she 
did not require any opiate drugs for maintenance. Failure of 
diamorphine to induce miosis in the porphyric patient while 
preserving both light and accommodation reflexes suggests that 
opioid receptors in the optic system were either non-responsive or 
depleted.
Morphine mediates its miotic, analgesic and respiratory depressant 
effects by activation of the mu opioid receptors (Appendix IV).
The lack of pain response to such a large dose of diamorphine 
while maintaining a normal respiratory rate and an alert state of 
consciousness supports the conclusion derived from the pupillary 
responses.
A more pronounced depressant cardiovascular effect might have been 
expected from the dose of diamorphine administered but there was 
only a slight reduction in the pulse and blood pressure.
Endogenous opioids can lower blood pressure - an effect reversible
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with naloxone (Lambie et al, 1977; Rubin et al, 1981). But 
morphine-induced hypotension appears to involve other non-opioid 
dependent mechanisms interacting with the autonomic system 
(Mcqueen, 1983). Therefore the explanation for the changes in 
pulse and blood pressure remains conjectural. It is noteworthy 
however that in the previous studies in which naloxone was 
administered after infusion of opioid agonists no rebound 
hypertension was noted.
Inhibition of pain by endogenous opioids is normally not a tonic 
phenomenon. It requires a pre-existing noxious stimulus to 
release the endogenous opioids which then activate the system.
This is why naloxone administration to someone not in pain does 
not cause hyperalgesia. But if opioids, whether endogenous or 
exogenous, are effectively relieving pain administration of 
naloxone in sufficient amounts will lead to an exacerbation of 
pain (Levine et al, 1979; Watkins & Meyer, 1982). Thus failure of 
naloxone to worsen the pain in the porphyric patients lends 
further credence to the possibility of underlying abnormal or 
depleted opioid receptors.
The vagus nerves and their associated brainstem nuclei are 
important structures in the regulation of autonomic reflexes; for 
example, cardiovascular control. Damage to these structures can 
cause neurogenic hypertension - as is the case in acute porphyria 
(Chapter 8). Opiate receptors have been located along the 
afferent fibres of the vagus nerves. They are also found in high 
concentrations in the nucleus tractus solitarius and nucleus 
commissuralis which receive visceral sensory fibres from the vagus
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and glossopharyngeal nerves (Atweh & Kuhar, 1977, 1983; Snyder, 
1977). The experimental findings of Atweh and his associates 
(1978) are therefore particularly relevant in this context. They 
have reported that lesions of the vagus nerves led to a 
significant loss of opiate receptors in all parts of the vagal 
system including the nuclei. Since degeneration of the vagus 
nerves and their nuclei is a recognised morphological feature in 
patients who have died from acute porphyria (Mason et al, 1933; 
Denny Brown & Sciarra, 1945; Gibson & Goldberg, 1956; Hierons, 
1957; Ten Eyck, 1961; Jedrzejowska et al, 1974), it is conceivable 
that porphyric neuropathy might cause a loss of opioid receptors 
in the brainstem nuclei. This would not only explain the 
mechanism of neurogenic hypertension in acute porphyria but also 
the lack of pain sensitivity to opiate analgesics. A similar 
train of events in the optic nervous system would account for the 
present observations on pupillary responses.
The feedback regulation of receptor function and eventually of 
receptor number occurs with a wide variety of neurotransmitters 
and hormone receptors (Davies et al, 1982; Snavely et al, 1983; 
Snavely et al, 1985; Lefkowitz et al, 1984). This phenomenon of 
receptor desensitisation, either by "down-regulation" or by 
covalent modification e.g. by phosphorylation (Lefkowitz et al,
1984) could offer an alternative explanation for the lack of 
response to opioid agonists. With intense chronic pain, release 
of endogenous opioids might cause rapid desensitisation of opioid 
receptors. By analogy patients with phaeochromocytoma have a 
normal resting pulse and blood pressure when circulating plasma
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catecholamines are greatly increased. In these patients blood 
pressure response to noradrenaline infusion is muted but not 
absent (Davies et al, 1982). Thus in desensitisation some response 
is still expected to occur with the administration of large doses 
of the agonist, and this should at least show partial 
reversibility to a specific antagonist with high receptor 
affinity. The data currently available in the pain studies, 
although limited, do not support this possibility.
A third possibility to consider is that the porphyrin precurors, 
especially ALA, or some abnormal metabolite could interfere with 
opioid receptors. Since urinary excretion of porphyrin precursors 
does not correlate with the presence or severity of abdominal pain 
in individual patients having recurrent attacks, as encountered in 
several of the patients studied, this possibility seems less 
likely. Indeed, latent cases can excrete large amounts of ALA and 
PEG and yet remain asymptomatic. Moreover removal of these 
precursors by haemodialysis and haemoperfusion did not improve the 
pain (Chapter 10).
Further work is required to define the abnormal opioid receptor 
response that has been demonstrated in some porphyric patients in 
acute attacks. Such studies will probably have to take into 
account the possibility of subtype and tissue-specific 
"down-regulation" as exists for alpha- and beta-adrenergic 
receptors (Snavely et al,1983).
Other than the nervous system the gut (Polack et al, 1977 ; 
Konturek, 1978; Orwell & Kendall, 1980) also has a rich supply of 
opioid peptides and opiate receptors. Opioid peptides form an
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important group of chemical messengers in a widespread and complex 
inhibitory system (Duggan, 1983; Watkins & Meyer, 1982) which 
modulate the transmission of nociceptive impulses from the viscera 
and peripheral sensory receptors. An abnormality of opioid 
receptors in the gut could provide a possible explanation as to 
why pain is primarily abdominal in acute porphyria. Indeed 
morphological degenerative changes have been described in the 
coeliac ganglia of these patients (Gibson & Goldberg, 1956; 
Hierons, 1957). The abnormal opioid receptor hypothesis does not 
however explain the nature of the initial nociceptive stimulus. 
Whether this is also due to the porphyric neuropathy, in a manner 
analogous to diabetic neuropathic pain, or to a circulating 
metabolic product is a matter of further speculation.
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10. CHARCOAL HAEMOPERFUSION AND HAEMODIALYSIS IN AIP -
A CASE REPORT
10.1 INTRODUCTION
The clinical manifestations of AIP have been explained on the 
basis of neurological dysfunction probably caused by the increased 
concentrations of circulating ALA. Charcoal haemoperfusion has 
been advocated as a potential means of removing ALA (Tishler et 
al, 1982; Tishler & Gordon, 1983). This treatment was tried in 
the following patient.
Case report
A 34 year old woman presented in 1974 with severe abdominal pain; 
she was taking the contraceptive pill. Increased urinary 
concentrations of ALA and PEG confirmed the diagnosis of AIP.
After the contraceptive pill was stopped she continued to have 
recurrent episodes of abdominal pain lasting for up to a week. In 
1981 after drinking some wine she developed a severe attack of 
porphyria with hypertension and peripheral motor neuropathy. 
Treatment with intravenous haematin produced little clinical 
benefit, and the attacks persisted for two months. Thereafter the 
attacks became more frequent and prolonged without any 
precipitating factor. Her most recent attack before this 
admission had continued for seven months, being unresponsive to 
intensive conventional treatment and to high doses of propranolol, 
vitamin B complex and folic acid. Pain was difficult to control 
despite administration of large parenteral doses of narcotic 
analgesics.
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After gaining written informed consent haemoperfusion was carried 
out with a 300 g activated charcoal column (Adsorba 300; Gambro, 
Sweden) in series with haemodialysis for two hours daily on four 
consecutive days. Figure 36 shows the effect of this treatment on 
mean daily pain scores and serum and urinary concentrations of ALA 
and PEG. Haemoperfusion caused considerable thrombocytopenia, as 
previously reported with this type of treatment. The platelet 
count, measured daily, fell from 204 x 10^/1 to 161 x 10^/1 after 
the first haemoperfusion and then steadily to 75 x 10^/1 after the 
fourth haemoperfusion, when treatment was stopped; but it had 
returned to normal by the seventh day after perfusion.
10.2 DISCUSSION
The link between the biochemical disturbance of synthesis of haem 
and the pathogenesis of pain in acute intermittent porphyria has 
remained speculative. A strong association exists, however, 
between raised serum concentrations of ALA and neurodysfunction. 
All four types of acute porphyria, in which concentrations of ALA 
are raised, are characterised by neurological dysfunction whereas 
the non-acute porphyrias, which have normal concentrations of ALA 
are not. Furthermore, peripheral neuropathy is a feature of lead 
poisoning (Dagg et al, 1964) and hereditary tyrosinaemia (Gentz et 
al, 1969) in which blood concentrations of ALA are raised.
Tishler et al (1982, 1983) have reported that activated charcoal 
cartridges effectively removed large amounts of porphyrins and 
their precursors from solution in vitro, these amounts being 
considerably greater than estimated daily production during an
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Figure 36: Sequential measurements of urinary and serum
concentrations of ALA and PBG in relation to 
mean daily pain score before and after four 
days of treatment with haemoperfusion and 
haemodialysis.
Broken lines indicate concentrations 
immediately after perfusion.
attack of porphyria. The removal of ALA and PBG, and possibly 
other neurotoxic compounds, by haemoperfusion through such 
sorbents might favourably alter the course of acute 
attacks.
In this study haemoperfusion with activated charcoal columns 
coupled with haemodialysis considerably reduced serum 
concentrations of ALA and PBG with a concomitant decrease in 
urinary porphyrin precursors. But serum concentrations had 
returned to pretreatment values within 24 hours and abdominal pain 
was not relieved after four days' treatment. The possibility that 
a longer course of treatment might have had a more favourable 
outcome cannot be excluded but this seems unlikely in view of the 
rapid rebound of serum concentration of ALA after each 
haemoperfusion. Furthermore, the resulting thrombocytopenia might 
present a major limiting factor to such treatment.
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SECTION III
CHAPTER 11
r.ARRAMA7.F.PINE--INDUCED NGN-HEREDITARY ACUTE PORPHYRIA
11. CARBAMAZEPINE-INDUCED NON-HEREDITARY ACUTE PORPHYRIA
11.1 INTRODUCTION
In AIP as a consequence of relative haem depletion the activity of 
the first and rate-limiting enzyme of the pathway, ALA.S, is 
increased, and excessive amounts of ALA and PBG accumulate in 
blood and urine. Several types of pyrrolic disturbances have 
already been produced de novo by drugs and toxins. For instance, 
many halogenated aromatic hydrocarbons, the best known being 
hexachlorobenzene, can cause cutaneous hepatic porphyria in all 
its clinical and biochemical manifestations, in both man and 
experimental animals by inhibiting uroporphyrinogen decarboxylase 
activity (Schmid, 1960; Ockner & Schmid, 1961). But there is 
still no satisfactory animal model for the human acute hepatic 
porphyrias. Although various chemicals such as AIA and 
griseofulvin have been shown to induce some of the porphyrin 
abnormalities seen in the acute porphyrias, none of the models 
proposed can reproduce any of the neuro-psychiatric features 
characteristic of these diseases (Smith & De Matteis, 1980). A 
case of toxic non-hereditary acute porphyhria following 
carbamazepine treatment of epilepsy is described for the first 
time, and its relevance as a possible human model of porphyria 
subsequently discussed.
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11.2 PATIENTS AND METHODS 
Ç a^ e^ 1^
A 38-year-old mentally handicapped man was admitted to the Western 
Infirmary, Glasgow, in January 1982, for investigation of AIP (Fig 
37). He had sustained brain damage after contracting measles 
encephalitis at age 3 years and had soon begun to have frequent 
generalised tonic-clonic seizures. Throughout his childhood and 
adolescence epileptic control had been difficult, despite 
combination therapy with primidone and phenytoin. Carbamazepine 
was added to his medication in a daily dose of 600 mg when he was 
28. Soon afterwards he experienced several episodes of 
unexplained general malaise and fever. In June 1980, he received 
a 9-month course of antituberculous chemotherapy for a prolonged 
bout of fever with radiological changes at the apex of his right 
lung, although tubercle bacilli were not isolated. At that time 
phenytoin was replaced by sodium valproate.
In October 1981, the dose of carbamazepine was increased to 1200 
mg daily, but seizure activity increased despite theoretically 
satisfactory drug concentrations. He became unwell and anorexic. 
He then experienced diffuse abdominal pain accompanied by frequent 
bouts of vomiting; he also had intermittent dysphagia.
Haemoglobin was 13.4 g/dl and serum amylase was normal. Upper 
gastrointestinal endoscopy, barium enema, and ultrasound scan of 
the liver and biliary tree were normal. At this time the passage 
of a dark urine raised the possibility of AIP. There was no 
family history of porphyria. On physical examination he looked 
toxic. Blood pressure was 120/55 mm Hg, pulse 118/min (sinus
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Figure 37: Patient fully recovered from acute
attack of porphyria following 
withdrawal of carbamazepine.
rhythm), respiratory rate 24/min, temperature 37.8oC. He had no 
lymphadenopathy or skin abnormality. Although he seemed to have 
abdominal pain, there were few clinical signs in the abdomen. 
Neurological assessment revealed a mild degree of longstanding 
left-sided spastic hemiparesis; no nystagmus or signs of 
peripheral neuropathy were noted. Sensory perception seemed 
unimpaired, but detailed testing was not possible.
Laboratory data revealed an erythrocyte sedimentation rate of 32 
mm in the 1st hour and a mild normochromic normocytic anaemia. 
Haemoglobin was 10.8 g/dl, white-cell count 8600/ul, platelets 
352,000/ul. Reticulocyte count was repeatedly less than 1%.
Serum ferritin and vitamin levels were normal. Whole-blood 
folate was initially low at 74 ng/ml but after correction with 
folic acid supplements the haemoglobin level remained unchanged. 
Tests for faecal occult blood were negative. Serum sodium was 128 
mmol/1. Serum aspartate aminotransferase was 63 U/1 and alkaline 
phosphatase 101 U/1 (normal 21-92 U/l). Bacteriological 
investigation for a low-grade pyrexia of unknown origin, including 
several blood, urine, and stool cultures, was negative.
Because AIP was supected, the anticonvulsants were gradually 
withdrawn. This resulted in a temporary worsening of the 
epilepsy, which necessitated the re-introduction of primidone and 
sodium valproate. Cessation of carbamazepine therapy resulted in 
a clear urine and the disappearance of fever, vomiting, and 
abdominal pain. The mild anaemia also improved.
Case 2
Whereas case 1 displayed both the clinical and biochemical 
features of AIP after treatment with carbamazepine, the following
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patient was symptom—free but had a lowered erythrocyte URO.S 
activity, as seen in AIP. A 34—year—old woman had severe
generalised tonic-clonic epilepsy from age 4 years as a result of
birth injury. Epileptic control had previous been very difficult
but for 2 years has been satisfactorily maintained with a
combination of sodium valproate, phenytoin, and carbamazepine, the 
last in a daily dose of 1200 mg. She has no abdominal pain or 
other features suggestive of AIP. No family history of porphyria 
was obtained. The serum concentrations of all three 
anticonvulsant drugs were closely monitored and maintained within 
the recommended therapeutic range.
^ilept.ic. Grou£. ^ tud%
Blood samples collected from 53 epileptic patients on a variety of 
drug regimens and 53 drug-free healthy controls matched for age 
and sex were assayed for URO.S activity. Nineteen of the 
epileptic patients were treated with carbamazepine alone, 14 with 
carbamazepine in combination with other anticonvulsants 
(phenytoin, phenobarbitone, and sodium valproate), 10 with 
single-drug anticonvulsant therapy other than carbamazepine, and 
10 with combination therapy excluding carbamazepine. The results 
of the URO.S assays were compared with those of the controls with 
the Mann-Whitney U test. URO.S activities from a group of 13 
patients with symptoms of AIP were included for comparison with 
the study groups.
MeUiod^
Urinary ALA, PBG and porphyrins; leucocyte ALA.S and erythrocyte 
URO.S were measured using standard methods.
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Figure 3 8 ; Time course of haem biosynthetic enzyme 
activities and urinary ALA, PBG, and 
uroporphyrin excretion following 
alterations in anticonvulsant therapy.
Erythrocyte
URO.S*
Leucocyte
ALA.S**
Urinary
ALA
(umol/1)
Urinary
DBG
(umol/1)
Urinary
uroporphyrin
(nmol/1)
Case 1 
Patient 9 394 171 194 1022
Mother 30 103 0 6 0
Father 29 • •
Case 2
Patient 18 210 10 10 0
(repeat
sample) 16 256 5 0 0
Mother 35 181 14 4 0
Father 32 117 0 0 0
Normal
ranges 24-54 20-279 0-40 0-16 0-49
* nmol porphyrins formed/ml red cells/h 
** nmol AIA/g protein/h
Table 16; Family studies: Enzyme activities and urinary
porphyrin precursors and uroporphyrin
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uroporphyrin levels were normal, but her HPLC excretion pattern of 
uroporphyrin, and penta-, hexa- and hepta-carboxylic porphyrins 
was qualitatively similar to that obtained from AIP patients (Fig
39). Yet, both her parents had normal HPLC porphyrin excretion 
profiles.
■lpii.§pt.ic. Groups Study
The mean erythrocyte URO.S activity was significantly lower in the 
patients treated with carbamazepine alone (24.8+^5.0 ISO nmol 
porphyrins formed/ml red cells/h) than in the control group 
(35.8^1.1 nmol porphyrins formed/ml red cells/h) (p < 0.001) (Fig
40). URO.S activity was lowest in the group treated with 
carbamazepine in combination with other anticonvulsants (20.1+10.1 
nmol porphyrins formed/ml red cells/h, p < 0.001). A small but 
significant reduction in URO.S activity was also noted in patients 
treated with anticonvulsants other than carbamazepine, either 
singly (28.5±5.6 nmol porphyrins formed/ml red cells/h, p < 0.01) 
or in combination (31.0+7.8 nmol porphyrins formed/ml red cells/h, 
p < 0.05).
11.4 DISCUSSION
Of the various neuropsychiatrie manifestations of acute porphyria 
generalised tonic-clonic seizures can occur either alone or as an 
accompaniment of an organic brain syndrome (Waldenstrom, 1957 ; 
Brodie & Goldberg, 1980). Despite their diverse chemical 
structures a large number of drugs have been suspected of 
precipitating an acute attack of AIP (Moore & Disler, 1983). The 
porphyrinogenicity of such drugs, which seems to depend in part on
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Figure 40; Erythrocyte URO.S activities in a group of 
AIP patients and in epileptic patients on 
different regimens of anticonvulsant therapy 
(•) and control (J).
their lipophilic properties (Murphy et al, 1975) has been 
attributed, in some cases, to their ability to induce the 
cytochrome P450-dependent mono-oxygenase system necessary for 
their metabolism in the liver (Moore et al, 1970). A partial 
block in haem biosynthesis can in effect lower intracellular haem 
concentrations which may then be further depleted by an increase 
in requirement of haemoprotein for hepatic mono-oxygenase 
synthesis. As a consequence further de-repression of ALA.S will 
occur. In case 1 the clinical and biochemical features at 
presentation were typical of AIP. Despite the past history of 
brain damage from measles encephalitis the diagnostic problem 
centred on whether the patient's uncontrolled epilepsy might have 
been due to an exacerbation of acute porphyria induced by 
inappropriate anticonvulsant therapy. Barbiturates, carbamazepine 
and sodium valproate have all been suspected of being 
porphyrinogenic because they can induce ALA.S activity both in 
vivo and in vitro (Magnussen et al, 1975; Larson et al, 1978; 
Bonkowsky et al, 1980). In the hereditary type of AIP URO.S 
activity would have been expected to remain unchanged after 
withdrawal of carbamazepine, but in case 1 it rapidly returned to 
a high normal level. Moreover, after réintroduction of an 
acceptable therapeutic dose of primidone (which is converted to 
phenobarbitone in vivo) and sodium valproate, erythrocyte URO.S 
activity remained normal and leucocyte ALA.S activity failed to 
increase. This suggests that the increased requirement of 
cytochrome P450 provoked by the enzyme inducers carbamazepine and 
primidone is unlikely by itself to account for the pathogenesis of 
the acute porphyria described.
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Although it would have been desirable to carry out a more 
extensive family study on case 1, this was not possible. But 
after discussion of the case with the general practitioner looking 
after the other members of the family and many of their close 
relations, no suggestion of any porphyric illness was evident 
amongst them. Being unable to settle beyond doubt the possibility 
of illegitimacy for case 1, inclusion of the family study on case 
2 supports the argument that the porphyrin abnormalties observed 
are carbamazepine-induced and not due to some rare variants of 
inherited AIP previously described (Mustajoki, 1981).
The lowered URO.S activity is probably due to a direct depressant 
effect of carbamazepine on this enzyme system. This possibility 
is strongly supported by the family studies carried out and by the 
HPLC excretion pattern of urinary porphyrins from case 1. Whereas 
the measurement of urinary ALA and PBG is rather insensitive in 
detecting latent porphyria concurrent assay of erythrocyte URO.S 
and leucocyte ALA.S activities is much more specific. In this way 
McColl et al (1982) showed that 49% of 35 symptom free first 
degree blood relatives of AIP patients had the porphyric enzyme 
pattern with no sex bias. It is therefore important that results 
of both urinary porphyrin screening and blood enzymatic assays 
were normal in the parents. In addition erythrocyte URO.S 
activity was found to be significantly reduced in epileptic 
patients receiving carbama^ine. Erythrocyte URO.S activity was 
further depressed when carbamazepine was given in combination with 
other anticonvulsants such as phenobarbitone and phenytoin. 
Surprisingly the latter also appeared to exert a smaller but
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significant depressant effect on this enzyme system when given 
alone. Sulphonamides which are known to provoke attacks of AIP 
have been shown to inhibit rat hepatic URO.S activity in vitro 
(Peters et al, 1980). It is still unclear whether the suppressive 
effect of these drugs on URO.S activity is a consequence of their 
capability to increase haem requirement by way of induction of the 
mono—oxygenase enzyme system or an entirely independent property. 
Although the molecular mechanism by which carbamazepine suppresses 
URO.S activity remains to be elucidated, the pathogenesis of the 
acute porphyria in case 1 can still be adequately explained.
After the administration of carbamazepine at a high dosage a 
potent depressant action was exerted on the haem biosynthetic 
pathway at the level of URO.S. As in hereditary AIP, this partial 
enzymatic defect produced clinical manifestations only when the 
system became overloaded with additional porphyrinogenic factors 
in the form of combination anticonvulsant therapy and reduced 
carbohydrate intake due to anorexia and vomiting. Carbamazepine 
itself is also a potent enzyme inducer in man (Rapeport et al, 
1983).
Case 1 probably illustrates a genuine case of non-hereditary 
"Haemato-porphyria acuta toxica" which Gunther in 1911 had hoped 
to differentiate from the familial type of acute porphyria 
exacerbated by drugs. It might seem surprising that this 
complication of carbamazepine has not been reported before, 
considering that a considerable number of patients receiving this 
drug have erythrocyte URO.S levels within the AIP range. Perhaps 
it has not been recognised as such before since the problem is
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compounded by the knowledge that enzyme—inducing drugs such as 
carbamazepine can precipitate an acute attack of porphyria. 
Moreover the majority of latent AIP cases are indeed asymptomatic, 
and are only brought to light by family screening of overt cases 
(McColl et al, 1982). In this regard, it is interesting to note 
that in earlier reports the incidence of acute porphyria in 
patients prescribed the now obsolete hypnotic drugs sulphonal and 
trional seemed higher than would have been expected from mere 
activation of the latent form of AIP (With, 1971). It is 
therefore probably that drugs other than carbamazepine will 
produce an acute form of porphyria just as toxic forms of 
cutaneous hepatic porphyria may be caused by hexachlorobenzene and 
other polyhalogenated compounds. It is interesting to note that 
Fuchs et al (1980) described another case of toxic non-hereditary 
acute porphyria in a 21-year-old man whose illness appeared to 
have been induced by a combination of phenytoin and phénobarbital.
FURTHER STUDIES OF CARBAMAZEPINE ON HAEM BIOSYNTHESIS
11.5 INTRODUCTION
Further studies were carried out to elucidate the mechanism by 
which carbamazepine interfered with the haem biosynthetic 
pathway. It was particularly important to investigate the 
possibility that carbamazepine might have interfered with the 
assay of erythrocyte URO.S in vitro. And since a depression of 
URO.S activity in the red blood cells does not necessarily 
accompany a similar decrease in the liver, as would be required
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for the induction of acute porphyria, further evidence for a 
hepatic URO.S defect was sought. As direct measurement of hepatic 
URO.S would have required tissue biopsy and was therefore not 
practical indirect evidence for such a defect was obtained in 
carbamazepine-treated subjects by measuring their urinary 
excretion products of porphyrins and precursors.
11.6 PATIENTS AND METHODS 
Itudy; 1
Until now carbamazepine has been unavailable in a parenteral 
form. An in vitro cross-incubation experiment was therefore 
performed using fresh serum obtaining from carbamazepine-treated 
patients with depressed erythrocyte URO.S activity - case 2 of the 
previous study. The patient's serum was incubated at different 
time intervals with erythrocytes from two age- and sex-matched 
healthy controls of the same blood group. Similarly the patient's 
erythrocytes were incubated with sera from the controls. The 
erythrocytes were thoroughly washed three times with normal 
phosphate buffered saline (PH 7.4) prior to incubation at 37^0. 
Measurement of URO.S activity was carried out by the standard 
method.
^tudx 2l Normal volunteer study
Six healthy male Caucasian subjects were given carbamazepine 400 
mg at night for a 22-day period. None of the subjects had 
evidence of hepatic, renal or haematological disease. Baseline 
haematology, electrolytes, liver function tests and blood lead 
concentrations were in the normal reference range. No other drugs
185
were taken in the month preceding the study or during the study 
period. Alcohol consumption was not allowed during the study.
Only one subject smoked cigarettes. Approval was obtained from 
the Western Infirmary Ethical Committee and all subjects gave 
written informed consent.
The subjects were studied one week before treatment with 
carbamazepine (day 0), and after the fifth (day 4), fifteenth 
(week 2) and twenty-second (week 3) doses and three weeks after 
the drug was discontinued (week 6 ). They were fasted overnight 
and venous blood was collected for URO.S and ALA.S activities at 
0900 h on each occasion. Urine was collected over 24-h periods 
and measurements of urinary porphyrins and precursors were 
performed. In addition the pattern of urinary porphyrin excretion 
was sequentially measured by HPLC method.
11.7 RESULTS 
Itudx 1
As shown in Tables 17a and 17b, the measurement of URO.S activity 
was unaffected by the presence of carbamazepine contained in serum 
from Case 2.
Itudx 1
Significant increases in leucocyte ALA.S activity was noted on the 
fourth day and were maximal on the seventh day. ALA.S activity 
slowly returned toward pre-treatment values during the subsequent 
treatment period, but all values remained elevated above baseline 
at all time points while carbamazepine treatment continued (Fig
41).
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Erythrocyte
In vitro 
incubation 
time (hrs)
+ Buffer solution 
(control)
+ Patient's serum 
containing carbamazepine 
(42 umol/L)
Epileptic Patient
- Case 2 0 20.4 21.0
1 18.1 20.7
17 18.1 17.0
25 16.0 14.0
41 15.8 13.0
First Normal
Control 0 47.4 53.4
1 43.9 49.4
17 45.7 47.8
25 43.6 42.9
41 43.4 42.0
Second Normal
Control 0 36.0 39.0
1 36.4 38.6
17 37.4 37.7
25 35.2 35.2
41 38.3 36.3
Table 17a: Erythrocyte URO.S results after incubation
at different time intervals
187
Incubated with serum from 
In vitro First Second Case 2
incubation normal normal (autologous
time (hr) control control serum)
0 21.4 20.4 18.6
Washed 1 19.5 19.3 21.2
erythrocytes 17 19.6 18.7 21.5
from 25 20.7 20.6 20.9
Case 2 41 18.3 20.3 18.8
Table 17b: Erythrocyte URO.S results following
incubation at different time levels
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Figure 41: Leucocyte ALA.S activities in six subjects
taking carbamazepine for three weeks. Cross 
bars represent the mean value.
Erythrocyte URO.S activity decreased in all subjects throughout 
the treatment period. Values were still significantly depressed 
three weeks following stoppage of carbamazepine (Fig 42). Urinary 
porphyrins and precursors are shown in Table 18. Significant 
increases in ALA and total porphyhrin excretion occurred during 
the first and second week of treatment. PBG excretion showed no 
consistent change. The HPLC pattern of porphyrin excretion was 
similar to that seen in AIP during carbamazepine therapy and 
reverted to normal on cessation of carbamazepine (Fig 43).
11.8 DISCUSSION
The results of the cross-incubation experiment confirmed that 
carbamazepine and its metabolites in the serum were unlikely to 
interfere with the assay of URO.S activity in vitro. Neither did 
they support the possibility of a direct effect on the peripheral 
red cells to decrease URO.S activity. The URO.S assay employed 
was an indirect method of measurement in that it used ALA as 
substrate and depended on a normal erythrocyte ALA.dehydratase, 
ALA.D activity after activation with zinc and dithiothreitol.
Using a different method of URO.S assay with PBG as substrate. 
Rideout et al (1983) provided some data to suggest that 
carbamazepine caused a decrease in erythrocyte ALA.D instead of 
URO.S activity. But Moore et al (1983) used an assay system (Ford 
et al, 1980) similar to that of Rideout et al; and they confirmed 
our observations by finding depressed URO.S activity in South 
African patients treated with carbamazepine. The mean activity (+. 
SD) of URO.S for five epileptic patients was 7.23 (± 1.41) nmol of
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Figure 42 : Erythrocyte URO.S activities in six normal
subjects givencarbamazepine for three weeks. 
Cross bars represent the mean values. 
Statistics by Student's t-test for paired 
values. Comparisons are with baseline values.
Time of 
collection
ALA
umol (24h)"l
PBG
umol (24h)~l
Porphyrins 
ug (24h)"l
Baseline 17 ±  9.7 Nil 64 +_ 9.4
Day 4 28 + 5.5* 1.5 + 1.4 85 + 22.3*
Week 1 23 ±  8.9 2.5 + 2.9 88 + 25.1*
Week 2 42 ±  6.0** Nil 87 + 47.6
Week 3 26 + 7.4 7.3 + 4.0 123 + 61.1
Week 6 17.5 + 5.8 8 + 4.0 61 + 24.3
Normal range < 40 < 16 < 306
* p < 0.05
** p < 0.02
Comparison with baseline by Student's paired t-test
Table 18; Serial daily ALA, PBG and total porphyrin excretion 
(mean + SD) in six healthy subjects taking 400 mg 
carbamazepine daily for 22 days
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Figure 43: Representative changes in HPLC pattern of
urinary porphyrin esters following 
carbamazepine therapy. These changes were 
seen in the urine of all subjects after 15 
days treatment. The urinary pattern after 
treatment bears striking abnormalities to 
that of AIP.
uroporphyrin/L erythrocytes/second as compared to 12.24 2.46)
for 31 normal subjects. They did not measure ALA.D activity but 
they found a significant increase in leucocyte ALA.S activity 
during the treatment period. Moore et al (1983) therefore 
concluded that the use of ALA as substrate for the measurement of 
URO.S activity was quite justifiable.
Previous animal studies have shown that in response to the 
administration of enzyme-inducing drugs hepatic ALA.S activity 
increased before a detectable rise in microsomal haemoprotein 
concentrations (Marver, 1974). In this present study, ALA.S 
activity increased maximally by the seventh day before returning 
to baseline levels despite continued carbamazepine 
administration. This time course was similar to that observed for 
the increase in 6^-hydroxycortisol excretion following induction 
with the antibiotic rifampicin (Park, 1981); it may represent the 
time required for new haemoprotein synthesis of the mono-oxygenase 
system. A similar pattern of ALA.S elevation has been reported in 
epileptic patients treated with phenytoin, another potent 
enzyme-inducer (McColl et al, 1980).
The fall in erythrocyte URO.S activity following administration of 
carbamazepine to healthy subjects is in keeping with the changes 
recorded in epileptic patients taking the same drug (Chapter 
11.3). Urinary ALA and porphyrins were significantly elevated, 
although values remained within the normal range for the assays. 
But this mild elevation was not seen with PBG excretion. In this 
study depression of hepatic URO.S activity was supported by the 
changes seen in the HPLC pattern of urinary porphyrin excretion.
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The pattern after carbamazepine ingestion closely resembled that 
of latent AIP,
McGuire et al (1985a) have recently confirmed that administration 
of carbamazepine can also reduced ALA.D activity (Rideout et al, 
1983) both in human erythrocytes and in rat liver. Erythrocyte 
ALA.D activity was depressed by nearly 50% in epileptic patients 
receiving long-term carbamazepine therapy. But attempts to 
reproduce this effect in vitro by direct addition of the drug or 
its main metabolite, carbamazepine 10, 11-epoxide, to whole blood 
were unsuccessful. In patients prescribed carbamazepine, 
depression of erythrocyte ALA.D activity was irreversible and 
could not be restored by the addition of enzyme activators, as 
happens with lead intoxication. Further experiments performed in 
our laboratory (McGuire et al, 1985b) have indicated that both 
parent carbamazepine and its epoxide derivative could reduce ALA.D 
activity in mitogen-stimulated human lymphocytes in culture. 
Contrary to their previous in vitro studies using human 
erythrocytes and rat liver preparations (McGuire et al, 1985a) 
exposure of the lymphocytes to carbamazepine for as little as five 
hours was sufficient to reduce ALA.D activity. These findings 
suggest that some form of intracellular biotransformation of 
carbamazepine epoxide must occur before it can reduce ALA.D 
activity. At present it is not known if a similar mechanism 
operates for the depressant effect of the drug on URO.S activity. 
In view of the large difference in the relative activities between 
erythrocyte ALA.D (2100 umol ALA/L erythrocytes/h) and erythrocyte 
URO.S (0.27 umol ALA equivalents/L RBC/h); and hepatic ALA.D (15.9
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nmol ALA/mg protein/h) and hepatic URO.S (0.15 nmol ALA 
equivalents/mg protein/h) (Elder, 1982) only a marked diminution 
in ALA.D activity (> 90%) as seen in lead poisoning would be 
required to limit substrate availability for URO.S (Moore et al, 
1980b). The urinary excretion of large amounts of PBG in the 
toxic case of acute porphyria described (case 1) suggested that 
the development of the disease probably arose from a depression of 
both URO.S and ALA.D activities induced by carbamazepine therapy. 
Thus the depressant effects of carbamazepine on the haem 
biosynthetic pathway in man may well provide a possible 
experimental human model for the acute hepatic porphyrias.
The interpretation of any future studies with this model from the 
point of view of the human acute hepatic porphyrias would have to 
take account of the fact that these diseases are all due to single 
enzyme defects (uroporphyrinogen I synthetase for acute 
intermittent porphyria, coproporphyrinogen oxidase for hereditary 
coproporphyria, and protoporphyrinogen oxidase for variegate 
porphyria) whereas carbamazepine inhibits delta-aminolaevulinic 
acid dehydrase as well as uroporphyringen I synthetase.
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SECTION III
CHAPTER 12
DEVELOPMENT OF AN IN VITRO MODEL USING HUMAN 
PERIPHERAL BLOOD MONOCYTES FOR STUDYING 
THE HAEM BIOSYNTHETIC PATHWAY
12. DEVELOPMENT OF AN IN VITRO MODEL USING HUMAN PERIPHERAL 
BLOOD MONOCYTES FOR STUDYING THE HAEM BIOSYNTHETIC
PATHWAY
12.1 INTRODUCTION
Numerous experimental models using either whole animals (With,
1980) or tissue cultures from other species have been described in 
the study of the haem biosynthetic pathway. None of these however 
can satisfactorily produce changes that reflect the clinical 
manifestations of the acute hepatic porphyrias. Efforts to 
elucidate the pathogenesis of the human disease have had to be 
approached clinically with the obvious limitations imposed by 
patient study.
Recent work has established the peripheral blood monocyte as a 
major secretory cell (Nathan, 1980). Although human monocytes 
constitute only 2 to 5% of the total white cell count such 
metabolically active cells are of bone-marrow origin, and if 
successfully cultured, could provide a useful in vitro model for 
investigating the haem biosynthetic pathway. This would be 
particularly desirable in view of the easy accessibility and 
availability of blood monocytes as compared to bone marrow or 
liver tissue.
In this study I have developed a highly purified human monocyte 
culture system and shown that proto-0 activity can be reliably 
measured in these cultured cells.
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12.2 MATERIALS AND METHODS 
Preparation o^ f_jmonocxte^  cultures
12.2.1 Abbreviations:
1. PBS: phosphate-buffered saline,^H 7.4 containing K2HPO4 
(0.34 g/L), KH2PO4 (1.21 g/L) and NaCl (8 g/L).
2. Human AB serum: human blood group AB serum.
3. RPMI: RPMI-1640 tissue culture medium.
4. RPMI-PBS-EDTA: Equal volumes of RPMI-1640 and PBS
containing EDTA (10 mmol L"^).
5. RPMI-FCS: RPMI-1640 containing 20% (V/V) heat-inactivated
(2 h at 560C) foetal calf serum.
6 . RPMI-ABS: RPMI-1640 containing 10% (V/V) heat-inactivated
(2 h at 56°C) human blood group AB serum.
7. Proto.0 buffer (pH 8.7) consisted of 100 mmol/L Tris HCl 
1 mmol/L EDTA and 5 mmol/L glutathione.
12.2.2 Preparation of monocyte monolayers (Appendix II)
Venous blood (60 ml) from normal volunteers was collected in 
preservative-free heparin. After centrifugation over 
Ficoll/Hypaque gradients (Boyum, 1968), the mononuclear leucocytes 
at the interphase were harvested and resuspended in 36 ml of 
RPMI-FCS. A 12 ml portion of the suspension was added to 
tissue-culture flasks that had been precoated with the 
micro-excudate of BHK (baby-hamster kidney) cells (Douglas et al, 
1981). After incubation at 37°C for 45 min, the culture medium 
containing non-adherent cells was decanted, and the monolayer 
washed three times with warm (37^0) RPMI 1640. Adherent platelets 
were then removed by a brief exposure (30s) to RPMI-PBS-EDTA. The
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adherent monocytes were detached from the flasks by a second 
incubation with RPMI-PBS-EDTA at 37°C for 15 min. The detached 
monocytes were washed once in ice-cold RPMI-ABS and then 
resuspended to 4 x lO^/ml in RPMI-ABS.
Portions (1 ml) of cell suspensions were added to the wells of 
Linbro tissue-culture plates, which were then incubated at 37°C 
for 3 h in a humidified atmosphere consisting of CO^/air (1:19). 
The supernatants were removed and the monolayers washed with warm 
RPMI 1640. The monocytes were finally cultured in 1 ml of 
RPMI-FCS per well. The incubation was continued for 10 days under 
the conditions described above to allow the monocytes to mature 
into macrophages (Strunk et al, 1983).
Qi^ ra_cjte_ri^ a_t i_on_o_f c.eils. ÂA_™ono.l^e.rx
All the cells present in monolayers stained positively for 
non-specific esterase (Horwitz et al, 1977). Over 90% were able 
to phagocytose latex and serum-treated zymosan particles.
12.2.3 DNA content of monolayers (Appendix III)
The DNA content of the lysates of monolayers was determined by 
spectrofluorimetry (Cesarone et al, 1979). The volume of the 
lysate was made up to 5 ml with PBS, and after the addition of 20 
ul of H33285 dye the content of DNA was measured by using a 
Shimadzu fluorimeter with transmission and emission wavelengths of 
364 nm and 448 nm respectively. A standard curve of known DNA 
content was included in all assays. By using this assay 1.1 ug of 
DNA corresponds to 1 x 10^ monocytes. Enzyme activity was 
expressed per ug DNA content of the cultured monocytes.
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12.2.4 Monocyte homosenate preparation
After the monocytes had been in culture for 10 days the 
supernatant was removed and the cells washed once with warm PBS 
(PH 7.4). The contents of three random wells from the Linbro 
culture plate were stored for DNA assay. To each of the remaining 
wells 250 ul of ice-cold proto.0 buffer was added. The plate was 
placed on crushed ice to prevent warming up of the homogenate 
during disruption of the cells by ultrasonic vibration. The 
monocytes were subject to two bursts of ultrasonic vibration for a 
total period of 30 seconds. The cell homogenate from half the 
number of wells was transferred into a test-tube and heated at 
75°C in a water-bath for 20 minutes to destroy proto.0 activity 
(Poulson, 1976). This heated tissue preparation was used in the 
non-enzymatic control (NEC) cuvettes.
12.2.5 Measurement of nrotoporphvrinogen oxidase (Proto.0) 
activity
Proto.0 activity was measured by spectrofluorimetry, based on the 
method of Brenner and Bloomer (1980b) with several modifications. 
This assay depends on the conversion of protoporphyrinogen IX to 
protoporphyrin IX (Proto.IX). 
podium amalgam preparation
The sodiiy^ amalgam was used to reduce the proto.IX to 
protoporphyrinogen. 3 gm metallic sodium, cut into small pieces, 
were added to a 200 ml volume of toluene which was then boiled on 
a hot-plate until the sodium formed small globules. 2.5 ml of 
mercury was slowly added into the toluene until solid amalgam 
formed at the bottom of the flask. After cooling the amalgam was
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A 1 ‘^  i
washed with^/petroleum s^ j^^ Wrt, dried and broken into fragments 
(1.0 cm in diameter). It was stored in a dessicator and discarded 
if not used within a week.
P^ repaxa.ti.on o.f_pxo^O£^orphyr.inoxen solution 
A stock solution of the disodium salt of proto.IX (Sigma 
Chemicals) - 1.5 mmol/L in 0.01 mol/L KOH containing 20% ethanol 
(V/V) - was diluted with degassed KOH-ethanol solution to a final 
concentration of 50 umol/L proto.IX (Sano & Granick, 1961). 
Immediately before use, the amalgam was finely crushed with a 
mortar and pestle. It was then transferred to a flask, shielded 
from light by aluminium foil, containing 3 ml of the proto.IX 
solution. About 2 gm of amalgam were added for each ml of 
proto.IX. The chemical reaction was allowed to proceed gently in 
the dark, under nitrogen, for about 3 minutes while the contents 
of the flask were gently shaken. The reaction was stopped when 
the proto.IX fluorescence could no longer be seen under 
ultraviolet light. The clear solution of protoporphyrinogen was 
rapidly transferred into a small beaker and its pH adjusted to 8.7 
with 40% phosphoric acid (W/V). 
jPro.to.».0 activity assay
Previous studies have shown that measurement of proto.0 activity 
in mammalian tissue was optimal at pH 8.7 (Poulson, 1976; Brenner 
& Bloomer, 1980b; Deybach et al, 1981). All reactions were 
therefore carried out at pH 8.7.
The standard reaction mixture was placed into a disposable 
fluorimetric cuvette and consisted of:
1. 400 to 1600 ul of either monocyte test homogenate or NEC
(200 ul being the volume retrievable from each culture well).
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2. 50 ul of freshly prepared protoporphyrinogen solution (1.2 
2.5 umol/L).
3. the appropriate volume of proto.0 buffer to make up a final 
volume of 2 ml.
Each assay always included a cell blank and a protoporphyrinogen 
(proto'ogen) blank in addition to the NEC. Immediately after the 
protoporphyrinogen solution was added to the cuvette, the reaction 
mixture was vortexed and allowed to settle for 3 minutes at room 
temperature in the dark. The fluorescence emission intensity of 
the whole contents of the cuvette was then measured at 620 nm with 
an Elmer-Perkin spectrofluorometer (Model 3000) using an 
excitation wavelength of 400 nm. The cuvettes were then incubated 
at 37°C in the dark and in air without any shaking. This was done 
to minimise non-enzymatic formation of protoporphyrin from its 
precursor. Fluorescence measurements were repeated after 30, 60 
and 90 minutes.
12.2.6 Calculation of results
The difference in protoporphyrin concentrations between the 
untreated cell homogenate and the corresponding non-enzymatic 
control represented the enzymatically generated protoporphyrin. 
This was calculated from the fluorescence readings at 90 minutes: 
(test sample - Proto'ogen blank)
- (NEC - proto'ogen blank).
The concentration of protoporphyrin was then determined by 
comparison with the copro I standard.
Proto.0 activity was expressed as the amount of protoporphyrin 
formed per ug DNA of the cultured monocytes per hour (pg proto, 
ug DNA-1 h-1).
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12.3 RESULTS
The fluorescence readings of Proto.IX solution was found to become 
unstable with the passage of time (Figs 44 and 45). In contrast 
fluorescence measurements of copro I remained constant for the 
duration of the experiment (Fig 46). The fluorescence- 
concentration relationship for both copro I and freshly prepared 
proto.IX solution was linear over the range of 1.2 to 75 nmol/L 
(Fig 47): in effect they were identical. Therefore copro I
solution was employed as the standard in the assay once it was 
calibrated with a freshly made proto.IX solution.
The results of proto.0 activity in the cultured monocytes of the 
same healthy subject obtained at 5 week intervals are shown in 
Tables 19 and 20. Proto.0 activity was 9.74 and 11.04 pmol 
proto.IX ug DNA”^h”  ^ on the two successive occasions. When fewer 
than 1.2 x 10  ^ cultured monocytes were used (i.e. contents of 
three wells) measurement of proto.0 activity in the cell 
homogenate was not possible, probably because of insufficient 
enzyme. Using the cell homogenate from three wells in the assay 
the mean DNA content per well was found to be 3.04 ug, and the 
mean proto.0 activity in the monocytes 10.37 pmol proto.IX ug 
DNA-^h-l (range 8.86 - 12.12) (Table 21). Since 1.1 ug DNA is 
equivalent to 10  ^monocytes, the mean proto.0 activity per 
cultured monocyte was 11.41 x 10”  ^pmol proto.IX ug DNA^^h""^. 
Increasing the amount of cell homogenate in the assay led to 
unacceptable neph|ometric interference with the fluorescence 
measurement. Attempts to circumvent this problem by diluting 0.1 
ml aliquots of the reaction mixture at the various incubation
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Normal subjects
Mean
DNA content 
(ug/well)
Proto 0 activity
pmol proto IX ug DNA"^h”^
1 3.21 11.04
2 2.98 8.86
3 2.86 9.46
4 3.11 12.12
Mean value 3.04 10.37
Table 21; Results of proto.0 activity in cultured
monocytes from four healthy male subjects. 
The cell contents from three culture wells 
(equivalent to 9.1 ug DNA) were used in 
these assays.
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time-points (Bloomer & Brenner, 1980b) was unsuccessful because of 
the low fluorescence generated. With the small number of 
monocytes in use (8 x 10  ^ to 1.6 x 10^) the assay was operating at 
the lowest range of sensitivity of the spectrofluorimeter. 
Increasing the concentration of protoporphyrinogen in the reaction 
mixture only caused a rise in the background fluorescence readings 
since the substrate was already in gross excess as compared to the 
amount of product formed. Several other changes were made to the 
operating conditions of the assay without any benefit:
1. Alteration of pH from 8.7 to 9.2 did not improve the 
sensitivity.
2. Use of protoporphyrinogen derived from porphyrin ester 
instead of proto.IX (Poulson & Polglase, 1975) conferred no 
advantage.
3. Addition of Tween 20 to the reaction mixture (Bloomer &
Brenner, 1980b; Deybach et al, 1981) caused fluorescence 
interference and troublesome frothing.
4. Lowering glutathione concentration in the buffer from 5 to 2
mM (Polglase, 1976; Deybach et al, 1981) resulted in similar 
proto.IX conversion.
5. Reading the fluorescence at emission intensity of 635 nm
using an excitation wavelength of 405 nm (Bloomer & Brenner, 
1980b) instead of 620 nm and 400 nm respectively made no 
significant difference.
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12.4 DISCUSSION
Peripheral human leucocytes have been shown to possess all the 
functionally active haem enzymes (Elder et al, 1976; Grandchamp et 
al, 1977; Brodie et al, 1977d; Sassa et al, 1978; Deybach et al,
1981). Indeed, in our laboratory, the measurements of the 
mitochondrial haem enzymes can all be performed on the white cell 
huffy coat. Following the observation that stimulated blood 
lymphocytes can produce porphyrins (Saillen et al, 1969; Josephson 
et al, 1972), Sassa and his associates (1978) have reported that 
URO.S activity is reduced by 50% in similarly transformed 
lymphocytes obtained from AIP patients. But stimulation of 
cultured lymphocytes by mitogens like phytohaemaglutinin or by the 
Epstein-Barr virus inevitably disrupts the normal regulatory 
mechanism of the cells. Consequently the usefulness of such 
models is greatly limited.
This study has shown that proto.0 activity can be measured in 
human blood monocytes maintained in culture for a period of 10 
days. It is therefore very likely that other haem enzymes can 
also be measured in these cells. Measurement of ALA.S would be 
particularly useful for assessing the potential porphyrinogenicity 
of drugs and chemicals. This human model could solve some of the 
problems associated with the methods currently employed for 
testing these drugs eg interspecies differences.
The limitations imposed by the spectrofluometric method 
necessitated the use of more cells than originally anticipated (ie 
contents of three instead of single wells). Since the optimal 
density for monocyte culture in the Linbro plates is between 4-6
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10  ^ cells, seeding the cells of a higher density will require 
different culture conditions. Since the yield of monocytes by the 
present method is on average 1 x 10  ^ sufficient cells are 
available for experimentation. Where a larger supply of 
monocytes is required I have satisfactorily used whole-blood-pack 
huffy coats, obtainable from the Regional Blood Transfusion 
Centre.
The homogeneous cell population provided by the highly purified 
(more than 99%) monocytes in culture offers an excellent in vitro 
model for investigating the molecular control of the haem 
biosynthetic pathway. Indeed the monocyte culture technique 
developed in the course of this study has already found such an 
application towards the understanding of the molecular basis of 
another inherited inborn error of metabolism - hereditary 
angioneurotic oedema (Yeung Laiwah et al, 1985).
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APPENDIX I
EXPLANATION OF NEUROPATHOLOGICAL TERMS
1. Segmental demyelination is the characteristic 
histopathological abnormality seen in neuropathies due to 
dysfunction of the Schwann cell. Short segments of myelin break 
down in a random manner between the nodes of Ranvier; there 
appears to be no predilection for distal involvement of the nerve 
cell. Following demyelination the process of remyelination can 
occur rapidly. And if the axon remains intact recovery can be 
complete. Segmental demyelination impairs the conduction velocity 
of the nerve cell considerably. When tested clinically conduction 
velocity in the affected peripheral nerves is typically reduced by 
more than 40%.
2. Axonal degeneration of the 'dying-back' type occurs when the 
most distal end of the nerve cell degenerates with dissolution of 
the axon and destruction of the accompanying myelin sheath. The 
myelin breaks up into small lipid globules which are phagocytosed 
by microglia ie Wallerian degeneration. Despite loss of the axon, 
the Schwann cells and their basal lamina persist and proliferate 
to form cords of cells within the endoneural tubes. Soon after 
the distal part of the axon degenerates the muscle fibres it 
supplies become atrophied. Axonal degeneration affects the most 
distal part of the axon first because it is the most vulnerable 
part to become compromised metabolically, being dependent on the
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cell body or perikaryon for somal irrigation. Axonal degeneration 
may occur in parenchymatous neuropathies, following application of 
toxic substances, from mechanical compression of the nerve or 
after death of the cell body.
In the absence of demyelination mild neuropathies of this type may 
be present without abnormalities of nerve conduction velocities 
when tested clinically because only a proportion of remaining 
unaffected nerve cells in the peripheral nerves with their intact 
myelin sheaths, is required to transmit the electrical impulse of 
the test unimpeded. Thus diseases which primarily affect the 
small fibres can have normal nerve conduction velocities. And 
even those diseases which cause a selective loss of the large, 
fast-conducting fibres often have a mild slowing of conduction 
velocities, the velocity being seldom reduced by more than 20 to 
30%.
The discussion into demyelinating and axonal neuropathies is 
somewhat arbitrary as few diseases fall entirely into one group or 
the other. In severe segmental demyelinating neuropathies some 
axonal degeneration takes place whereas primary axonal neuropathy 
can cause some secondary paranodal demyelination.
3. Chromatolysis refers to degenerative and reactive changes in 
the body of the nerve cell perikaryon as a result of axonal 
injury or destruction. The cell body becomes swollen and 
pale-staining and its nucleus becomes eccentric in position. The 
cytoplasmic Nissl granules disintegrate into dust-like basophilic 
particles. The ultrastructural component of chromatolysis is 
fragmentation of the granular endoplasmic reticulum.
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Chromatolysis is associated with increased nucleic acid and 
protein turnover. If the axon regenerates the cell body may 
return to normal. If it does not, or if the axon is damaged close 
to the cell body, the nerve cell dies.
4. Following axonal damage, attempted regeneration can take 
place to re-innervate motor end plates. Fine axon sprouts grow 
from the proximal stumps of the injured cell into the distal 
region of the nerve where the Schwann cells have formed cords of 
cells. With repeated axonal degeneration and regeneration, the 
large myelinated fibres tend to decrease with a relative increase 
in the small myelinated fibres. Eventually there will be a 
predominance of non-myelinated fibres as the small myelinated 
fibres also disappear.
5. Electromyographic findings Normally with a single motor 
unit stimulation the action potential has a characteristic bi- or 
tri-phasic form, the amplitude being proportional to the number of 
muscle fibres, and the duration of the wave form being 
proportional to the area over which the muscle fibres span. With 
denervation of the muscle fibres the following changes can be seen 
on the electromyographic recording:
1. Excessive polyphasic activity (more than 5 phases)
2, Giant potential with amplitude of more than 5 mV (normally
less than 4 mV)
3, Spontaneous activity with frequent positive sharp waves _ie.
Fibrillation and Fasciculation
4. Reduction in interference ox recruitment pattern on muscle 
contraction.
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APPENDIX II
DEVELOPMENT OF THE HUMAN MONOCYTE CULTURE METHOD
In the original method described by Douglas et al (1981) monocytes 
were incubated in tissue culture medium (RPMI-1640) containing 20% 
foetal calf serum (FCS). This method proved to be repeatedly 
unsuccessful in my hands because by day 7 of culture between 
50-90% of the monocytes became non-adherent and were loose in the 
culture supernatant.
A number of experiments were performed to determine the optimal 
culture conditions for obtaining a monocyte monolayer. The 
modifications that ensued have been adopted in the method 
described.
Peripheral monocytes were obtained from blood of normal healthy 
volunteers. The cells were separated by centrifugation over 
Ficoll-Hypaque gradients and passaged through tissue-culture 
flasks pre-coated with the micro-exudate of baby-hamster kidney 
cells. The purified monocytes were then cultured at a 
concentration of 10^ cells/ml for varying periods of time in 
RPMI-1640 enriched with sera of different types at various 
concentrations. At the end of the culture period the supernatant 
was removed from each well and the non-adherent cells separated by 
centrifugation. The DNA contents of the adherent and non-adherent 
cells were then assayed separately.
It was discovered that the type of serum used to enrich the 
culture medium had a critical effect on the adherence of the 
monocytes to the culture plate.
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The results of representative experiments are presented. 
Abbreviat ions : RPMI = Tissue culture medium RPMI-1640 
FCS = Foetal calf serum 
Human AB = human blood group AB serum
Expt BHK 3 
Culture medium
RPMI-20% FCS. 
RPMI-20% FCS
Duration of 
culture (days)
7
14
% remaining 
adherent cells
29
22
% loose 
cells
59
55
% cells 
lysed
12
23
After seven days, 57 14% of the loose cells could be made to readhere
if replated in a new well, and they still remained adherent after nine 
days in culture.
Expt BHK 16 Effect of different types of enrichment sera on the 
adherence of monocytes in culture for ten days
Type of serum
10% human AB
10% human 
autologous
20% FCS
Adherent cells 
(ug DNA/well)
2.12 + 0.31
2.02 + 0.57 
0.21 + 0.10
*10% human 
autologous (3h)
followed by 20% FCS 0.98+0.27
Loose cells 
(ug DNA/well)
1.04 + 0.55
1.28 + 0.41 
2.72 + 0.95
1.90 + 0.35
Total DNA % adherent 
content cells
3.16 + 0.42 6 7 + 9
3.30 + 0.16 61 + 14
2.93 + 1.05 7 + 1
2.88 + 0.08 3 4 + 9
* Monocytes were plated for 3h in 10% human autologous serum. Culture 
medium was then removed and replaced with 20% FCS.
Inference: 10% human serum achieved best cell adherence in culture.
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Expt BHK 18 
Type of serum 
20% FCS
10% human AB (24h) 
followed by 
20% FCS
10% human AB (72h) 
followed by 
20% FCS
10% horse serum 
with 10% FCS
Effects of different types of enrichment sera on 
monocyte adherence after 10 days in culture
Adherent cells 
(ug DNA/well)
0.54 + 0.01
1.73 + 0.11
1.58 + 0.04
0.56 + 0.11
Loose cells 
(ug DNA/well)
1.31 + 0.11
0.54 + 0.33
0.94 + 0.08
1.23 + 0.23
Total DNA 
content
% adherent 
cells
1.85 + 0.10 3 0 + 2
2.27 + 0.34 6 7 + 5
2.25 + 0.05 6 3 + 2
1.79 + 0.12 3 1 + 6
_Inf.exence.' Initial incubation of monocytes in human serum seems to 
be critical for their adherence to the well although they can subsequently 
be cultured in FCS-containing medium.
Expt BHK 21 The monocytes were initially plated in 10% human 
AB s erum
Effects of various types of enrichment sera in the 
maintenance culture medium on cell adherence 
after 10 days
Enrichment serum
10% FCS
20% FCS
10% FCS and 
10% horse serum
Adherent cells 
(ug DNA/well)
1.48 + 0.01
1.70 + 0.21
1.79 + 0.01
Loose cells 
(ug DNA/cell)
1.18 + 0.04
1.35 + 0.08
1.42 + 0.03
Total DNA % adherent 
content cells
2.66 + 0.04
3.05 + 0.28
55 + 1 
66 + 2
3.21 + 0.04 6 6 + 3
Conclusion
After passage of the monocytes through the BHK-coated flasks the 
cells were allowed to adhere to the wells of the Linbro culture 
plates in RPMI-1640 enriched with 10% human AB serum. The medium 
was then changed to RPMI-1640 containing 20% FCS for the rest of 
the culture period.
Figure 48 show the microscopic appearances of human monocytes soon 
after plating and after 10 days in culture respectively.
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Figure 48: Human blood monocytes in culture for 10 days,
(a) well-established cell monolayer.
(b) note considerable spreading and pleomorphism 
of established monocytes. Identity of these 
cells cannot be ascertained by morphological 
appearances alone.
APPENDIX III
HOECHST DNA ASSAY ^
The main problem that had to be overcome in the development of 
this assay was to find a detergent that would lyse the monocytes 
without causing significant interference with the fluorescence 
measurement.
Method
0.2 ml of the detergent solution was added to each well containing 
the monocyte monolayer. Thorough mixing was carried out by 
repeated pipetting. One ml PBS (PH 7.2) was then added to each 
well and the total contents transferred into a tube containing 
another 4 ml of PBS. 20 ul of Hoechst 33285 dye (7.5 x 10""^  M) 
were added to each tube and the contents were vortexed before 
incubation in the dark for 20 min at room temperature. The 
reaction mixture was then read spectrofluorimetrically at 
excitation and emission wavelength of 364 nm and 448 nm 
respectively.
The effects of different detergents were assessed to the highest 
concentrations at which fluorescence measurements became 
significantly altered:
1. Deoxycholate (Sigma Chemicals) 0.5%: monocytes were
incompletely lysed.
2. Tween (Sigma Chemicals) 0.5%: Cell-clumping and
incomplete lysis 
occurred.
3. Nonidet P40 (BDH) 0.5%: Similarly caused cell-
clumping and incomplete 
lysis
4. Triton XlOO (BDH) 0.1%: Clumps of nuclei were
observed microscopically
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The effects of repeated cycles of freezing (-8OOÇ for 45 minutes) 
and thawing (370C) before and after exposure to the different 
detergents did not significantly improve the problem.
Finally lysis of the monocytes was satisfactorily achieved with 
0.05% SDS.
A linear relationship was obtained between the fluorescence 
readings and the number of monocytes lysed (Fig 49). 10^
monocytes are equivalent to 1.1 ug DNA using purified calf thymus 
DNA as standard in the presence of 0.05% SDS.
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Figure 49: Spectrofluorimetric readings of the
DNA content of increasing number of 
monocytes on day 1 of culture. 
Purified calf thymus DNA (ug) was 
used as standard.
APPENDIX IV
OPIOIDS AND OPIATES
"Opiate" refers specifically to the products derived from the 
juice of the opium poppy (although it has been loosely applied to 
morphine derivatives). "Opioid" refers to any directly acting 
compound whose effects are stereospecifically antagonised by 
naloxone. Peptides with this property are known as "opioid 
peptides".
Following the discovery of specific brain opiate receptors by 
Goldstein and his associates in 1971 several types of receptors 
have been described on the basis of their interaction with 
morphine and other synthetic non-peptide opiates. It is currently 
thought that the mu, kappa and delta receptors are the most 
important physiologically (Paterson et al, 1983; Thompson, 1983). 
Evidence to date supports the mu receptors as being important in 
analgesia and the delta receptors in the modulation of emotional 
behaviour (Snyder, 1980; Zhang & Pasternak, 1980), In addition to 
mediating analgesia, mu receptors are probably involved in causing 
respiratory depression and pupillary construction. But more than 
one class of receptor or ligand seem to function in pain 
modulation since animals made tolerant to the analgesic actions of 
morphine can still respond to a relatively specific delta-receptor 
agonist, D-ALA-D-Leu-encephalin (Tung & Yaksh, 1982).
Opioid receptors are widely distributed in nervous tissue. They 
are found in highest concentrations in the peri-aquaductal grey 
matter, rostro-ventral medulla, layers I, IV and VI at the
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cerebral cortex, hypothalamus, thalamus and dorsal horn of the 
spinal cord (Atweh & Kuhar, 1983). Experiments in 
surgically-induced selective lesions were performed and have 
indicated that orally or parenterally administered opiates produce 
analgesia primarily by their actions at the supraspinal sites 
(Barton et al, 1980).
Morphine and its analogues bind preferentially to mu-receptors 
which are highly responsive to the blocking action of the specific 
opioid antagonist naloxone. Naloxone has no agonist activity and 
is relatively selective for only one receptor type, the 
mu-receptor (Chang & Cuatrecasas, 1981). It rapidly penetrates 
the blood-brain barrier and its brain concentration closely 
follows the changing serum levels (Ngai et al, 1976). Its plasma 
half-life is about one hour but its duration of action can last 
four hours after a single injection (Bradberry & Raebel, 1981; 
Gourlay & Coulthard, 1983).
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